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Both protein and RNA quality control are critical for cell survival during stress and are disrupted in 
the neurodegenerative diseases amyotrophic lateral sclerosis (ALS) and frontotemporal dementia 
(FTD). ALS is the most common adult onset motor neuron disease, while FTD is the second most 
common type of dementia for individuals under 65. Both are characterized by the accumulation of 
proteins in intracellular inclusions and are thought to be part of a continuous clinical spectrum, but 
their causes are largely unknown. Stress granules (SGs), a type of RNA granule, have recently emerged 
as potential seed sites for patient protein inclusions that incorporate both protein quality control (PQC) 
factors and RNA binding proteins (RBPs). SGs transiently sequester stalled translation initiation 
complexes and apoptosis signaling molecules in response to stress. These dynamic particles form via a 
liquid-liquid phase separation mediated by oligomerization of the low complexity prion-like domains 
in RBPs bound to RNA in a process tuned by RNA length and structure.  Stable interactions between 
these proteins in SGs leads to the formation of protein aggregates. The PQC factors that regulate the 
dynamic incorporation of RBPs into SGs to prevent aggregate formation remain largely unknown. 
In 2011, missense mutations in the ubiquitin-like protein ubiquilin 2 (UBQLN2) were found to cause 
ALS with FTD in rare X-linked cases. In an effort to characterize UBQLN2’s normal cellular functions, 
I performed a proteomic screen for UBQLN2 interactors and found an enrichment of RBPs including 
SG components under non-stress conditions.  Using an unconventional staining technique, I 
confirmed that UBQLN2 localizes to SGs under a variety of stress conditions and found that this 
association is transient.  In the time period that UBQLN2 localizes to SGs, it also suppresses large SG 
formation suggesting that it modulates incorporation of SG components. 
To characterize UBQLN2’s regulatory role in SG formation, I focused on its interaction with the RBP 
fused in sarcoma (FUS).  FUS was not only the most enriched RBP among the UBQLN2 interactors, 
but also is genetically and pathologically linked to ALS/FTD.  In a single molecule Förster resonance 
energy transfer (FRET) assay, UBQLN2 increased the dynamics of FUS-RNA interaction, increasing 
the fluidity of FUS-RNA complex formation. This effect translated to a decrease in FUS partitioning 
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into liquid droplets in vitro and suppression of FUS-GFP recruitment into SGs in cells suggesting that 
UBQLN2 slows FUS recruitment into SGs by increasing the dynamics of its interaction with RNA.  
ALS/FTD-linked mutations in UBQLN2 partially impaired UBQLN2’s ability to increase the 
dynamics of FUS-RNA interaction and suppress SG formation, indicating a partial loss of UBQLN2 
function. These results reveal a previously unrecognized role for UBQLN2 in regulating the early stages 
of liquid-liquid phase separation of RBPs in SG formation by affecting the dynamics of RNA-protein 
interaction. Because SGs potentially seed toxic ALS/FTD patient inclusions, these findings have 
implications for understanding ALS/FTD pathogenesis and designing new treatments for these 
diseases. 
Thesis advisor: Dr. Jiou Wang 
Thesis readers: Dr. Jiou Wang, Dr. Michael J. Matunis, Dr. Susan Michaelis, Dr. Marie Hardwick  
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Chapter 1 Introduction 
Cells intimately depend on protein and RNA quality control to survive during stress.  Dysregulation of 
protein and RNA homeostasis in neurons is central to the pathogenesis of the progressive 
neurodegenerative diseases amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). 
In this work I describe a previously unrecognized role for the ALS/FTD-linked ubiquitin-like protein 
Ubiquilin 2 (UBQLN2) in regulating the cellular response to stress in cytosolic RNA-protein 
compartments known as stress granules (SGs).  Because mutations in the UBQLN2 gene cause ALS 
with FTD and SGs may serve as the seed sites for patient inclusions, this role is relevant to 
understanding and designing new treatments for these devastating neurodegenerative diseases. Here I 
have laid out background on ALS/FTD pathology, SGs, and Ubiquilins that forms the basis of this 
thesis work. 
ALS/FTD symptoms and etiology 
ALS and FTD are two devastating, neurodegenerative diseases for which there are few effective 
treatments. ALS, also known as Lou Gehrig’s disease is the most common adult onset motor neuron 
disease occurring in 5 out of every 100,000 people in the United States, while FTD is the second most 
common type of dementia for people younger than 65 accounting for 5-15% of dementia cases (Mehta, 
2018; Ratnavalli et al., 2002). ALS is characterized by skeletal muscle wasting stemming from 
degeneration of both upper and lower motor neurons. Upper motor neurons include motor neurons 
descending from the motor cortex to the brainstem and spinal cord, while lower motor neurons include 
bulbar and spinal motor neurons descending to skeletal muscles (Taylor et al., 2016).  Loss of upper 
motor neurons leads to jerky reflexes, clumsiness, spasticity, and functional limitations, while loss of 
lower motor neurons initially leads to weakness, cramps and fasciculations in limbs (spinal onset) or 
problems with speech or swallowing (bulbar onset) that spreads (Taylor et al., 2016).  The French 
physician Jean-Martin Charcot played a pivotal role in distinguishing the symptoms of ALS from 
related motor neuron diseases in the mid-19th century. While working as a medical intern in the 
“Hospital de la Salpêtrière” which he dubbed the “grand asylum of human misery” he systematically 
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recorded and paired patient symptoms with postmortem anatomy from among the nearly 3000 patients 
with neurologic disorders housed at the facility (Charcot and Joffroy, 1869; Katz et al., 2015; Kumar 
et al., 2011). Using these criteria, he laid out criteria to distinguish ALS, a progressive neuropathy, from 
similar motor neuropathies and myopathies, diseases of muscle alone, many of which are still in use 
today.  
Only recently was it recognized that 50% of ALS patients also show signs of dementia with 15% of 
patients meeting the criteria for FTD, suggesting that these diseases are part of a continuous clinical 
spectrum (Van Langenhove et al., 2012). FTD, also called Pick’s disease for the physician Arnold Pick 
who first described it in detail, is characterized by changes in personality, behavior and language ability 
associated with atrophy of regions of the frontal and temporal lobes, where pyramidal neurons are 
most affected.  Memory, however, is usually spared until the end stages of the disease (Pick, 1892; 
Rademakers et al., 2012). In FTD, like ALS, symptoms vary but can be subdivided into three clinical 
variants: behavioral, and two types of language and cognition loss termed primary progressive aphasia 
and semantic aphasia respectively.  Besides ALS, FTD has also been associated with Parkinson’s disease 
(Rademakers et al., 2012). The heterogeneity of FTD symptoms like ALS have made the disease 
difficult to characterize but recent determinations of disease linked mutations and identifying pathology 
are bringing both ALS and FTD into focus. 
The overlap of ALS and FTD symptoms suggests that pathology in more than one neuronal and/or 
glial cell type may contribute to the disease progression. Motor neurons, whose degeneration is 
associated with ALS, are highly asymmetric cells with long axons that extend up to 1 meter from the 
cell body to enervate skeletal muscles controlling voluntary movement.  These axons are insulated by 
oligodendrocytes in the brain and spinal cord and Schwann cells in the peripheral nervous system. 
Dendritic architecture differs between upper and lower motor neurons, but they are highly excitable 
and respond to glutamate input. The first FDA approved drug for ALS, riluzole, actually targets 
glutamate uptake, although its efficacy in extending life is somewhat limited.  Glia such as astrocytes 
and microglia also contribute to motor neuron survival (Robberecht and Philips, 2013; Taylor et al., 
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2016).  In contrast, pyramidal neurons associated with FTD are large multipolar neurons, but are 
restricted to the frontal and temporal lobes.  Apical and basal dendrites as well as the axons are large 
and can be highly branched, while short dendritic spines are numerous and receive synaptic input.  
These basic morphological differences in the cell types affected by ALS and FTD in the brain suggests 
that a basic rather than specialized cellular pathology may contribute to ALS/FTD pathology. 
ALS and FTD have also interestingly been genetically and pathologically linked to some of the same 
proteins involved in both protein and RNA homeostasis. An estimated 90-95% of ALS and 50-75% 
of FTD cases occur without any prior family history of the disease (sporadic) (sALS/sFTD), while 
the remaining cases can be traced within families (fALS/fFTD) (Robberecht and Philips, 2013).  All 
ALS cases and the majority of FTD cases appear to be linked to a defect in protein clearance due to 
the hallmark accumulation of intracellular protein inclusions (called Pick bodies in pure FTD) in 
patient brain tissue.  Missense mutations in the SOD1 gene encoding the superoxide dismutase 1 
enzyme resulting in SOD1 aggregate formation, were the first to be linked to ALS in 1993 and 
account for 10% of fALS (Rosen et al., 1993). Missense mutations in the microtubule associated 
protein tau (MAPT) were linked to FTD in 1998 and are also present in ubiquitinated FTD 
associated inclusions (Hutton et al., 1998). Interestingly, prior to this discovery, the tau protein was a 
known component of intracellular tangles found in Alzheimer’s disease, but without any known 
pathology (Alzheimer, 1991; Rademakers et al., 2012).  These discoveries made understanding 
protein clearance mechanism central to understanding ALS and FTD pathology. 
However, recent discoveries suggest that defects in RNA homeostasis and protein trafficking also are 
central to ALS/FTD pathology. Since 1993, mutations in more than 30 other genes have been linked 
to ALS/FTD. Protein quality control factors include autophagic receptors SQSTM1/p62 and 
optineurin, VCP, and UBQLN2, the subject of this thesis, RNA homeostasis factors such as TAR-
DNA binding protein, fused in sarcoma (FUS), Ewing sarcoma protein (EWS), TAT-binding protein 
associated factor 15 (TAF-15), hnRNPA1 and hnRNPA2/B1 and protein traffickers such as profilin 
1 (PFN1), dynactin (DCTN1), and neurofilament heavy chain (NFH) have all been found to cause 
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ALS/FTD by pedigree analysis (Table 1-1).  The recently identified repeat expansion in the C9orf72 
gene linked to more than 60% of ALS/FTD cases, appears to cause both RNA toxicity and 
proteotoxicity, highlighting the dual role of protein and RNA homeostasis in ALS/FTD disease 
pathology. For example, the C9orf72 hexanucleotide repeat causes RNA toxicity through formation 
of a G-quadraplex structure that acts as an RNA binding protein sponge, and proteotoxicity through 
production of dipeptide repeats that interfere with protein degradation by both the proteasome 
(Gupta et al., 2017; Haeusler et al., 2014). Additionally, a decrease in C9orf72 protein levels 
associated with the repeat region may also interfere with degradation of proteins in the cell through 
autophagy (DeJesus-Hernandez et al., 2011; Ugolino et al., 2016). These dipeptide repeats also 
interfere with the dynamic exchange of RNA binding proteins (RBPs) into and out of the 
cytoplasmic RNA granules known as stress granules (SGs) (Lee et al., 2016; Zhang et al., 2018c). 
Notably, the RBPs FUS and TDP-43 are principle components of patient inclusions in both ALS and 
FTD, so much so that FTD cases have been subclassified as FTLD-TDP, FTLD-FUS, and FTLD-
tau, FTLD-UPS based on the presence of TDP-43, FUS, tau and other ubiquitin-proteasome 
components respectively (Arai et al., 2006; Munoz et al., 2009; Neumann et al., 2006, 2009a, 2009b; 
Rademakers et al., 2012). However, how RBP protein solubility is maintained in the cell and RBP’s 
function in ALS/FTD pathology is still unclear (Ling et al., 2013; Robberecht and Philips, 2013). 
Protein and RNA homeostasis intersect in RNP granules 
A prominent feature of the ALS/FTD associated RBPs is their propensity to form dynamic 
ribonucleoprotein particles (RNPs), mainly composed of RNAs and proteins.  In these granules, 
protein-bound RNA’s form membraneless condensates that concentrate RNA processing and 
regulatory factors by a process increasingly recognized as a liquid-liquid phase separation (Boeynaems 
et al., 2018) (Figure 1-1B).  Like oil in water, RNP granules exhibit the dripping, wetting and fusing 
behavior of spherical phase-separated liquid droplets (Hyman et al., 2014; Lin et al., 2015; Molliex et 
al., 2015; Patel et al., 2015).  In cells, RNPs show the spherical distribution and viscoelastic properties 
expected of a phase separated liquid (Boeynaems et al., 2018; Patel et al., 2015).  These properties 
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translate to the formation of dynamic liquid particles in which components are rapidly exchangeable, 
are deformable, and fuse to form larger and larger droplets over time. 
The properties of RNA and protein that drive RNP granule formation continue to be more precisely 
defined, but several factors distinguish them. First, long stretches of low complexity amino acid 
sequence that oligomerize and RNA recognition motifs have been shown to mediate RBP phase 
separation (Mittag and Parker, 2018; Wang et al., 2018). Low complexity regions are stretches of amino 
acids containing a limited number of amino acids.  Many of these stretches are intrinsically disordered 
regions (IDRs) and are thus flexible and able to adopt a variety of different structural conformations.  
This heterogeneity facilitates weak multivalent interactions and more stable induced structural 
interactions depending on the amino acid residues represented. Low complexity regions containing 
concentrated hydrophobic or aromatic kinked segments (LARKS), degenerate repeats, short regions 
that adopt discrete structures known as short linear interaction motifs (SLiMs), alternating charge 
blocks, and glutamine-asparagine (QN-rich) prion-like domains have been identified to mediate RNP 
granule formation (Boeynaems et al., 2018; Mittag and Parker, 2018). Protein posttranslational 
modifications that alter the conformational flexibility and/or surface charge of RBPs such as 
serine/tyrosine phosphorylation, arginine methylation, ubiquitylation, sumoylation, O-GlcNAC 
glycosylation, and parylation, have all in some way been observed to alter partitioning of proteins into 
RNP granules (Altmeyer et al., 2015; Boeynaems et al., 2018; Higgins et al., 2015; Leung et al., 2011; 
Nott et al., 2015; Ohn et al., 2008; Shen et al., 2006; Tourrière et al., 2003). RNA itself has also been 
observed to phase separate and drive RBPs into granules (Jain and Vale, 2017; Mao et al., 2011; Treeck 
et al., 2018). When RNA and purified proteins are combined, RNA length and structure tune both the 
viscosity and dynamics of RBP phase separation (Elbaum-Garfinkle et al., 2015; Langdon et al., 2018; 
Zhang et al., 2015).  Consistent with a role of multivalent protein interactions regulating RNP granule 
formation, local protein concentration regulated by nucleocytoplasmic transport and interaction with 
microtubule transport motors such as dynein and kinesin also drive RNP formation (Kwon et al., 2007; 
Loschi et al., 2009; Zhang et al., 2018a). Thus, in the emerging model of RNP formation, both 
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structured and unstructured RBP-RBP, RBP-cytoskeleton, RBP-RNA, RNA-RNA interactions 
regulate RNP granule formation. 
In cells, RNP granule formation has been observed both in the nucleus and cytoplasm (Figure 1-1A, 
C). In the nucleus, RNP granules include nucleoli, sites of ribosomal assembly, Cajal bodies, sites of 
pre-mRNA splicing, nuclear speckles, interchromatin regions also enriched in pre-mRNA splicing 
factors, and promyelocytic leukemia (PML) bodies, sites of recruitment of SUMoylated proteins 
(Brangwynne et al., 2011; Spector, 2001) (Figure 1-1C). In the cytosol, these RNP granules include 
processing bodies (P-bodies), constitutively present sites of mRNA decapping and degradation, and 
stress induced granules known as stress granules that are the focus of this study (Figure 1-1A).  Other 
RNP granules in specialized cell types that have been investigated include neuronal granules, which 
carry mRNA to local sites of translation near the synapse, P-body-like structures in the dendrites of 
neurons (Cougot et al., 2008; Krichevsky and Kosik, 2001) and two types of germline RNP granules 
in the oocytes of the round worm Caenorhabditis elegans: germline messenger RNP processing bodies 
(grPBs) present in cell cycle arrested oocytes and processing bodies in the differentiated oocyte (PBs) 
(Brangwynne et al., 2009; Hubstenberger et al., 2015). All of these granules concentrate RNA and RBPs 
to perform specific RNA processes and the condensation of RNA and RBPs is critical to their 
formation.  However, this condensation process also provides the opportunity for the weak dynamic 
interactions that drive RNP formation to slip into low energy stable conformations (Figure 1-1B). 
In vitro, studies have shown that prolonged residence of proteins in these phase separated droplets leads 
to a liquid-to-solid phase transition that may be a precursor to toxic inclusions seen in 
neurodegenerative diseases such as ALS/FTD (Figure 1-1B) (Kim et al., 2013; Lin et al., 2015; 
Mackenzie et al., 2017; Molliex et al., 2015; Murakami et al., 2015; Patel et al., 2015).  Both LARKs and 
QN-rich PrDs have also been shown to adopt amyloid-like stacked β-sheet structures that are more 
solid-like, suggesting that RBP dynamics within RNP granules is critical to RBP solubility (Mackenzie 
et al., 2017; Mittag and Parker, 2018; Murray et al., 2017). How the dynamics of RNPs is explored in 
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this thesis where I have specifically focused on maintenance of stress granules (SG) whose components 
have also been found in ALS/FTD patient inclusions. 
SGs as precursors to ALS/FTD patient inclusions  
SGs are one type of RNP granule that transiently forms in the cytoplasm in response to stress.  Stress 
induces sequestration of stalled translation initiation complexes including 40S ribosomes, RBPs, 
mRNA, and translation initiation factors along with apoptotic factors into these cytoplasmic granules 
(Anderson and Kedersha, 2009).  The first evidence for SGs came from biochemical and electron 
microscopy studies on Peruvian tomato (Lycopersicon peruvianum) cells exposed to heat shock in which 
specific untranslated mRNAs were observed to associate with heat shock proteins in particles in the 
cytosol (Nover et al., 1983, 1989; Scharf et al., 1998). Fifteen years later Kedersha et. al. reported the 
recruitment of silenced mRNA and RBP T-cell restricted intracellular antigen-1 (TIA-1), TIA-1 related 
(TIAR) and polyA binding protein I (PABP 1) in response to heat, hypoosmolarity, ultraviolet light 
and sodium arsenite treatments in mammalian cells (Kedersha et al., 1999).  This formation was 
triggered by, but not dependent on, phosphorylation of the translation initiation factor eIF2 at serine 
51 (Kedersha et al., 1999). SG formation could also explain earlier observations that cells rapidly 
recover from heat stress in a process requiring no new RNA or protein synthesis (Kedersha et al., 1999; 
Lindquist, 1981; Panniers and Henshaw, 1984; Storti et al., 1980). 
Further studies suggested that mRNA rather than ribosomes or protein signaling factors is critical for 
mediating SG formation. eIF2 phosphorylation by one of the stress responsive kinases: protein kinase 
R (PKR), PKR-like endoplasmic reticulum kinase (PERK) or pancreatic eIF2 kinase (PEK), general 
control nonderepressible 2 (GCN2), heme-regulated initiation factor 2 (HRI), and Z-DNA kinase 
inhibits formation of the ternary eIF2-GTP-tRNAiMet responsible for inserting the first methionine 
charged tRNA into the start site on the ribosome induces SG formation. Notably, however, inhibitors 
that bypass eIF2 phosphorylation such as puromycin, which promotes dissolution of polyribosomes 
on mRNA by promoting prematurely terminated protein formation and hippuristanol or pateamine A, 
which inhibit RNA helicase activity of eIF4A also induce SG formation (Dang et al., 2006; Kedersha 
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et al., 2000; Mazroui et al., 2006; Mollet et al., 2008). A subset of stresses (sodium selenite, hydrogen 
peroxide, cleaved tRNAs) that promote translational stalling through hypophosphorylation of the 
4EBP-cap binding protein also induce SG formation (Emara et al., 2010, 2012; Fujimura et al., 2012; 
Ivanov et al., 2011; Panas et al., 2016).  In contrast, inhibitors that trap ribosomes on mRNA such as 
emetine or cycloheximide, inhibit SG formation (Kedersha et al., 2000). These observations suggest 
that ribosome-free mRNA and bound RBPs rather than stalled 48S preinitiation ribosomes are the 
substrates for SG formation (Panas et al., 2016; Protter and Parker, 2016). 
Despite an understanding of the driving forces of SG formation, the function of SGs remains 
incompletely understood. 60S ribosomal subunits and incompletely transcribed transcripts appear to 
be normally excluded from SGs counter to the hypothesis that 48S particles might be selectively 
incorporated into SGs to translate a subset of transcripts (Kedersha et al., 1999; Seguin et al., 2014). 
SG’s do appose Processing-bodies (P-bodies), sites of mRNA decapping and degradation and 
exchange mRNA and RBPs under some stress conditions, but do not affect the deadenylation of 
polyA-RNA that precedes mRNA degradation in P-bodies.  Even if mRNA is trapped in polysomes 
deadenylation is inhibited under stress, suggesting that SGs do not directly regulate mRNA stability 
(Buchan and Parker, 2009). Inhibition of SG formation also does not interfere with translation 
inhibition, suggesting that there is not a positive feedback loop from SG formation to the integrated 
stress response kinases that inhibit translation (Anderson and Kedersha, 2008).  SG formation does 
repress the translation of some housekeeping genes and enhance translation of some stress responsive 
transcripts. However, recent reports suggest that as low as 15% of mRNA may be transiently 
sequestered in stress granules at one time consistent with proteomic studies showing that specific SG 
components and mRNAs incorporated into SGs are stress and cell type specific (Markmiller et al., 
2018a; Treeck et al., 2018). These reports suggest that SGs function to integrate specific mRNAs and 
proteins with specific stress signals.  The function of this sequestration is not yet well understood. 
Cells that form SGs under many conditions do however survive better than those in which SG 
formation is inhibited, suggesting that SG formation is an adaptive response (Eisinger-Mathason et al., 
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2008; Kim et al., 2012; Kwon et al., 2007; McEwen et al., 2005). The mechanism of this adaptive 
response is also incompletely understood but sequestration of apoptotic and anti-apoptotic factors into 
SGs could explain the integration of apoptotic signaling with SG formation in the cellular stress 
response. For example, the receptor of activated protein C kinase 1 (RACK1) and TNF-receptor 
associated factor 2 (TRAF2) are proapoptotic factors sequestered into stress granules whose 
association with proapoptotic factors mitogen activated MAP kinase, kinase, kinase 4 (MTK1) and 
transcription factor NF-B is required for induction of apoptosis (Arimoto et al., 2008; Buchan and 
Parker, 2009; Kim et al., 2005). In contrast, the anti-apoptotic factors ribosomal S6 kinase (RSK2) and 
Fas-activated serine/threonine kinase (FAST) kinase are two rare near static components (with a 
recovery time following photobleaching in FRAP experiments greater than 10 min) of SGs that bind 
to the QN-rich region of TIA-1 that suppresses TIA-1’s apoptotic activity (Buchan and Parker, 2009). 
These factors all “piggy-back” onto core assembly factors: RSK2 and FAST with TIA-1, RACK1 with 
40S ribosomes, and TRAF2 with eIF4G to be incorporated into SGs (Buchan and Parker, 2009).  By 
a similar mechanism, raptor a component of the mTORC1 complex that inhibits autophagy is 
sequestered by the SG component astrin, suppressing apoptosis in response to oxidative and metabolic 
stresses (Protter and Parker, 2016; Thedieck et al., 2013).  By an as yet unknown mechanism, loss of 
core stress granule component eIF3 associated with enhanced production of reactive oxygen species 
and depletion of ATP may mediate the conversion of SGs from anti-apoptotic to pro-apoptotic in 
nature (Aulas et al., 2018; Fujimura et al., 2012). Thus, incorporation of signaling molecules into SGs 
through their association with core SG components integrates formation of SGs with specific cellular 
stress responses. 
While SG formation may allow cells to adapt to stress, because they concentrate intrinsically disordered 
proteins, SGs may also serve as the seed sites for the intracellular inclusion formation associated with 
ALS/FTD (Aulas and Vande Velde, 2015; Li et al., 2013). Like other RNP granules, SGs contain stable 
“cores” visible by electron microscopy that can be isolated via subcellular fractionation and 
immunoprecipitation (Jain et al., 2016; Ohn et al., 2008; Souquere et al., 2009), but also a dynamic 
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responsive “shell” thought to be formed by the oligomerization of low complexity, prion-like domains 
(PrDs) in RBPs (Kroschwald et al., 2015; Lin et al., 2015; Mittag and Parker, 2018; Molliex et al., 2015; 
Patel et al., 2015).  These shell proteins may adopt more solid-like states as stress is prolonged and as 
SGs recruit additional components. Importantly, an increasing number of ALS/FTD-associated 
proteins found in patient inclusions have also been found in SGs, including FUS, TDP-43, C9orf72 
protein and its poly-dipeptide repeats, ataxin 2, hnRNPA2/B1, hnRNPA1, SOD1 and profilin 1 
(Boeynaems et al., 2017; Bosco et al., 2010; Dewey et al., 2011; Figley et al., 2014; Gal et al., 2016; Kim 
et al., 2013; Liu-Yesucevitz et al., 2010; Nonhoff et al., 2007; Sama et al., 2013). ALS/FTD-linked 
mutations in RBPs FUS and hnRNPA1 that phase separate into SGs, accelerate the phase transition 
of these proteins from a dynamic liquid state to a solid fibril state (Kim et al., 2013; Mackenzie et al., 
2017; Molliex et al., 2015; Patel et al., 2015).  Importantly, core SG components TIA-1, eIF3A, PABP, 
and eIF4G have also been found in patient inclusions (Aulas and Vande Velde, 2015; Mackenzie et al., 
2017). Additionally, PQC factors linked to ALS, such as the disaggregase VCP, play a role in both 
assembling and disassembling SGs and shuttling them to the autophagosome-lysosome system for 
degradation (Buchan et al., 2013; Seguin et al., 2014). These data suggest that development of 
ALS/FTD inclusions may be inherently linked to the process of SG formation. 
Protein quality control at SGs 
Due to the promiscuous nature of the interactions that drive SG formation, PQC factors may play an 
active role in maintaining SG fluidity. Consistent with this hypothesis, components of the two systems 
of protein clearance in the cell, autophagy and the ubiquitin-proteasome system, localize to and regulate 
SG composition. For example, mono-ubiquitin, unanchored ubiquitin chains and unconjugated LC3B, 
E3 ubiquitin ligases, deubiquitinases (DUBs), and the proteasome have all been shown at SGs (Buchan 
et al., 2013; Markmiller et al., 2018b; Mateju et al., 2017; Mazroui et al., 2007; Seguin et al., 2014; 
Turakhiya et al., 2018; Xie et al., 2018). ROQUIN (RING finger and CCCH-type zinc finger domain-
containing protein 1), its mammalian paralogue MNAB (membrane-associated nucleic acid binding 
protein) and TRAF-2 (TNF receptor-associated factor 2) are all RING-type E3 ligases that localize to 
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SGs with the effect of altering stability of particular mRNAs (Athanasopoulos et al., 2010; Kim et al., 
2005).  The DUBs USP5 and USP13 were recently found to regulate SG disassembly (Xie et al., 2018), 
while in a function not requiring its catalytic activity the DUB USP10 was found to limit G3BP 
incorporation into SGs by competing with caprin 1 (Kedersha et al., 2016).  While the coordinated role 
of both the ubiquitin-proteasome system and autophagy in SG disassembly is still unclear, components 
of both PQC clearance systems in the cell appear to be present. 
Several PQC factors do function at SGs to prevent the aberrant incorporation of misfolded, 
ubiquitinated proteins which disturb SG dynamics into SGs. Ubiquitinated prematurely terminated 
ribosomal transcripts (termed defective ribosomal products or DRiPs) induced by puromycin 
treatment were found to disrupt RBP fluidity in SGs and promote conversion of liquid SG assemblies 
into solid assemblies (Ganassi et al., 2016; Mateju et al., 2017).  The ATPase activity of a small heat 
shock protein HSPB8, HSP70 and its nucleotide exchange factor BAG3 in cooperation with VCP/p97 
and its cofactors UFD1L and NPL4 were found to actively extract DRiPs from SGs and transfer them 
to the aggresome for degradation by autophagy (Buchan et al., 2013; Ganassi et al., 2016; Seguin et al., 
2014) (Figure 1-1B).  In a non-mutually exclusive mechanism, VCP (yeast cdc48) was also recently 
found to cooperate with the human ZFAND1 (AN1-type zinc finger protein 1) (yeast Cuz1) and the 
proteasome to clear SGs during recovery from stress (Turakhiya et al., 2018). The specific karyopherin 
β2 specifically known for its solubilizing effect on the FG repeats of the nuclear pore complex appear 
to directly solubilize solid-like RBPs such as FUS in SGs (Guo et al., 2018; Hofweber et al., 2018; 
Qamar et al., 2018; Yoshizawa et al., 2018) Jain et. al. (2016) also implicated the ATP-dependent 
chaperonins RuvB, MCM, and TriC in regulating SG formation but their mechanisms of action remain 
to be tested. These studies suggest that PQC factors clearly play a role in preventing and clearing 
aberrant SGs, but other PQC factors that directly mediate the formation and maintenance of RBP 
fluidity in SGs, the topic of this thesis, are unknown. 
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UBQLN2 is a PQC factor genetically and pathologically linked to ALS/FTD 
In 2011, Deng et. al. identified single point mutation in the UBQLN2 gene that causes a rare X-linked 
form of ALS with dementia in a 5-generation family with 19 affected individuals without male-to-male 
transmission (Deng et al., 2011). This inherited mutation mapped to a proline in a unique 12x PXX 
repeat in the UBQLN2 protein c.1490C.A (p.P497H) (Figure 1-2). This mutation resulted in 90% 
penetrance by age 70 with an age of onset between 17 and 71 years. Four other proline mutations 
mapping to this repeat were later identified in four unrelated families in this cohort (P497S, P506T, 
P509S, P525S) (Figure 1-2).  These sequence variants were not present in the SNP database or 928 age 
matched controls (Deng et al., 2011).  In another 5-generation family, a P497L mutation resulted in an 
earlier age of onset of 10 years of age in males and between 20 and 30 years of age in females, suggesting 
that mutations in UBQLN2 can cause severe motor neuron degeneration (Fahed et al., 2014). Missense 
mutations in other residues within and outside the PXX region have since been identified in 
French/French-Canadian, Italian, German, Australian, New Zealander and Turkish cohorts in both 
inherited and sporadic cases of ALS/FTD (Daoud et al., 2012; Fahed et al., 2014; Gellera et al., 2012; 
Huang et al., 2017; Özoğuz et al., 2015; Scotter et al., 2017; Synofzik et al., 2012; Williams et al., 2012) 
(Figure 1-2). One mutation identified (A282V) resulted in a pure FTD phenotype, while another 
(T487I) resulted in a pure ALS phenotype (Synofzik et al., 2012; Williams et al., 2012) suggesting that 
gene mutations in UBQLN2 can result in heterogenous pathology in the clinical spectrum of 
ALS/FTD.  These studies bolster evidence that mutations in UBQLN2 cause both sporadic and 
familial ALS/FTD.   
Interestingly, UBQLN2 is also pathologically associated with ALS/FTD. Both wild type and mutant 
UBQLN2 have been found in sporadic and familial ALS/FTD ubiquitinated inclusions with and 
without UBQLN2 mutations present (Brettschneider et al., 2012; Deng et al., 2011). In patients with 
and without UBQLN2 mutations, UBQLN2 stained characteristic ALS-linked skein-like spinal cord 
inclusions also containing other ALS/FTD-linked PQC factors p62, optineurin and ubiquitin, and 
RBPs TDP-43 and FUS.  In addition, in the hippocampi of other ALS patients with dementia and 
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FTD patients with ubiquitin-positive inclusions examined, wild type UBQLN2 was present in dentate 
granular cell inclusions that were positive for p62, ubiquitin and optineurin (Deng et al., 2011).  There 
is also a correlation between UBQLN inclusions in the cerebellar granular region and hippocampi of 
ALS/FTD patients with a hexanucleotide repeat expansion in an intronic region of the C9ORF72 gene, 
(Brettschneider et al., 2012).  Distinct from the spinal cord neurons, UBQLN2 positive inclusions 
generally do not contain FUS and sometimes are negative for TDP-43.  Mutant UBQLN2 P506T itself 
forms inclusions in the hippocampus in cases with dementia that may be unique to mutant UBQLN2 
pathology (Deng et al., 2011). These observations indicate that while UBQLN2 positive inclusions are 
distinct in motor neuron and hippocampal cells, both wild type and mutant UBQLN2 are involved in 
ALS/FTD pathology associated with patient inclusion formation. 
Aspects of UBQLN2 pathology seen in human ALS/FTD patients have also been recapitulated in 
mouse, rat and Drosophila models (Ceballos-Diaz et al., 2015; Gorrie et al., 2014; Hjerpe et al., 2016; 
Kim et al., 2018; Le et al., 2016; Wu et al., 2015). Several mutant UBQLN2 mouse models showed 
cognitive deficits along with hippocampal inclusions characteristic of FTD. Transgenic mice that 
expressed human UBQLN2 from the Y-chromosome under the endogenous UBQLN2 promoter 
showed delayed fear response and poor performance in a Morris water maze associated with the 
accumulation of ubiquitinated aggregates in the dendritic spines of hippocampal neurons (Gorrie et al., 
2014). Mice transduced with an adeno-associated virus carrying UBQLN2 P497S and P506T via 
somatic brain transgenesis showed clasping and rotarod deficits at 3-4 months of age (Ceballos-Diaz 
et al., 2015).  And a P520T (P506T equivalent in mice) CRISPR knock-in mouse also showed 
impairment in novel object recognition and placement.  In these mouse models, impaired synaptic 
function and protein aggregates were evident without neuronal loss. A rat overexpressing mutant 
UBQLN2 P497H did show cognitive deficits and neuronal loss without any motor deficits (Wu et al., 
2015). Only when the UBQLN2 mutant (P497S or P506T) was expressed under a Thy1.2 neuronal 
mouse promoter were motor deficits and neurodegeneration observed in addition to cognitive deficits. 
(Le et al., 2016). Independently, mutant UBQLN2 aggregation has also been studied in the Drosophila 
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compound eye (Kim et al., 2018). Despite the mix of symptoms of neurodegeneration, all of these 
models showed accumulation of UBQLN2 in ubiquitinated intracellular neuronal inclusions suggesting 
that a defect in protein clearance is associated with the disease pathology. 
The dominant inheritance of UBQLN2 gene mutations suggests that a gain of toxicity, dominant 
negative effect or haploinsufficiency contribute to the disease pathology. Given the heterogeneity of 
symptoms associated with ALS/FTD associated UBQLN2 mutations, one or more of these 
mechanisms may contribute to the disease.  The fact that a UBQLN2 knockout rat failed to show any 
phenotype while a rat overexpressing UBQLN2 showed cognitive decline could indicate that a simple 
“loss of function” associated with haploinsufficiency is not relevant to the disease pathology.  
However, there have been several examples of knockout animals that failed to recapitulate the 
symptoms of the disease in which loss of function clearly contributed to the disease pathology. For 
example, both the alsin (ALS2) knockout mouse (Cai et al., 2005; Deng et al., 2007; Devon et al., 2006; 
Hadano et al., 2006; Yamanaka et al., 2006) reviewed in (Cai et al., 2008) and the PINK1 knockout 
mouse (Morais et al., 2009) failed to show disease specific pathology. However, the loss of function 
mechanisms clearly contributed to these forms of disease. The knock-in UBQLN2 mutant mouse 
model also failed to show a “gain of toxicity” or “dominant negative” effect on motor neuron function 
or survival (Hjerpe et al. 2016)). It is conceivable that both loss of UBQLN2’s cytoprotective effect 
and toxicity of the mutant protein could together contribute to the disease mechanism. Further 
characterization of UBQLN2 function may be required for a more detailed mechanism of 
pathogenesis. These studies together implicate mutations in UBQLN2 as both a genetic cause of 
ALS/FTD and UBQLN2 as part of ALS/FTD pathology, but the mechanism(s) by which it causes 
pathogenesis are unclear. 
UBQLN2 has a conserved, modular domain structure 
UBQLN2 is a type II ubiquitin-like protein encoded by an intronless gene with a cryptic intron on the 
X-chromosome. It is 74% identical to its nearest human homolog UBQLN1 with 11 exons encoded 
on chromosome 1. Ubiquilins have a conserved amino-terminal ubiquitin-like domain (Ubl) that is 
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only 36% identical to ubiquitin but adopts a highly similar fold (Figure 1-3 A, B). Like ubiquitin’s Leu8, 
Ile44, Val76 hydrophobic pocket, this Ubl contains an Ile75 and Val101 important for its interaction with 
ubiquitin-interacting motifs (UIMs) of the proteasome, E3 ubiquitin ligases, DUBs and the ESCRT 
machinery (Beal et al., 1996; Walters et al., 2002). While it lacks the C-terminal Gly-Gly required for 
E1 activating enzyme conjugation in the ubiquitin conjugation cascade, it does interact with its own 
carboxy-terminal ubiquitin-associated domain (Uba). 
The Uba domain in Ubiquilins is a 40 amino acid, 3 helix bundle that binds ubiquitin (Figure 1-3A, B).  
This domain was the first bioinformatically predicted ubiquitin binding domain from an alignment of 
a number of ubiquitin binding protein sequences (Hofmann and Bucher, 1996; Hurley et al., 2006). 
The Uba domain in UBQLN2 and its closet human homolog UBQLN1 has one of the strongest 
affinities for ubiquitin without chain-type specificity (Kd 20 μM) (Raasi et al., 2005; Zhang et al., 2008). 
Repeats of this Uba domain were thus used in the first molecular traps for ubiquitin chains, termed 
tandem-repeated ubiquitin-binding entities (TUBES) (Gao et al., 2016; Hjerpe et al., 2009).  The Kd 
of this Uba’s interaction with its own Ubl domain is ten-fold lower than that of its interaction with 
ubiquitin, which affects the availability of these domains to interact with ubiquitin and UIM containing 
proteins (Itakura et al., 2016; Lowe et al., 2006; Nguyen et al., 2017). 
Between the Ubl and Uba domains in UBQLN2 is a flexible linker region of 474 amino acids that 
encompasses 76% of UBQLN2’s composition (Figure 1-2A, B). This region contains a set of 
conserved Sti1-like repeats that appear to have been replicated in the evolution of ubiquilins from yeast 
to higher eukaryotes (Kaye et al., 2000; Marín, 2014) (Figure 1-3A). Sti1/p60 in yeast and HIP in 
humans, binds to the ATPase domain of Hsp70 stabilizing the ADP bound state of Hsp70 and 
promoting Hsp70-Hsp90 complex formation (Höhfeld et al., 1995; Lässle et al., 1997). Consequently, 
the Sti1-like repeats in UBQLN2 are part of a minimum binding region in the ATPase domain of the 
Hsp70 Stch (HSPA13) (Kaye et al., 2000).  Whether these Sti1-like repeats stabilize client protein bound 
to Hsp70 or Hsp90 remains to be determined (Hjerpe et al., 2016; Kaye et al., 2000). However, both 
we and others, found that UBQLN2, but not UBQLN1 or UBQLN4, immunoprecipitates HSP70, 
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suggesting that these repeats do not bind HSP70 in all contexts (Hjerpe et al., 2016; Alexander et al., 
2018).  The repeats have been implicated, however in UBQLN oligomerization and phase separation, 
a topic relevant to this study (Dao et al., 2018; Ford and Monteiro, 2006; Sharkey et al., 2018). 
Bioinformatics predict that the first set of Sti1-like repeats in yeast Dsk2/Dph2 was replicated during 
the evolution of higher eukaryotes. This second set of Sti1-like repeats that have been implicated in 
UBQLN oligomerization are specific to higher eukaryotes (Dao et al., 2018; Kaye et al., 2000; Marín, 
2014). The presence of these Sti1 repeats also distinguishes UBQLN’s from other Ubl-Uba type 
proteins such as hHR23A, B (yRad23), hDdi1, KPC2 (Kip1 ubiquitylation promoting complex), 
hNUB1 (NEDD8 ultimate buster 1), and p62 that also contain this Ubl-Uba domain architecture and 
associate with UIMs, but lack these repeats (Su and Lau, 2009). 
Prior to the identification of the Sti1-like repeats in UBQLN2, the central low complexity region of 
UBQLN2 was defined by 18 NPXφ repeats in UBQLN 1/2/4 where X is any amino acid and φ is any 
hydrophobic amino acid (Mah et al., 2000; Wu et al., 2002) (Figure 1-2 B). Three of these repeats are 
NPF, a recognized epsin homology (EH) binding motif, although later studies found that the Ubl 
domain alone was sufficient to bind the UIMs of endocytic adaptors Eps15, HRS and HBP containing 
the epsin homology domain (Regan-Klapisz et al., 2005). The significance of these repeats thus still 
remains unclear.  
The Ubl and Uba domains of UBQLN2 are highly conserved among Ubiquilin paralogs, whereas the 
linker region is more variable and may be the source of protein functional specificity. Humans contain 
at least four Ubiquilins UBQLN1, UBQLN2, UBQLN3, UBQLN4 (Marín, 2014).  UBQLN1, 2, and 
4 are ubiquitously expressed, while UBQLN3 is testes specific and appears to have lost some of the 
Sti1 repeats (Conklin et al., 2000; Kim et al., 2014; Yuan et al., 2015).  Its closest homolog, which may 
also be testes specific, UBQLNL contains only a Ubl domain followed by regions of low complexity 
without any Sti1 repeats (Figure 1-3 C) (Yuan et al., 2015).  UBQLN4 is most similar to yeast homolog 
Dsk2, while UBQLN2 appears to be duplicated from UBQLN1 and shows higher expression in the 
brain and spinal cord (Marín, 2014). UBQLN1, 2, and 4 can homo- and hetero-dimerize as will be 
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discussed further below (Ford and Monteiro, 2006; Lee et al., 2013a), but also appear to have distinct 
localizations and functions at the cellular level (Hjerpe et al., 2009; N’Diaye and Brown, 2003; N’Diaye 
et al., 2008). 
Between the Sti1-like repeats are a number of other low complexity regions annotated by the simple 
modular architecture research tool (SMART) (Schultz et al., 1998).  These low complexity regions 
contribute to the compositional bias in UBQLN2. Ser, Pro, Gln, Ala, Leu, Gly compose nearly 60% 
of UBQLN1/2/4 sequences, with the addition of Gln in yeast Dsk2 (ProtParam). This composition 
is in stark contrast to the low complexity regions in RBPs that mediate LLPS which includes Asn, Gln, 
Tyr and Gly. UBQLN1 and 2 for example have only 4 Tyr.  This difference may in part explain the 
difference in phase separation behavior of Ubiquilins vs. RBPs previously observed (Dao et al., 2018). 
Compositionally, ubiquilins have several other distinguishing features.  First, UBQLN1/2 contain no 
cysteine residues, but have an overabundance of Met’s (10%).  Second, Lys residues are restricted to 
the Ubl domain.  And third, there are a limited number of aromatic residues: Trp (1), Tyr (4), His (4), 
and Phe (17). UBQLN1/2/4 contain only one Trp in the distinctive sequence PLPPNPWAPPP in 
UBQLN2 located between the two sets of Sti1 repeats of unknown function. UBQLN2 in particular 
also contains a unique PXX repeat region to which the majority of ALS/FTD mutations map (Figure 
1-2 A, B).  This repeat has been compared to an SH3 binding domain, collagen, elastin, and the 
herpesvirus saimiri oncogene STP-C488 phosphoprotein, but the PXX repeat has no true sequence 
homologues (Dao et al., 2018; Kaye et al., 2000; Mah et al., 2000) and its function is still unclear.  
Currently there is no evidence that the prolines in these PXX repeats are hydroxylated as in collagen, 
however ALS/FTD linked mutations in this region do interfere with UBQLN2 function as a 
proteasome adaptor (Chang and Monteiro, 2015; Hjerpe et al., 2009; Sharkey et al., 2018). 
Ubiquilins function as both chaperones and shuttles 
The Ubiquilin Ubl-Uba domain structure suggests that these proteins may bridge ubiquitylated proteins 
with UIM containing proteins such as the proteasome, E3 ubiquitin ligases, DUBs and the ESCRT 
machinery (Heir et al., 2006; Kleijnen et al., 2000; Ko et al., 2004; Regan-Klapisz et al., 2005). 
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Consistent with this functional role at the proteasome, UBQLN1 and 2 interact with the proteasome 
cap subunits S5a (Rpn10) and ADMR1 (Rpn13 via both the Uba and Ubl domain (Chen et al., 2016; 
Walters et al., 2002). This interaction has been proposed to function in proteasome shuttling of 
ubiquitinated substrates, protection of proteasome substrates from deubiquitinases, a ubiquitin-chain 
length sensor for the proteasome, and more recently, a ubiquitin-proteasome vs. autophagy pathway 
selector (Fushman and Wilkinson, 2011; Hartmann-Petersen et al., 2003; Kleijnen et al., 2003; Ko et 
al., 2004; Lu et al., 2017).   
This regulatory function can translate to either a stabilizing or destabilizing effect.  For example, for 
p53 and IkB which are ubiquitinated by the HECT-type E3 ligase UBE3A (E6AP) and the SCF-type 
E3 ubiquitin ligase F-box/WD repeat-containing protein 1A (βTRCP), UBQLN1/2 overexpression 
inhibited their degradation.  UBQLN2 overexpression, however, did not inhibit degradation of 
ornithine decarboxylase (ODC) indicating that UBQLN2 did not interfere with the proteasome itself, 
but instead its substrates (Kleijnen et al., 2003).  In contrast, UBQLN overexpression accelerated the 
degradation of misfolded endoplasmic reticulum (ER) substrates in ER associated degradation 
(ERAD) facilitated by an interaction with the molecular motor VCP and a Ubx protein (Erasin 
(UBXD8) and HERPUD1 for UBQLN1 and FAF2 for UBQLN2) (Lim et al., 2009; Su et al., 2010; 
Xia et al., 2014).  In hepatitis C infected Huh7 hepatoma cells, UBQLN1 overexpression also 
accelerated the polyubiquitination and degradation of the hepatitis C virus RNA-dependent RNA 
polymerase (NS5B) (Gao et al., 2003). 
The stabilization or destabilization of UBQLN substrates can in part be attributed to the domain of 
UBQLN protein required for the interaction, such that interaction with the Ubl or central domain of 
UBQLN proteins is stabilizing and interaction with the UBA domain is destabilizing (Kurlawala et al., 
2017a). Recent evidence suggests that the low complexity flexible linker region of Ubiquilins may 
participate with the Uba domain in selecting substrates for proteasome degradation giving Ubiquilins 
a broad substrate specificity (Itakura et al., 2016). Consequently, UBQLN2 has been shown to mediate 
the degradation of substrates as diverse as misfolded ERAD substrates, mitochondrial precursor 
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proteins, and intermediate filament proteins (Gavriilidis et al., 2018; Itakura et al., 2016; Xia et al., 
2014). So UBQLN2 clearly regulates degradation of ubiquitinated substrates but the mechanism of this 
action is unclear. 
Ubiquilin function as a proteasome shuttle may be coupled to its function as a molecular chaperone. 
As noted above, previous reports have suggested that ubiquilins stabilize protein substrates in the ER 
and Golgi (Ayadi et al., 2012; Massey et al., 2005; Saliba et al., 2008). In vitro, UBQLN1 stabilized a 
temperature-sensitive citrate synthase mutant and promoted firefly luciferase refolding after thermal 
denaturation suggesting that this stabilizing effect is a molecular chaperone effect (Ayadi et al., 2012).  
UBQLN1 has also been shown to stabilize model nuclear encoded mitochondrial precursor proteins 
OMP25, TOM5, BAK and ATP5G via its Sti1-like linker region (Itakura et al., 2016). Notably, 
introduction of ubiquitinated OMP25 in vitro stabilized UBQLN1 interaction with OMP25 and 
promoted UBQLN1 binding to the proteasome and enhanced OMP25 degradation (Itakura et al., 
2016).  These data suggest that ubiquilins may have two interconvertible modes of action, one as a 
stabilizing molecular chaperone and the other as a proteasome shuttle.  In the case of mitochondrial 
precursor proteins, UBQLN1 interconversion between a molecular chaperone and proteasome shuttle 
was induced by UBQLN1 Uba domain binding to ubiquitin.  Given that the Uba domain has a ten-
fold lower affinity for its own Ubl domain than ubiquitin, ubiquitin binding freed the Ubl domain to 
interact with the proteasome (Itakura et al., 2016; Lowe et al., 2006). This model in other systems is 
also supported by the observation that UBQLN2 binding to the molecular chaperone Hsp70 via its C-
terminus (including the Uba domain) in the presence of thermally denatured luciferase promoted its 
binding to the proteasome (Hjerpe et al., 2016). Effectively, ubiquilins respond to substrate 
ubiquitination by changing conformation. It will be interesting if this conformational switching model 
applies to other cellular functions of ubiquilins. 
In addition to its conformational state, the oligomerization states of ubiquilins may also contribute to 
their functional roles in the cell.  Intermolecular interactions between Uba and Ubl domains may also 
be functionally important (Ford and Monteiro, 2006; Kang et al., 2007; Lee et al., 2013a; Lowe et al., 
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2006). While UBQLN1, 2, and 4 may have distinct substrate specificities, homo- and hetero-
dimerization of ubiquilins may expand this substrate specificity further (Ford and Monteiro, 2006).  
For example, UBQLN1 and 4 were found to form a heterodimer that acts as an autophagic receptor.  
In this role, UBQLN4 binds to the autophagosome membrane via an LC3B recognition domain while 
UBQLN1 binds to ubiquitinated substrate (Lee et al., 2013a).  UBQLN2 has also recently been shown 
to form oligomers that phase separate in warm temperature, high salt conditions suggesting that they 
are mediated by interactions between hydrophobic regions of the low complexity and Sti1-like repeat 
regions (Dao et al., 2018). Based on studies in yeast, human ubiquilin oligomerization state might be 
critically important for determining the fate of bound protein substrate shuttling to the proteasome or 
autophagosome.  Unlike human ubiquilins, the yeast ubiquilin Dsk2 lacks the second set of Sti1-like 
repeats found to mediate ubiquilin oligomerization (Kaye et al., 2000). In yeast, instead the ubiquitin 
receptor Cue2 oligomerizes.  In an assay in which the half-life of a wild type or mutant protein prone 
to misfolding and degradation was measured, strains expressing oligomerization competent and 
incompetent ubiquitin receptors Cue2 and Dsk2 respectively differentially mediated protein 
degradation. Dsk2 mediated proteasomal degradation of soluble protein as a monomer, while Cue2 
mediated autophagosomal degradation of insoluble aggregated protein as an oligomer (Lu et al., 2017).  
Whether this functional difference is conserved in higher eukaryotes remains to be tested, but is an 
intriguing possibility. 
Levels of ubiquilins determine their cytoprotective vs. cytotoxic effect 
The relative levels of ubiquilins to their substrates appears to determine their cytoprotective vs. 
cytotoxic effects.  In healthy cells, overexpression of ubiquilin has been found to be cytotoxic at both 
cell and organismal levels. Overexpression of the yeast ubiquilin, duplication suppressor of a Kar1 
defect (DSK2) interferes with the G2/M transition during mitosis eventually leading to yeast cell death 
(Biggins et al., 1996). Overexpression of the Xenopus laevis frog ubiquilin (XDRP1) in egg extracts 
inhibits cell cycle progression by interfering with degradation of cyclin A (Funakoshi et al., 1999). 
Overexpression of the fly Drosophila melanogaster ubiquilin (DSK2) causes morphological abnormalities 
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in late pupal stages and later death (Lipinszki et al., 2011). This toxicity is associated with DSK2 
interference with proteasome degradation by saturating the proteasome ubiquitin receptors (Lipinszki 
et al., 2011). In all of these studies increasing the concentration of ubiquilin protein relative to the 
proteasome or its substrate was in some way toxic to cells by interfering with proteasomal degradation. 
In contrast, increasing the concentration of ubiquilin in the presence of a toxic misfolded substrate is 
cytoprotective. For example, the yeast DSK2 protein was originally identified as a high copy number 
suppressor in cells with a kar1 allele with a spindle pole body duplication defect (Vallen et al., 1994). 
Overexpression of ubiquilin in the presence of polyglutamine, polyalanine, amyloid beta, TDP-43 and 
Huntington fragments, lessened the burden of toxic aggregates that cells accumulated (Adegoke et al., 
2017; Ayadi et al., 2012; Hanson et al., 2010; Lim et al., 2009; Safren et al., 2015; Wang and Monteiro, 
2007a, 2007b). Ubiquilin depletion via transcript silencing sensitizes cells to nutrient starvation and 
heat stress, stressors which increase the burden of misfolded proteins that tend to aggregate (Hjerpe 
et al., 2009; Rothenberg et al., 2010). Natural aging also reportedly leads to a decline in UBQLN1 levels 
in the brain making cells more susceptible to amyloid beta and Huntingtin protein aggregation in 
Alzheimer’s and Huntington’s diseases respectively (Safren et al., 2015). The cytoprotective effect of 
increasing ubiquilin levels or cytotoxic effect of suppressing ubiquilin levels in all of these cases 
depends on the presence of an aggregation prone substrate. Consistent with these observations, 
stresses that increase the burden of misfolded proteins in the cell, such as sodium arsenite, hypoxia 
and ER stressors, lead to an increase in ubiquilin transcript levels (Esler et al., 2002; Heir et al., 2006; 
Ko et al., 2004; Tsukamoto et al., 2015), suggesting that the cell uses ubiquilin to buffer against 
aggregation in response to a higher burden of misfolded proteins. 
Ubiquilins function in diverse cellular contexts 
Like the ubiquitous protein tag, ubiquitin, ubiquilins function in a broad range of cellular contexts. The 
lack of ubiquilin specificity for a particular ubiquitin-chain linkage type (Raasi et al., 2005; Zhang et al., 
2008) and flexible linker region may allow it to function in these many different contexts.  Cell 
homeostasis is integrally dependent on regulated proteolysis, protein assembly, translocation and 
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assembly at the correct location in the cell.  Ubiquilins not only function as a proteasome shuttles in 
the cytosol, but also at the ER, Golgi, plasma and mitochondrial membranes and in cell signaling, 
transcription and autophagy as discussed below. 
Initially many of the substrates for UBQLN1, 2, and 4 were identified via yeast two-hybrid screens. 
UBQLN1, 2, and were originally identified as interactors for the proteasome, both HECT and RING 
type E3 ubiquitin ligases, presenilin, mTor, the Hsp70 Stch, the DAN tumor suppressor protein, the 
integrin associated receptor CD47, and the basic helix loop helix (bHLH) transcription factor achaete-
scute homolog 1 (HASH1) (Kaye et al., 2000; Kleijnen et al., 2000; Mah et al., 2000; Ozaki et al., 1997; 
Persson et al., 2004; Wu et al., 2002).  UBQLN4 which has a more nuclear distribution than UBQLN1 
and 2, and is most similar to the yeast Dsk2 protein, was identified as an interactor for ataxin 1, 
connexin 43 and the ER targeting signal sequence of Hsp47 by this method (Davidson et al., 2000; Li 
et al., 2008; Matsuda et al., 2001).  From these screens, several classes of interactors for UBQLN1, 2, 
and 4 emerged, placing ubiquilins in diverse contexts in the cell. 
First, UBQLN1 and 2 appear to play an integral role in membrane protein biogenesis in the ER, Golgi, 
plasma membrane in the secretory pathway. Membrane protein interactors for UBQLN1 include 
presenilin, GABAA receptor, retinoic acid receptor, nicotinic acid receptor, the DAN tumor 
suppressor and the amyloid precursor protein (Bedford et al., 2001; Ficklin et al., 2005; Hiltunen et al., 
2006; Massey et al., 2004; Ozaki et al., 1997; Zhu et al., 2010). UBQLN1 stabilizes the membrane 
insertion of GABAA receptors by stabilizing them in the ER (Saliba et al., 2008). UBQLN1 expression 
suppresses endoproteolysis of the amyloid precursor protein to the neurotoxic amyloid beta fragment 
42 (Aβ42) by sequestering it in the Golgi (Ayadi et al., 2012). At the mitochondrial and ER membranes 
UBQLN1 and 4 appear to cooperate in targeting nascent tail anchored proteins respectively (Itakura 
et al., 2016; Suzuki and Kawahara, 2016). This stabilizing regulatory mechanism depends on the ability 
of ubiquilins to bring together ubiquitinated proteins and the proteasome at the membrane.  
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Less well studied functions of ubiquilins include UBQLN1’s role in calcium homeostasis by regulating 
stability of the store operated calcium channel protein Orai1, and apoptosis by stabilizing the anti-
apoptotic factor Bcl-b (Beverly et al., 2012; Lee et al., 2013b). A recent report cites the transcriptional 
role of Drosophila Dsk2 in development (Kessler et al., 2015). A role for ubiquilins in DNA repair has 
yet to be shown. Overall ubiquilins show functions in a diverse set of cellular processes suggesting 
their broad specificity. Note however, that majority of these studies have focused on UBQLN1 or 4 
except for the specific characterization of UBQLN2’s interaction with Hsp70 and its role in G-protein 
coupled receptor mediated endocytosis (Hjerpe et al., 2016; Kaye et al., 2000; N’Diaye and Brown, 
2003).  UBQLN2’s specific substrates prior to this study have largely been uncharacterized. 
Thesis summary/rationale 
To investigate specific cellular functions of UBQLN2 associated with ALS/FTD in collaboration with 
Akhilesh Pandey’s lab, I performed a proteomic screen for UBQLN2 interactors. Among those 
interactors, I found an enrichment of stress granule (SG) components. In Chapter 2, I show that 
UBQLN2 associates with SGs via its linker region and plays a negative regulatory role in SG formation 
in the cytosol.  In Chapter 3, I focus on the interaction between UBQLN2 and the ALS/FTD linked 
RNA binding protein FUS. I show that UBQLN2 forms a complex with FUS and increases the 
dynamics of FUS-RNA interaction, increasing the fluidity of FUS-RNA complex formation. This 
effect translates to a decrease in the size of phase-separated FUS droplets in vitro and suppression of 
FUS phase separation into SGs in cells. ALS/FTD-linked mutations within the low complexity linker 
region of UBQLN2 partially impair UBQLN2’s ability to increase the dynamics of FUS-RNA 
interaction and suppress SG formation. These data suggest that UBQLN2 plays a previously 
unrecognized role in regulating the early stages of SG formation by disrupting RBP-RNA interaction. 
In Appendix A, full lists of UBQLN1, UBQLN2 and UBQLN4 interactors and a brief comparison of 
their association with SGs is given.  In Appendix B, extended methods and tools for studying UBQLNs 
cellular function are described. Together this data provides support for a previously unrecognized 
function of UBQLN2 in SG formation by modulating the dynamics of hnRNP-RNA interaction. 
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Because SGs potentially seed toxic ALS/FTD patient inclusions, these findings have implications for 
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Figure 1-1 RNP granules and a model of SG granule formation 
(A) Immunofluorescence (IF) images of cytoplasmic ribonucleoprotein (RNP) granules in 
HeLa cells after 30 min of heat stress (43.7C). Mouse anti-G3BP [BD 611126] and 
goat anti-4E-T [Santa Cruz sc-13453 (N18)] mark SGs and P-bodies respectively. White 
arrows point to juxtaposed P-bodies (red) and SGs (green). 
(B) Model of RNP liquid-liquid phase separation focusing on SG formation. (Left panel) 
Molecular level diagram (Right panel) Cellular level diagram.  Stress induces a redistribution 
of RNA binding proteins (RBPs) and stalled poly(A)-mRNA from the nucleus to the 
cytoplasm where they oligomerize and phase separate into liquid-like granules.  Prolonged 
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stress or aging leads to the conversion of these dynamic granules into static solid-like granules.  
These solid-like granules may be trafficked to perinuclear aggresomes and degraded by 
autophagy and potentially serve as the seed sites for toxic intracellular inclusions associated 
with neurodegenerative diseases such as ALS/FTD. Protein quality control factors VCP and 
HSP70 extract ubiquitinated misfolded proteins from SGs to the aggresome for degradation. 
Karyopherin β2 disassociates solid-like granules. (Center Box) SGs fuse like liquid droplets 
to form larger droplets.  As liquid droplet components solidify, the droplets lose their 
spherical structure and grow in size. Ribbons in grey are RNA. Grey spheres are other SG 
components. 
(C) IF images of some nuclear RNP granules in HeLa cells.  Mouse anti-nucleophosmin 
[Abcam ab10530 (FC82291)], rabbit anti-coilin [Abcam ab11822], mouse anti-SC35 
(phospho) [Abcam 11826], and rabbit anti-PML [Abcam ab200200 (EPR16768)] mark 
nucleoli, Cajal bodies, nuclear speckles and PML bodies respectively.   These granules 
differ in composition, localization and morphologies, but are all thought to form via a 




Figure 1-2 ALS/FTD linked mutations in UBQLN2 map to the Sti1-like linker region 
(A) Domain map of UBQLN2 drawn to scale with amino acid residues affected by ALS/FTD-linked 
mutations highlighted in red. fALS mutations are shown in blue, while sALS mutations are shown 
in purple. The M392V mutation resulted in a pure FTD phenotype, while the T487I mutations 
resulted in a pure motor neuron phenotype, indicating that UBQLN2 mutations cause a spectrum 
of ALS/FTD pathology. 
(B) ALS/FTD-linked mutations shown in the context of the UBQLN2 protein sequence (RefSeq 
NP_038472.2). The Ubl domain is in blue (33-107). The Uba domain (581-621) is in red. Boxes 
outline the predicted Sti1-like repeats (I 178-206, II 208-247, III 379-426, IV 430-462), and the 
PXX repeat (491-526) is underlined and shown in bold.  Asparagine-proline (NP) repeats are 
highlighted in orange. Domains are shown were annotated by SMART (Schultz et al., 1998).  






Figure 1-3 UBQLNs have a conserved modular domain structure 
(A) Domain map of human ubiquilin structure drawn to scale. Ubl=ubiquitin-like domain 
Uba=ubiquitin-associated domain. Sti1=Sti1-like repeat. The orange box highlights the portion of 
ubiquilins believed to have been replicated from the first set of Sti1-like repeats in yeast Dsk2 
during the evolution of higher eukaryotes. 
(B) Ribbon drawings of the UBQLN2 Ubl domain, ubiquitin, and UBQLN1 Uba domain rendered in 
PyMOL (Shrödinger, LLC).  UBQLN2 and ubiquitin have similar β-grasp folds.  The Uba domain 
forms a three-helix bundle that binds ubiquitin. 
(C) Tree map showing the evolutionary distance between human UBQLNs. UBQLN1 and 2 are 74% 
identical. UBQLN4 is most similar to Dsk2. UBQLN3 is testes specific and contains only 1 Sti1-
like domain. UBQLNL contains a Ubl but its Sti1 repeats and Uba have been replaced by a low 




Table 1-1 ALS-linked genes 
Protein qualty control factors
Gene Protein ALS Inheritence Citation




ALS14 Dominant Johnson JO, et al. (2010)
UBQLN2 Ubiquilin 2 ALS15 X-linked Deng H-X, et al. (2011) 
SQSTM1 (p62) Sequestosome 1 ALS Dominant Fecto F, et al. (2011) 
Freischmidt A, et al. (2015)















Chow CY, et al. (2009)
RNA Binding Proteins
Dominant Sreedharan J, et al. (2008) 
Rutherford NJ, et al. (2008) 
Dominant Kwiatkowski TJ, et al. (2009) 




















Kim HJ, et al. (2013) 
MATR3 Matrin 3 ALS21 Dominant Johnson JO, et al. (2014) 
ANG Angiogenin ALS9 Dominant Greenway MJ, et al. (2006)
SETX Senataxin ALS4 Dominant Chen Y-Z, et al. (2004) 
TBK1 Tank Binding Kinase 1 ALS Dominant
TARDBP
TAR DNA-binding protein 
43
ALS10





Gene Protein ALS Inheritence Citation







DeJesus-Hernandez M, et al. 
(2011)
Trafficking Proteins




Dominant? Figlewicz DA, et al. (1994)
PFN1 Profilin 1 ALS18 Dominant Wu C-H, et al. (2012) 
TUBA4A Tubulin 4A Smith BN, et al. (2014) 
Neuron Excitotoxicity
DAO D-amino-acid oxidase ALS Dominant Mitchell J, et al. (2010)
Other
SOD1 Superoxide dismutase 1 ALS1 Dominant Rosen DR, et al. (1993)








Bannwarth S, et al. (2014)
NEK1
Ser/Thr Protein Kinase 
NEK1
ALS Kenna KP, et al. (2016)
C21ORF2













Role in protein homeostasis
Involved in RNA homeostasis
Involved in cytoskeletal trafficking




Chapter 2 UBQLN2 associates with SGs and negatively regulates SG 
formation 
INTRODUCTION 
Both protein and RNA homeostasis have been both genetically and pathologically linked to cases of 
the neurodegenerative diseases amyotrophic lateral sclerosis (ALS) and frontotemporal dementia 
(FTD). However, a role for these molecular players in a common cellular pathway has not been well 
characterized (Robberecht and Philips, 2013; Taylor et al., 2016). In September of 2011, when I started 
my PhD rotation in the Wang lab, ubiquilin 2 (UBQLN2) was identified as one of the first bona fide 
protein quality control (PQC) factors to cause ALS with FTD in rare dominant X-linked cases of this 
disease (Deng et al., 2011).  UBQLN2 is one of four conserved ubiquilins with an amino-terminal 
ubiquitin-like domain (Ubl) and carboxy-terminal ubiquitin-associated domain (Uba) separated by a 
long low complexity linker region.  This modular domain structure suggests that ubiquilins can bridge 
ubiquitinated substrates and ubiquitin binding proteins, however, very few specific cellular roles for 
UBQLN2 except as a proteasome shuttle had been identified. ALS/FTD mutations in UBQLN2 did 
inhibit degradation of a model proteasome substrate, but its specific substrates had not been 
characterized (Deng et al., 2011).  
Through a quantitative proteomic screen for UBQLN2 interactors in collaboration with the Pandey 
lab, I identified an enrichment of RNA binding proteins also found in stress granules (SGs). This 
enrichment coincided with emerging evidence suggests that SGs seed ALS/FTD patient inclusions (Li 
et al., 2013).  SGs form by dynamically concentrating proteins with intrinsically disordered prion-like 
domains (PrDs) in a process recently recognized as a liquid-liquid phase separation. Prolonged stable 
incorporation of PrDs in SGs disrupts SG dynamics leading to large aberrant SG formation.  These 
aberrant SGs misincorporate ubiquitinated proteins potentially serving as the seed sites of patient 
ALS/FTD inclusions (Kroschwald et al., 2015; Mateju et al., 2017). ALS/FTD-linked protein quality 
control factors such as VCP have been shown to mediate disassociation of ubiquitinated proteins from 
SGs, but PQC factors that mediate the process of SG formation have not been well characterized. 
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In this chapter, I present the first pieces of evidence that UBQLN2 suppresses large aberrant SG 
formation by modulating the dynamics of PrD protein incorporation into SGs. Using an 
unconventional stress granule staining technique, I found that under stress conditions, UBQLN2 is 
recruited to SGs and this association is transient. With a stable cell line that inducibly expresses 
UBQLN2 at near endogenous levels, I determined that this recruitment is mediated by a low 
complexity region within the linker of UBQLN2.  Furthermore, I found that UBQLN2 overexpression 
suppresses SG formation, while UBQLN2 depletion enhances the rate at which SG size increases 
without affecting basal levels of core SG components TIA-1 or G3BP or stalled translation initiation 
complexes. 
These results suggest that UBQLN2 physically interferes with the process of SG formation bridging 
protein and RNA homeostasis at SGs. UBQLN2 protein carrying ALS/FTD-linked mutations failed 
to suppress SG formation as well as the wild type UBQLN2. Given that aberrant SGs are thought to 
seed toxic ALS/FTD patient inclusions, these results support the conclusion that UBQLN2 plays a 
protective role at SGs and ALS/FTD-linked mutations lead to a loss of this function. 
 
Note: The results presented here are given with minor modifications to fit the thesis format from the 
published manuscript: Alexander EJ, Niaki AG, Zhang T, Sarkar J, Liu Y, Nirogi RS, Pandey A, Myong 
S, and Wang J (2018) Ubiquilin 2 Modulates ALS/FTD-linked FUS-RNA Complex Dynamics and 
Stress Granule Formation. PNAS 115(49): E11485-E11494. 
 
RESULTS 
UBQLN2 associates with SG components 
To identify specific cellular functions for the UBQLN2 protein, working with Raja Sekhar from 
Akhilesh Pandey’s lab, I performed an unbiased quantitative proteomic screen for UBQLN2-
interacting partners by stable isotope labelling with amino acids in cells (SILAC) coupled with liquid 
chromatography-tandem mass spectrometry (SILAC LC-MS/MS) (Ong et al., 2002). I first prepared 
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stable HEK293T cell lines with an integrated tetracycline-inducible FLAG-UBQLN2 construct and 
cultured them with 13C615N4 Arg and 13C615N2 Lys heavy isotope media until complete labelling was 
attained, which Raja assessed by mass spectrometry. I extracted proteins from cell lysate with CHAPSO 
lysis buffer, co-immunoprecipitated them with FLAG-UBQLN2 on anti-FLAG (M2) beads and eluted 
them with FLAG peptide. Identically processed lysate from 12C614N4 Arg and 12C614N2 Lys light-labelled 
HEK293T cells treated with doxycycline was used as a control. Raja and I pooled the eluants, separated 
them by SDS-PAGE, and trypsin digested the proteins and extracted the peptides for LC-MS/MS 
analysis, which Raja performed (Figure 2-1A, B). 
From this proteomic analysis, we identified 180 putative interactors for UBQLN2 enriched over 1.5-
fold, 13 of which were enriched more than 10-fold (Figure 2-1). These interactors could be 
subclassified by domain structure into four groups: molecular chaperones, AAA ATPases, RNA/DNA 
binding proteins, and transmembrane proteins (vesicle trafficking, ER/Golgi/lysosomal membrane, 
and mitochondrial membrane proteins) (Figure 2-1D).  Included in this list were previously identified 
UBQLN2 interactors: Hsp70 molecular chaperones HSPA1A, HSPA8 and HSPA13/Stch, ERAD 
chaperones FAF2/UBXD8 and HERPUD1, AAA ATPases VCP, proteasome cap subunits, hnRNPU, 
hnRNPA3, and membrane proteins ESyt2 and INSR (Table A-1) (Gilpin et al., 2015; Hjerpe et al., 
2016; Kaye et al., 2000; Kim et al., 2008; Kleijnen et al., 2000; Kurlawala et al., 2017b, 2017a; Xia et al., 
2014). Western blot validation of some of the most enriched interactors confirmed our peptide search 
results from this proteomic analysis (Figure 2-2).  
During the course of this analysis, I noticed that members of every group except the membrane 
proteins were also represented in the SG proteome (Jain et al., 2016; Markmiller et al., 2018a; Ohn et 
al., 2008; Youn et al., 2018). To identify functional classes of proteins in SGs that UBQLN2 binds, I 
mapped the connectivity of SG-associated UBQLN2 interactors via STRING network analysis 
(Szklarczyk et al., 2015). Four major classes of proteins emerged from this analysis: heterogenous 
ribonucleoproteins (hnRNPs) (I), molecular chaperones (II), translation factors (III), and RNA 
trafficking proteins (IV) (Figure 2-1E).  The majority of ATP-dependent molecular chaperone 
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assemblies found in the G3BP-dependent SG proteome, including VCP/p97, MCM, RuvB, and TriC 
(Jain et al., 2016), were also identified as UBQLN2 interactors (Group II, IV). The karyopherins, A2 
and B1, a class of proteins recently identified to solubilize hnRNP fibrils (Guo et al., 2018; Hofweber 
et al., 2018; Qamar et al., 2018; Yoshizawa et al., 2018) were present in Group IV. Notably however, a 
subclass of ALS-linked hnRNPs known as the FET family, including FUS, EWS, and TAF15 
(Couthouis et al., 2011, 2012; Ticozzi et al., 2011), were also identified (group I). FUS among RNA 
binding proteins (RBPs) showed the highest peak intensity among the hnRNPs (Table 3-1). Overall 
the results of this proteomic analysis indicated that UBQLN2 associates with SG components in the 
absence of stress. 
UBQLN2 localizes to SGs 
To determine if UBQLN2 localizes to SGs with SG components, I examined cells by 
immunofluorescence staining with UBQLN2-specific antibodies (Figure B-1) to detect endogenous 
UBQLN2 protein under stress conditions. In response to acute sodium arsenite stress (0.5 mM, 30 
min), endogenous UBQLN2 formed cytoplasmic puncta that colocalize with core SG components 
G3BP and TIA-1 in HeLa cells (Figure 2-3 A middle row; Figure 2-3 D second row). Depleting 
UBQLN2 with a specific shRNA (Figure B-1) eliminated the UBQLN2 signal in G3BP-containing 
SGs, confirming that the UBQLN2 signal in SGs is specific (Figure 2-3A bottom row, Figure 2-10, 
bottom row). 
Visualization of UBQLN2 in SGs was enhanced by use of an unconventional SG staining technique.  
I found that simultaneously fixing and permeabilizing cells with paraformaldehyde and Triton X-100 
effectively limited the background cytoplasmic signal revealing UBQLN2’s underlying localization to 
SGs (Figure 2-4). UBQLN2 could also be detected in SGs by the conventional SG staining technique 
(Kedersha and Anderson, 2007), but its localization with SG marker TIA-1 is largely obscured by its 
strong cytoplasmic signal (Figure 2-4, third row). This method of simultaneously fixing and 
permeabilizing cells was particularly effective in HeLa cells where the cytoplasmic volume is more 
compressed than in other cell types such as U2OS cells. I am not aware of any previously published 
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reports in which this method systematically used to detect SG components, but a similar approach was 
used previously to wash away nucleoplasmic components to enhance the detection of substructures of 
the nucleus (Fey et al., 1986; Guzzo et al., 2012).  Although this method does not allow calculation of 
the percentage of total protein in SGs, it does provide clear evidence of SG localization for proteins 
with strong cytoplasmic signals and did not appear to influence detection of core SG components 
G3BP or TIA-1 used in later experiments. Using this method, I was able to show that other predicted 
SG components, such as VCP, TriC, Hsp72, and Hsc70 (Jain et al., 2016), are in fact present in SGs 
(Figure 2-5). As negative controls, other functionally related Ubl/Uba proteins SQSTM1/p62 and/or 
BAG6 were not found to be components of SGs (Figure 2-6) (Mateju et al., 2017). Based on this 
finding, I believe this method may prove useful for examining the SG association of proteins with 
strong cytoplasmic signals. 
Since some proteins localize to SGs only under specific conditions, I next tested if under other stress 
conditions UBQLN2 localizes to SGs. When treated with oxidative (CCCP, H2O2), heat, proteotoxic 
(MG132) and osmotic stressors (sorbitol, NaCl), UBQLN2 invariably localized to SGs (Figure 2-3D, 
Figure 2-7). Some SG components are also cell line-dependent (Anderson and Kedersha, 2009), so I 
then tested if UBQLN2 localizes to SGs in other cell lines, such as HEK293T (human embryonic 
kidney), U2OS (bone marrow), and SHSY-5Y (neuroblastoma) cells. In all tested cell lines, UBQLN2 
localized to SGs (Figure 2-8).  Based on these results, UBQLN2 appears to universally localize to SGs. 
Notably, under all of the acute stress conditions tested initially, nearly all cells formed SGs containing 
UBQLN2, indicating that UBQLN2 is a SG component. However, SGs grow in size and change 
morphology and composition over time, so I then tested the types of granules with which UBQLN2 
associates. After 30 min of heat stress, HeLa cells contained a variety of SG morphologies that I 
classified as i) diffuse ii) concentrated but not punctate iii) perinuclear punctate iv) large cytoplasmic 
puncta (Figure 2-3E). Interestingly, enrichment of UBQLN2 was mainly found in cytoplasmic punctate 
granules. UBQLN2 appeared to only weakly associate with perinuclear punctate SGs at 30 min. These 
cells were rounded and the cytoplasm was highly compressed. As stress was prolonged, this cell 
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morphology predominated and UBQLN2 visibility in SGs weakened (Figure 2-9). This loss of 
UBQLN2 in SGs corresponded with the relocalization of UBQLN2 to the nucleus as previously 
reported (Hjerpe et al., 2016). After this time point, cells begin to undergo apoptosis. This selective 
association of UBQLN2 with a subset of SGs, suggests that UBQLN2 localization is functionally 
linked to SG morphology and/or composition. 
P-bodies, unlike SGs, are constitutively present in the cytosol and contain enzymes for RNA decapping 
and degradation. Some components of P-bodies are also present in SGs and vice versa (Anderson and 
Kedersha, 2009). I next tested if UBQLN2 could also localize to P-bodies. Staining for UBQLN2, 
however, did not overlap with P-bodies under nonstress conditions (Figure 2-10). Only in cases where 
the P-bodies were directly juxtaposed to SGs, did UBQLN2 show partial overlap with P-body marker 
4E-T (Figure 2-10, second row). Thus, UBQLN2 localizes to SGs in response to stress, not P-bodies. 
The Sti1 linker region is sufficient for UBQLN2 sequestration into SGs 
To predict if annotated low complexity regions in UBQLN2 might be functionally relevant to its 
localization to SGs, I first performed bioinformatic analysis of this region. Between the Ubl and Uba 
domains in UBQLN2 is a 474 amino acid stretch that composes the Sti1-like linker region. This region 
contains several low complexity regions annotated by the SMART algorithm (Schultz et al., 1998). 
Analysis of the full-length protein via PLAAC (Prion-like Amino Acid Composition) software revealed 
that UBQLN2 contains two putative prion-like domains (PrD), a type of low complexity domain that 
can mediate protein self-association (March et al., 2016) within this linker (Figure 2-11A). The first 
region is located just downstream of the Ubl domain prior to the first set of Sti1-like repeats. The 
second region includes a second set of Sti1-like repeats specific to higher eukaryotes (Kaye et al., 2000). 
The second region is the same one recently found to be essential for UBQLN2 oligomerization (Dao 
et al., 2018). The liquid droplet theory of SG formation predicts that low complexity flexible regions 
in SG proteins can oligomerize to drive the phase separation of these proteins with RNA into granules. 




To test if the Sti1-linker of UBQLN2 is sufficient to drive it into SGs, I constructed a new regulatable 
FLAG-UBQLN2 Flp-In HeLa cell line that would be ideal for imaging. This cell line inducibly 
expresses UBQLN2 at near endogenous levels when treated with a low level of tetracycline (1 μg/mL). 
The full-length FLAG-UBQLN2 but not FLAG-GFP colocalized with SG marker TIA-1 after 30 min 
of heat stress, indicating that the FLAG tag itself does not drive protein localization to SGs ( 
Figure 2-11B). The expression of FLAG-tagged Sti1-linker in the Flp-In system was relatively low, but 
it colocalized with SGs indicating that the linker region is sufficient for UBQLN2 localization to SGs. 
UBQLN2 negatively regulates SG formation 
Overexpression of core SG components that contain low complexity domains such as TIA-1, G3BP, 
FUS and TDP-43 alone can drive SG formation. To test if UBQLN2 alone could seed SG formation, 
I overexpressed FLAG-tagged UBQLN2 in transiently transfected HeLa cells (Figure 2-12C) and 
stained for SG marker TIA-1. In no case did overexpressing UBQLN2 drive SG formation (Figure 
2-12A, second column, D). Instead, overexpressing UBQLN2 suppressed SG formation. The 
percentage of cells with large SGs was significantly decreased at all time points during heat stress in the 
presence of elevated levels of UBQLN2 (Figure 2-12D). ALS-linked mutants P497H or P506T partially 
interfered with UBQLN2’s ability to suppress SG formation (Figure 2-12A, third and fourth column, 
D) despite being overexpressed at the same level as the wild type protein (Figure 2-12C). 
Next, I asked if depleting endogenous UBQLN2 would enhance SG formation. 96 hrs after 
transfection with UBQLN2 specific shRNAs, HeLa cells were exposed to heat stress. The depletion 
of UBQLN2 resulted in a nearly twofold increase in the percentage of cells with large SGs beginning 
at 30 min (Figure 2-12B, F). As the percentage of cells with SGs increased to nearly 100% at 2 hrs, 
UBQLN2 levels no longer affected the percentage of cells with large SGs, indicating that SGs enlarge 
faster when UBQLN2 levels are decreased (Figure 2-12F). Even among the cells treated with UBQLN2 
shRNA, those with higher levels of UBQLN2 expression showed a significantly lower level of large 
SGs (Figure 2-13), supporting this finding. This increase in the percentage of cells with large SGs 
corresponded with a significant increase in SG cross-sectional area and an increase in number of all 
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SGs per cell at time points prior to 2 hrs of heat stress (Figure 2-14). This change could not be 
adequately explained by increases in levels of core SG components G3BP or TIA-1 (Figure 2-15) or 
an increase in stalled ribosomes marked by eIF2α phosphorylation (Figure 2-16), suggesting that 
depletion of UBQLN2 led to a concentration of SG components in larger SGs rather than altered core 




In this chapter, I provide the first evidence for a previously unrecognized role for the UBQLN2 protein 
in modulating SG formation.  UBQLN2 interacting proteins identified by quantitative nLC-MS/MS 
analysis contained four groups of SG components: hnRNPs, molecular chaperones, translation factors, 
and RNA trafficking proteins.  Under stress conditions, I verified that UBQLN2 localizes to SGs using 
an unconventional staining method and determined that the low complexity linker region alone of 
UBQLN2 was sufficient for this recruitment.  UBQLN2 overexpression suppressed SG formation, 
while UBQLN2 depletion enhanced SG size indicating that UBQLN2 negatively regulates SG 
formation.  Mutations in UBQLN2 impaired UBQLN2’s negative regulatory function.  These results 
expand on the known cellular roles of UBQLN2 and provide a potential direct link between protein 
and RNA homeostasis in normal stress responses and the pathogenesis of ALS/FTD. 
The role of UBQLN2 as a negative regulator of SG formation represents a function for UBQLN2 
independent of its previously established roles in mediating protein clearance. Instead of engaging with 
the proteasome or autophagy machinery via its Uba and Ubl domains, UBQLN2 associates with SG 
components through its Sti1-like region and influences the early stages of SG formation. Our 
quantitative proteomic analysis shows that UBQLN2 associates with SG components under 
homeostatic conditions, suggesting that these interactions exist prior to SG formation and UBQLN2 
acts to regulate the exchange of these components into and out of SGs. Our time course analysis of 
SGs demonstrates that UBQLN2 is not a stable component of SGs but is present instead at the initial 
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phases of SG assembly, delaying SG initiation, resulting in negative regulation of SG size. Notably, 
UBQLN2 does not appear to regulate the levels of core SG components and inhibition of translation. 
The function of UBQLN2 in decelerating the rate of expansion of individual SGs, potentially expands 
the mechanisms of SG regulation. By bioinformatic analysis of UBQLN2’s amino acid composition, I 
discovered that UBQLN2 contains two putative prion-like domains in the long linker region between 
Ubl and Uba domains, and that this linker region is sufficient for UBQLN2s recruitment to SGs. 
However, unlike RBPs with low complexity PrDs TIA-1, TDP-43, and FUS and signaling protein 
G3BP, that seed SG formation (Gilks et al., 2004; Liu-Yesucevitz et al., 2010; Patel et al., 2015; Reineke 
et al., 2012; Tourrière et al., 2003), UBQLN2 inhibits SG formation.  The ATP-dependent molecular 
chaperones Hsp70 and VCP that act as SG disaggregases are also incorporated in SGs (Buchan et al., 
2013; Jain et al., 2016), but this association has not been associated with a PrDs in these proteins, as is 
true for UBQLN2. Consistent with the observation by us and others that UBQLN2 moves out of SGs 
during prolonged stress, UBQLN2 could also participate in extraction of misfolded RBPs or aggregates 
from SGs in cooperation with other ATP dependent chaperones.  The loss of UBQLN2 mutant 
function in suppressing SG formation suggests UBQLN2 links PQC and RNA homeostasis in ALS 
pathology. This study opens the door to mechanistically understanding the negative regulatory role of 
the network of molecular chaperones in the early stages of SG formation and ALS/FTD pathogenesis 




pcDNA3.1 was modified to include a tetracycline operator (SacI-tetO-SacI), amino-terminal 3xFLAG 
tag (HindIII-3xFLAG-HindIII), attR1-CmR-ccdB-attR2 Gateway destination cassette (from pQXCP-
DEST), and TetR-IRES-PuroR cassette (from Tet-pLKO-Puro). This CMV/TO-n3xFLAG-attR1-
CmR-ccdB-attR2 DEST cassette was then introduced into pcDNA5-FRT by Gibson assembly and 
transformed into electrocompetent ccdB Survival T1 E. coli cells by electroporation. UBQLN2 wild 
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type, mutants, and fragments along with GUS and GFP were cloned into Entry vector pENTR221. 
pENTR221 was then used to introduce this cDNA into the modified pcDNA3.1 and pcDNA5-FRT 
DEST vectors by LR Gateway cloning (ThermoFisher, Waltham, MA).  
All shRNAs were cloned into the BamHI/HindIII restriction sites in the p-RFP-C-RS vector from 
Origene, which was modified to remove RFP by MluI, BglII digestion followed by blunting and 
religation.  The scramble control was also from Origene (TR30015). shRNA targeting sequences were 
as follows: gcactaccagagctaactcagatagtact (non-targeting), tgtatatgaccttaatctttgtgcagcct (UBQLN2-1), 
aaccacgagtcctacatcagaatctggac (UBQLN2-2), ctgaactacagagtcagatgcagcgacaa (UBQLN1-1), 
tacatcctctggtgaaggtagtcaacctt (UBQLN1-2), gctgctcagatgatggtgaatgtgccgct (UBQLN4-1) and 
ggcttcatcaatcgtgaggctaacctgca (UBQLN4-2).  
Cell Culture 
HeLa, U2OS, and HEK293T were cultured in DMEM with 10% FBS. SHSY-5Y cells (Sigma) were 
cultured in Ham’s F12: EMEM (EBSS) (1:1) + 2mM Glutamine + 1% Non-Essential Amino Acids + 
15% Fetal Bovine Serum at 37C/5% CO2 in standard tissue culture dishes.  HEK293T clones with 
randomly integrated, linearized pcDNA3.1_CMV/TO_n3xFLAG-UBQLN2_TetR_IRES_Puro were 
selected, expanded, and subcloned under continuous 3 μg/mL puromycin treatment.  UBQLN2 
overexpression was induced with 1 μg/mL doxycycline for 24-72 hrs. Flp-In UBQLN2 fragment HeLa 
cells were generated by cotransfecting pcDNA5_FRT_nxFLAG-UBQLN2 fragments with pOG44 at 
a 9:1 molar ratio.  Integrants were selected with 400 μg/mL Hygromycin B and 16 μg/mL Blasticidin 
and pooled.  1 μg/mL tetracycline was used to induce fragment expression for 24 hrs. 
Transfection was performed with lipofectamine 2000 (Invitrogen) in Opti-MEM (Gibco) reduced 
serum media, halving the manufacturers recommended volumes and following the manufacturer’s 
protocol. Opti-MEM was replaced with DMEM/10% FBS 5 hrs after transfection for HeLa cells, and 
12 hrs after transfection for HEK293T cells. 
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For cell stress experiments the following treatments/reagent concentrations were used unless 
otherwise indicated in figure legends: 43.7C, 0.5 mM NaAsO2, 1 μM CCCP in Glucose-free DMEM, 
0.4 M Sorbitol, 0.2 M NaCl, 2 mM H2O2.  
Antibodies for Western blotting and Immunocytochemistry 
Rabbit anti-UBQLN2 (Sigma HPA0006431) and mouse anti-UBQLN2 (Novus, NBP2) antibodies 
were used to specifically detect UBQLN2 via immunofluorescence and western blot (Appendix B). 
Goat anti-TIA-1 (Santa Cruz, C-20) and Mouse anti-G3BP (BD 611126) were used to detect SGs, and 
goat anti-4E-T (Santa Cruz, N-18) to detect P-bodies. Mouse and rabbit anti- DYKDDDDK (Sigma 
F3165 and CST) respectively were used to detect FLAG constructs by Western blot, whereas mouse 
anti-DYKDDDDK (Sigma F1804) was used for immunocytochemistry (ICC).  Antibodies used to 
validate high SILAC hits include rabbit anti-ALDH3A2 (Genetex), mouse anti-HSP70 (Enzo ADI-
SPA-822-D), mouse anti-ESYT2 (Sigma HPA002132), and mouse anti-LETM1 (Proteintech, 16024-
1-AP).  Rabbit anti-eIF2-pSer51 (CST 9721) and mouse anti-eIF2 (Abcam ab119495) were used to 
track translation inhibition. Rabbit anti-SQSTM1 (CST D10E10), rabbit anti-BAG6 (gift, Yihong Ye), 
mouse anti-VCP (Novus NBP120), goat anti-TCP1 theta (Santa Cruz sc-13891), rat anti-Hsc70 (Enzo 
ADI-SPA-815-D), and mouse anti-Hsp72 (Enzo ADI-SPA-810-D) to check localization of other 
proteins to SG by immunofluorescence staining. Mouse anti--actin (Santa Cruz, C4) was used as a 
loading control for Western blots. Secondary antibodies Donkey anti-goat IgG-Alexa fluor 647 nm, 
Donkey anti-mouse IgG-Alexa flour 488 nm, and Donkey anti-rabbit IgG-Alexa fluor 555 nm 
(Invitrogen) were used for 3 color immunofluorescence staining. Cell nuclei were stained with DAPI 
(4′,6-diamidino-2-phenylindole). Secondary antibodies Goat/Donkey anti-mouse IgG and anti-rabbit 
IgG-800CW and 680LT pair were used for two color Odyssey Western blots (Licor). 
SDS-PAGE and Immunoblotting 
Cell lysates were collected in 1% CHAPSO [3-([3-Cholamidopropyl]dimethylammonio)-2-hydroxy-1-
propanesulfonate], 50 mM HEPES pH 7.9, 150 mM NaCl, 2 mM EDTA supplemented with 1x 
Protease Inhibitor Cocktail (Sigma P8340) and 0.2 mM Na3VO4 and sonicated using a Diagenode 
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Bioruptor 5 min (high setting, 30 sec pulse, 5 min) prior to spinning at 20,000 x g at 4C. In our 
experience, ubiquilin protein separated well on an 8% isocratic Tris-Gly SDS-PAGE gel with 4% 
stacking gel at 65V or TGX Criterion 4-20% gradient gel at 85V (Bio-rad). Protein was transferred to 
0.2 μm nitrocellulose membrane via Bio-rad Turboblot transfer (25V, 1.3 Amp, 12-15 min), the 
membrane was blocked with 5% Milk/TBS-T (20 mM Tris pH 7.6  0.1, 150 mM NaCl, 0.1% Tween 
20), and then incubated with primary antibody in 5% BSA, TBS-T, 0.03% Sodium Azide solution at 
4C overnight.  Secondary antibodies Donkey anti-Mouse IgG-680LT or 800CW and Donkey anti-
Rabbit IgG-680LT or 800CW (Licor Biosciences, Nebraska, USA) at 1:10,000-1:20,000 in milk were 
incubated 1-2 hrs at room temperature protected from light to detect primary antibody. An Odyssey 
scanner (Licor Biosciences, Nebraska, USA) equipped with 700 nm and 800 nm laser channels was 
used to image the blot. 
Immunoprecipitation for SILAC LC-MS/MS analysis 
Expression of FLAG-UBQLN2 in stable HEK293T cells was induced by treatment with 1 μg/mL 
doxycycline for 72 hrs.  Equal numbers of cells were washed with phosphate buffered saline (1 mM 
Na2HPO4, 0.2 mM KH2PO4, 0.27 mM KCl, 13.7 mM NaCl pH 7.4  0.2) (PBS), pelleted and 
resuspended in lysis buffer (1% CHAPSO, 50 mM HEPES pH 7.9, 150 mM NaCl, 2 mM EDTA, 0.2 
mM NaVO4, 2x Protease Inhibitor Cocktail (Sigma P8340)).  Cells were rocked in lysis buffer 30 min 
at 4C, sonicated in 10 sec intervals, 3x on high power, and passed through a 25G needle 10x on ice, 
then spun at 20,000 x g, 10 min at 4C to pellet insoluble debrís.  Equal amounts of lysate were then 
loaded directly onto FLAG-M2 antibody coated agarose magnetic beads (Sigma M8823) and rocked 
overnight at 4C.  Beads were washed with wash buffer (lysis buffer without detergent), 5 min at room 
temperature 5x, and FLAG-UBQLN2 was eluted with 300 ng/μL FLAG peptide (Sigma F4799) in 
wash buffer 30 min at 4C at 850 rpm 3x.  Eluant was flash frozen in liquid N2 for storage until analysis.  
The amount of target protein immunoprecipitated was checked against a BSA standard via Blue-Silver 
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staining of protein separated by Tris-Gly-SDS-PAGE or Silver staining using the Pierce Silver Stain kit 
(Cat. No. 24612). 
SILAC LC-MS/MS Analysis 
HEK293T stable cell lines were cultured for more than 6 generations in heavy (13C6,15N4 L-
Arginine, 13C6,15N2 L-Lysine) or light (12C6,14N4 L-Arginine, 12C6,14N2 L-Lysine) SILAC DMEM 
supplemented with 10% Gibco Performance FBS, and Penicillin-Streptomycin Solution. Lysate was 
checked for labeling completion by mass spectrometry. Immunoprecipitate eluants were quickly 
thawed on ice, pooled, dialyzed, concentrated and separated via Tris-Gly SDS-PAGE.  Proteins were 
visualized by silver staining or colloidal Coomassie. Individual bands were cut out and protein was 
digested in-gel with trypsin. Peptides were extracted, precipitated and separated via capillary 
electrophoresis through an Easy nLCII liquid chromatography system, then analyzed in an Orbitrap 
Elite mass spectrometer.  Peptides were matched via the Proteome Discoverer 1.4 Suite against human 
Refseq 59 protein database applying a 1% peptide-spectrum-match and peptide-level false discovery 
rate.  Proteins were groups by domain structure based on DAVID GO term analysis and manual 
annotation from the UniProt database and visualized using Revigo software. 
STRING network analysis 
Proteins that immunoprecipitated with both UBQLN2 (our study) and G3BP under sodium arsenite 
stress (Jain et al., 2016), as a representative of SGs, were identified using the vlookup function in Excel. 
Network analysis was performed using the publicly available STRING tool (Szklarczyk et al., 2015). 
All proteins from the UBQLN2 SILAC analysis with H/L  1.5 or no detected ratio with more than 
one peptide were included in the analysis. Proteins were clustered using an mcl clustering value of 3, 
and a “high confidence” network association level of 0.7.  For completeness, I included hnRNPA1 as 
another SG protein that interacts with UBQLN2 as previously identified (Gilpin et al., 2015). 
Immunofluorescence microscopy 
Cells grown on glass coverslips were simultaneously fixed and permeabilized to visualize UBQLN2 in 
SGs (Figure 2-4, Table 2-1). Coverslips were washed with PBS prior to blocking with 5% 
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Donkey/Horse serum in 0.25% Triton X-100 for 1 hr at room temperature or overnight at 4C. 
Primary antibody was incubated 3 hrs at room temperature or overnight at 4C and secondary antibody 
was incubated 2 hrs at room temperature in the dark. DAPI was diluted to 1 μg/mL with secondary 
antibody to label cell nuclei. Primary and secondary antibodies were diluted in a 3% BSA, 0.25% Triton 
X-100 solution.  Three washes for 5 min each were performed after primary and secondary antibody 
incubations at room temperature on an orbital shaker.  Coverslips were mounted with Prolong Gold 
mounting media (Molecular Probes) and allowed to cure 24 hrs at room temperature in the dark prior 
to imaging on a Leica SP8 scanning confocal microscope.  All solutions were buffered with PBS. Live 
cell images of FUS-GFP were taken on a Nikon fluorescent microscope. 
Colocalization Analysis 
Pearson’s R correlation coefficient analysis was performed using the Colocalization threshold plugin, 
Costes method in Fiji. 50 cells chosen were chosen at random and outlined with the polygon tool for 
analysis.  Data analysis was performed in GraphPad Prism. 
Percentage of cells with SGs analysis 
Cells were counted by DAPI stained nuclei by applying the Analyze Particle function in Image J to 
smoothed, automatically thresholded, MIPs of confocal z-stacks.  The number of cells with SGs was 
manually counted using the Counter plugin in ImageJ and data was graphed and analyzed in GraphPad 
Prism. 
SG size distribution analysis 
To determine the SG size distribution in fixed cells, a maximum intensity projection (MIP) of each 
confocal image stack was created in Fiji to measure the cross-sectional area of SG particles. Images 
were automatically thresholded via the Renyi Entropy method and converted to binary images using 
the Threshold plugin in Fiji.  Particles in the binary image were then analyzed and added to the ROI 
manager using the Analyze Particles Plugin with a minimum particle size of 4 pixels and no limits on 
circularity. ROI’s were overlayed onto the original MIP and used to measure SG area. The fraction of 
cells with SG area >1 um2 was calculated in GraphPad Prism. 4 fields were analyzed for each time 
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point.  Significance was calculated using a two-way ANOVA with the Sidak’s method of multiple 
comparisons. 
Prion-like amino acid composition analysis (PLAAC) 
Analysis of prion-like domains in UBQLN2 was performed using a hidden Markov model on the MIT 
resource (http://plaac.wi.mit.edu/Accessed September 6, 2017) (Alberti et al., 2009; Lancaster et al., 
2014). A default core length of 60 amino acids and a relative weighting of background probabilities α 
of 50 (meaning 50% yeast, 50% human composition bias) was used for this analysis.   
Statistical analysis 
All statistical analysis for cell data was performed in GraphPad Prism 7.  Column data was analyzed by 
a standard one-way ANOVA with Dunnett’s method of correction for multiple paired comparisons. 
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FIGURES & TABLES 
 
Figure 2-1 SG components immunoprecipitate with UBQLN2 
(A) Schematic of SILAC coIP LC-MS/MS analysis. Heavy isotope labelled stable HEK293T cell lines 
that inducibly express amino-terminal FLAG-UBQLN2 were treated with doxycycline and lysed 
in buffer containing the detergent CHAPSO. Light isotope labelled HEK293T cells treated with 
doxycycline were used as a control. Lysates were incubated with FLAG M2-magnetic beads and 
eluted with FLAG peptide.  Eluants were pooled in a 1:1 ratio and separated by SDS-PAGE. 
Bands were cut out and proteins were digested with trypsin. Peptides were then extracted, 
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separated via nano-scale liquid chromatography (nLC), and injected via electrospray ionization into 
an LTQ Orbitrap Elite mass spectrometer for analysis. 
(B) Representative silver stained gel of UBQLN2 CHAPSO IP.  The red arrow points to exogenously 
expressed FLAG-UBQLN2 protein. 
(C) Cumulative frequency distribution of SILAC Heavy (UBQLN2)/Light (Control) (H/L) ratios 
from LC-MS/MS analysis of proteins that coimmunoprecipitate with FLAG-UBQLN2. 26 known 
interactors are shown in a separate category.  A total of 240 putative novel interactors were 
identified, many of which cluster into complexes as shown in (E) for SG components.  
(D) Classes of UBQLN2 interactors grouped by domain structure. 
(E) STRING network of UBQLN2 interactors found in the G3BP-dependent SG Proteome (Jain et 
al., 2016). Dotted lines represent lower confidence connections, whereas solid lines represent 
higher confidence connections. Members represented in the four clusters include I hnRNPs, II 
molecular chaperones, III translation factors and IV RNA trafficking proteins. I focused further 





Figure 2-2 Western blot validation of SILAC nLC-MS/MS top results 
(A) SILAC LC-MS/MS data for highly enriched UBQLN2 associated proteins. SILAC ratio is the 
HEAVY (UBQLN2 IP)/LIGHT (CONTROL IP) peptide average ratio. * indicates that a 
corresponding light peptide was not identified by peptide search software. Peptides are the number 
of Peptide-Spectrum-Matched Hits. Intensity is the integrated precursor ion peak density. 
(B) Western blot of proteins coimmunoprecipitated with FLAG-UBQLN2 or its paralog UBQLN1 
from HEK293T cell lysate.  The Control is FLAG-GUS (β-glucuronidase derived from plants).  
Hsp70 was the only strong interactor that immunoprecipitated only with UBQLN2.  Validation of 




Figure 2-3 UBQLN2 localizes to SGs 
(A) Immunofluorescence (IF) images of endogenous UBQLN2 at SG in response to sodium arsenite 
stress (30 min, 0.5 mM NaAsO2) in HeLa cells. G3BP marks SG.  Regions of UBQLN2-G3BP 
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overlap are yellow.  Specific depletion of UBQLN2 eliminates the UBQLN2 signal and regions of 
overlap. Ctrl shRNA is a scrambled non-targeting shRNA. 
(B) Western blot of average endogenous UBQLN2 protein level depletion 96 hrs post-shRNA 
transfection of the cells shown in (B). β-actin is a loading control. 
(C) Scatter plot showing the Pearson’s R coefficient of overlap for 50 individual cells chosen at random 
(dots) between the G3BP (green) and UBQLN2 (red) signal shown in (A). Error bars are 1 SD. 
**** p<0.0001 by Dunnett’s multiple comparison test done with a one-way ANOVA.  UBQLN2 
(-) represents the partial shRNA depletion of UBQLN2 shown in (B). The UBQLN2 signal in SGs 
appears specific based on this analysis.   
(D) IF images of UBQLN2 localization under different stress conditions. HeLa cells were fixed and 
permeabilized simultaneously as shown in (A).  Stress conditions include: 0.5 hr 0.5 mM NaAsO2, 
1 hr 43.7C Heat Stress, 1.5 hr 1 μM CCCP in Glucose free media, 1hr 10 μM MG132. 
(E) IF images showing localization of UBQLN2 to SGs with differing morphologies and localization 
after 30 min of heat stress at 43.7C. G3BP SG distribution is i) diffuse ii) concentrated but not 






Figure 2-4 Visualization of endogenous UBQLN2 at SGs is enhanced by simultaneous 
fixation and permeabilization. 
Immunofluorescence images of HeLa cells exposed to heat stress at 43.7C for 45 min prior to fixation.  
See Methods section for details of individual fix/permeabilization protocols. Graphs to the right are 
line scans of fluorescence intensity.  Intensity is the grey scale value.  Distance is distance along the 
line. UBQLN2 colocalization with SG is visible under all fix/stain conditions except MeOH alone, but 






Figure 2-5 Other PQC factors visible in SGs with simultaneous fixation and 
permeabilization 
Immunofluorescence images of other putative SG components in U2OS cells following 2 hrs 0.5 mM 
NaAsO2 treatment. Cells were fixed and permeabilized simultaneously. TCP1 (TriC), VCP, and Hsp70 
(Hsp72, Hsc70) were identified as putative SGs in the SG Proteome. White arrows point to regions of 
overlap.  *Marks Hsc70 puncta that do not overlap with SG marker TIA-1. Either G3BP or TIA-1 






Figure 2-6. Related Ubl/Uba proteins like UBQLN2 not found in SGs 
(A) Domain maps of UBQLN2, BAG6, and p62/SQSTM1 highlighting UBQ (ubiquitin-like) and 
UBA (ubiquitin-associated) domains in orange generated by SMART (Schultz et al., 1998). PB1 is 
another type of Ubiquitin-like domain. Low complexity regions are shown as grey rectangles. Only 
UBQLN2 contains the predicted STI1-like repeats in grey. The domains were drawn to scale. 
(B) Immunofluorescence images of U2OS cells following 2 hrs 0.5 mM NaAsO2 treatment after 
simultaneous fixation and permeabilization as described. White arrows point to regions of overlap.  
Either G3BP or TIA-1 was used as a SG marker depending on the species of the other antibody 








Figure 2-7 UBQLN2 localizes to SGs under many different stresses 
Immunofluorescence images of fixed HEK293T cells. HEK293T cells were treated with the stressor 
indicated for 2 hrs prior to fixation. Concentrations of each stressor used were as follows: 0.5 mM 
NaAsO2, 0.2 M NaCl, 0.4 M Sorbitol, 0.2 mM H2O2. Colocalization of UBQLN2 and SG marker TIA-
1 is seen as white pixels. SG formed under the different stress conditions have different morphologies, 






Figure 2-8 UBQLN2 localizes to SGs in different cell types 
Immunofluorescence images of fixed cells. Cells were treated with 0.5 mM NaAsO2 for 2 hrs prior to 
fixing and permeabilizing simultaneously. Overlap of UBQLN2 and the SG marker TIA-1 is shown as 






Figure 2-9 UBQLN2 localization to SGs changes over time 
(A) Immunofluorescence (IF) images of HeLa cells exposed to acute heat stress (43.7C) fixed at the 
time points shown. Overlap between UBQLN2 (red) and SG marker G3BP (green) is shown as 
yellow pixels. UBQLN2 colocalization with SGs changes as SG morphology and localization 
changes. 
(B) Scatter plot showing the Pearson’s R coefficient of overlap for G3BP (green) and UBQLN2 (red) 
for 50 individual cells with SGs (open circles) of each cell type after 30 min of heat stress at 43.7C 
as in (A). Error bars are 1 SD from the mean. **** p<0.0001 by Tukey’s multiple comparison test 
done with a one-way ANOVA p<0.0001.   
(C) Bar graph showing the proportion of each cell type present in the cell population from four 246 







Figure 2-10 UBQLN2 is in SGs not P-bodies 
Immunofluorescence images. Single channel images of the 5x magnified region are shown to the right 
of the full-scale image to the left. Cells were exposed to 30 min of heat stress at 43.7C prior to 
simultaneously fixing and staining. G3BP marks SG and 4E-T marks P-bodies.  White arrows mark 
juxtaposed SGs and P-bodies. UBQLN2 depletion in the bottom panel eliminates the UBQLN2 signal 
colocalizing with G3BP as in Fig. 1A. UBQLN2 only appears to colocalize with SGs when P-bodies 





Figure 2-11 The Sti1-like linker alone is sufficient for UBQLN2 localization to SGs 
(A) Prion-like domain (PrD) analysis of UBQLN2. The dotted line highlights the bounds of the linker 
region tested in (B). Identified PrD 1 is amino acids 105-143. PrD 2 is amino acids 338-460 of 
human UBQLN2. 
(B) Scatter plots showing the Pearson’s R coefficient of overlap between FLAG-tagged proteins 
(magenta) with SG marker TIA-1 for 50 individual cells (open circles) chosen at random.  FLAG-
tagged proteins were expressed from an integrated FRT site in HeLa Flp-In TRex cells and 
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exposed to 60 min of heat stress at 43.7C. Error bars are 1 SD from the mean. **** p<0.0001, 
***p=0.0006 by Dunnett’s multiple comparison test. 
(C) Representative immunofluorescence images of HeLa Flp-In TRex cells expressing FLAG-tagged 




Figure 2-12 UBQLN2 levels negatively regulate SG assembly 
(A) Immunofluorescence (IF) maximum intensity projections (MIPs) of SGs in Mock, FLAG-
UBQLN2 wild type (WT), FLAG-UBQLN2 P497H, and FLAG-UBQLN2 P506T transfected HeLa 
cells fixed and stained before and after heat stress. TIA-1 was used as a SG marker. A Western blot 
showing the level of UBQLN2 WT and mutant overexpression is shown in (B). β-actin is used as 
loading control.  
(C) Quantitation of percentage of cells with SGs larger than 1 μm shown in (A). 
(D) IF MIPs of SGs in control and UBQLN2 specific shRNA treated HeLa cells before and after heat 
stress. G3BP was used as a SG marker with DAPI marking nuclei of individual cells.  A Western blot 
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showing the level of UBQLN2 depletion by the two UBQLN2 specific shRNAs is shown in (E). 
Approximately double the number of UBQLN2 shRNA depleted cells show large cytoplasmic SGs 
after 30 min of heat stress. 
(F) Quantitation of percentage of cells with SGs larger than 1 μm shown in (D). 
 ****p<0.0001 ***p<0.001, **p<0.01, *p<0.05; P values are for Sidak’s multiple comparison tests. A 
representative data set is shown. More than 400 cells from 4 fields of view were imaged and averaged 
at each time point. Error bars are SD. The experiments were repeated using both G3BP and TIA-1 






Figure 2-13 UBQLN2 affects SG size among UBQLN2 shRNA treated cells 
(A) A representative confocal immunofluorescence image of UBQLN2 shRNA transfected HeLa cells 
after 30 min of heat stress (43.7C). Dotted lines outline cells with a higher UBQLN2 expression 
level. 
(B) Quantitation of (A). Cell numbers were quantitated from four fields totaling more than 400 cells 
at each time point.  The experiment was repeated twice.  A standard two-way ANOVA. P value 
for the effect of brightness was 0.0006. The results of Sidak’s multiple comparisons are shown as 
**** p<0.0001, **p<0.01, ns=not significant. Error bars are SEM.  In cells with higher UBQLN2 






Figure 2-14 UBQLN2 depletion leads to an increase in SG size and number 
(A) Histogram of SG particle size. 
(B) Graph of fraction of large SGs >1μm2.  
(C) Graph of number of SGs per cell. 
This data represents further analysis of data presented in Fig. 2-8 (D)-(F). Four fields with more than 
400 fixed HeLa cells were imaged for each condition. A representative data set is shown. A standard 
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two-way ANOVA was performed for (B) p=0.0012 and (C) p=0.0221 for the effect of UBQLN2 level 
respectively. All error bars are SD.  ***p<0.001, **p<0.01, *p<0.05, ns not significant (p>0.05) for 







Figure 2-15 G3BP and TIA-1 levels are not perturbed by UBQLN2 depletion 
Western blot showing levels of G3BP and TIA-1 46, 69 and 93 hrs post-transfection of HeLa cells.  
After 46 hrs post-transfection, the majority of UBQLN2 has already been depleted.  Levels of G3BP 







Figure 2-16 eIF2 phosphorylation is unaltered by UBQLN2 depletion 
Representative Western blot showing Ser51 phosphorylated and total eIF2 levels during heat stress 
as indicated relative to UBQLN2 level.  Results from at least three independent experiments are 
quantitated in (B) and (C). Error bars are SD. ns = not significant for Sidak’s multiple comparison 
tests, significance level was set at 0.05.  Results were analyzed by 2-way ANOVA with P=0.1692 for 





Table 2-1 Fixation/permeabilization techniques used for immunofluorescence staining 
 
 
Time and temperature for each condition is listed.  Each step was performed sequentially from left to 
right. In Methods 1 and 2 fixation and permeabilization were performed simultaneously. Method 2 is 
a harsher variation of Method 1. In Method 3, cells were fixed with PFA, then permeabilized with 
TX100 sequentially. In Method 4, cells were sequentially fixed with PFA then proteins were 
precipitated with MeOH. In Method 5 cells were permeabilized and proteins were precipitated 
simultaneously with MeOH. Method 1 was adapted from (Guzzo et al., 2012) and Method 4 from 
(Kedersha and Anderson, 2007). All fix/perm solutions were buffered with PBS. TX100=Triton X-
100, PFA=Paraformaldehyde, MeOH=Methanol, r.t.=room temperature, ice cold=4C to -20C. 




Chapter 3 UBQLN2 modulates ALS/FTD-linked FUS-RNA complex 
dynamics and SG formation 
INTRODUCTION 
Based on the localization and negative regulatory function of UBQLN2 at stress granules (SGs), I 
reasoned that UBQLN2 may physically interfere with the process of SG formation. To investigate the 
molecular mechanism of UBQLN2’s function, I thus focused on UBQLN2’s interaction with the 
highest ranked heterogenous ribonucleoprotein (hnRNP) from our proteomic analysis, FUS, which 
also has a well-established link to ALS/FTD (Table 3-1) and is present in inclusions in a large subset 
of ALS/FTD patients (Mackenzie et al., 2010). Over 40 mutations in FUS have been linked to 
ALS/FTD cases, including some of the most aggressive, juvenile-onset forms of the disease, in both 
familial and sporadic patients (Kwiatkowski et al., 2009; Vance et al., 2009). At the cellular level, FUS 
is an RNA binding protein (RBP) involved in the maintenance of genomic integrity, transcription, pre-
mRNA splicing, and microRNA regulation (Ishigaki and Sobue, 2018). It contains two amino terminal 
intrinsically disordered regions (QGSY-rich and Gly-rich) (Figure 3-2A) that allow it to form 
biologically functional complexes in the cell such as SGs, but also make it prone to aggregate. ALS-
linked mutations in FUS accelerate its recruitment to SGs in the absence of stress and the rate of 
formation of patient-associated inclusions (Patel et al., 2015). How FUS solubility is maintained in the 
cell and FUS functions in ALS/FTD pathology is still unclear.  
Here, I report a direct role for UBQLN2 in modulating FUS solubility during SG formation. 
Mechanistically, UBQLN2 increased the fluidity of ALS-linked mutant FUS-RNA complexes leading 
to an increase in the dispersion of FUS liquid droplets and suppression of FUS-seeded SGs. ALS-
linked mutations impaired the function of UBQLN2 in regulating RNP dynamics and SG formation. 
These results reveal a previously unrecognized role for UBQLN2 in directly modulating the early stage 




Note: The results presented here are given with minor modifications to fit the thesis format from the 
published manuscript: Alexander EJ, Niaki AG, Zhang T, Sarkar J, Liu Y, Nirogi RS, Pandey A, Myong 
S, and Wang J (2018) Ubiquilin 2 Modulates ALS/FTD-linked FUS-RNA Complex Dynamics and 
Stress Granule Formation. PNAS 115(49): E11485-E11494. 
 
RESULTS 
UBQLN2 forms a complex with FUS and suppresses its recruitment to SGs 
To confirm the interaction between UBQLN2 and FUS detected in our SILAC analysis (Figure 2-1), 
with help from postdoc Tao Zhang, I performed co-immunoprecipitation experiments with FLAG-
tagged UBQLN2 and V5-tagged FUS. FUS immunoprecipitated with FLAG-tagged UBQLN2 but not 
FLAG-tagged GUS control protein (Figure 3-1A). The introduction of an ALS-linked UBQLN2 
mutation, P497H or P506T, significantly decreased the interaction between UBQLN2 and FUS despite 
similar FUS protein expression level (Figure 3-1A, B). 
I then tested if UBQLN2 regulates the recruitment of FUS to SGs. I first developed a system in HeLa 
cells to monitor SG formation with a FUS-GFP construct which spontaneously forms SGs in a small 
percentage of cells in the absence of stress. I designed this C-terminally tagged FUS construct with a 
long linker (13 amino acids) between FUS and GFP to limit GFP interference with the FUS QGSY-
rich/Gly-rich intrinsically disordered region (Figure 3-2A). The carboxy-terminally tagged FUS-GFP 
spontaneously formed SGs in the absence of stress in a small percentage of cells (Figure 3-2B). 
UBQLN2 was co-transfected with FUS-GFP and its effects on SG formation were monitored. Under 
heat stress, FUS-GFP positive SGs robustly formed in cells with endogenous UBQLN2 levels (Figure 
3-1C, D). However, in cells in which UBQLN2 levels were elevated, there were significantly fewer 
large SGs present (Figure 3-1C, D), indicating that UBQLN2 interferes with FUS-GFP recruitment to 
SGs. These data are consistent with the observation that UBQLN2 negatively modulates large SG 
formation (Chapter 2). 
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Next, in collaboration with the Myong lab, I asked if UBQLN2 affects the formation of FUS-RNA 
complexes in an electromobility shift assay (EMSA). Monomer FUS formed a discreet complex with 
polyurdine-50 (polyU50) RNA (Figure 3-1E). Increasing the FUS protein concentration from 5 nM to 
500 nM caused the probe signal to shift to a higher molecular weight position corresponding to FUS 
multimer. The Myong lab then added native purified UBQLN2 protein (Figure B-4) to test the effect 
of UBQLN2 on FUS-RNA complex formation. At a 500 nM concentration of FUS, UBQLN2 
supershifted the FUS-RNA complex. Since UBQLN2 does not bind the RNA probe (Myong lab, 
personal communication), this result indicates that UBQLN2 can form a complex with FUS protein 
in the presence of RNA. Furthermore, increasing concentrations of UBQLN2 protein freed RNA from 
the FUS-RNA monomer complex and FUS monomer from the FUS-RNA multimer complex (Figure 
3-1E), suggesting that by binding to FUS, UBQLN2 can disrupt FUS-RNA complex formation.  
Because FUS-RNA complex formation mediates the partitioning of FUS into and out of stress 
granules, these observations also suggest that UBQLN2 could mediate FUS SG formation by 
modulating FUS-RNA complex formation. 
UBQLN2 promotes ALS-linked FUS-RNA complex dynamics 
Next, we asked if UBQLN2 could affect the dynamics of individual FUS-RNA complexes. Based on 
our observation that UBQLN2 freed RNA from the FUS-RNA monomer complex and FUS-RNA 
monomer from the FUS-RNA multimer complex, we expected that UBQLN2 would decrease the 
stability of FUS-RNA complexes formed.  To test this hypothesis, we employed a single molecule 
fluorescence resonance energy transfer (smFRET) assay to measure the dynamics of FUS-RNA 
complex assembly by tracking the RNA conformation.  FUS binding to single stranded RNA perturbs 
RNA conformation in a concentration dependent manner (Figure 3-3B, panel 1-3). The Förster 
resonance energy between a Cy3 and Cy5 tag on opposite ends of a stretch of single stranded 
polyuridine (polyU) RNA was measured using a total internal reflection (TIRF) microscope (100 msec 
resolution). Addition of FUS to the RNA changes the distance between the Cy3 and Cy5 tags reflected 
by the FRET ratio change and alters the stability of the RNA conformation reflected by the FRET 
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fluctuation (Sarkar and Myong, 2018). We expected that addition of UBQLN2 protein would increase 
the static interaction of FUS Gly-rich region mutant R244C with RNA. In the absence of FUS, the 
RNA probe exhibited a steady low FRET signal due to the Cy3-Cy5 dye separation by polyuridine 50 
(pU50) (Figure 3-3B, C panel 1). The addition of FUS R244C at high concentration (1 μM) resulted in 
a nearly static FUS-RNA interaction (Figure 3-3B, C, panel 3) in greater than 85% of molecules (Figure 
3-3D, 0 min). Addition of wild type UBQLN2 to this complex, consistently shifted its dynamics from 
static to dynamic. Within 5 min of UBQLN2 addition, the proportion of dynamic molecules increased 
from 18% to 55% (Figure 3-3D, 5 min). After 40 min, nearly 65% of molecules were classified as 
dynamic (Figure 3-3D, 40 min). However, not only did the number of dynamic molecules increase but 
also the frequency of the FRET fluctuation among those dynamic molecules. Analysis of 300 time 
intervals between FRET peaks from over 100 single molecules revealed that between 5 and 20 min the 
time constant, τ, for the exponential decay fit decreased from approximately 10 sec down to 1 sec 
(Figure 3-3E). This change in dynamics indicates that UBQLN2 is able to increase the dynamics of 
FUS mutant interaction with RNA over time decreasing complex stability consistent with our EMSA 
results showing that UBQLN2 frees RNA bound FUS from soluble FUS complexes. 
The FUS-bound RNA FRET ratio reflecting the conformation of the complex was also altered by 
addition of UBQLN2. At this high FUS concentration (1 μM), two populations of high and 
intermediate FRET signal molecules exist. The intermediate FRET signal represents RNA bound to 
soluble multimerized FUS, whereas the high FRET signal represents RNA bound to higher order 
insoluble FUS. Addition of UBQLN2 to this complex lead to a decrease in the intermediate FRET 
signal, between 5 and 20 min (Figure 3-3C, panel 3-6) on the same time scale that we saw an increase 
in FUS dynamics (Figure 3-3B, panel 3-6). The high FRET signal was unaltered by UBQLN2 addition. 
This shift suggests that UBQLN2 dissociates soluble FUS-RNA complexes.  UBQLN2 was unable to 
alter the insoluble FUS-RNA complex composition. These data are consistent with the conclusion that 
UBQLN2 alters the dynamics of FUS-RNA complex formation during the early stages of liquid-liquid 
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phase separation, shifting the equilibrium of FUS into the soluble rather than the granular phase of the 
cytoplasm.  
Furthermore, in contrast to WT UBQLN2, P497H and P506T mutant UBQLN2 failed to restore 
mutant FUS dynamics, with only 10%, 30% of molecules showing dynamic single molecule FRET 
signals, respectively (Figure 3-3B panel 7,8, D). This failure to affect FUS-RNA complex assembly 
dynamics indicates a partial compromise of UBQLN2 function conferred by these ALS-linked 
mutations. 
UBQLN2 suppresses FUS liquid-liquid phase separation 
The dynamics of RBP-RNA complex formation directly impact the liquid-liquid phase separation of 
RBPs into liquid droplets (Sarkar and Myong, 2018). The dynamic interaction of WT FUS with RNA 
leads to the formation of smaller liquid droplets. In contrast, the static interaction of FUSR244C with 
RNA leads to the formation of large liquid droplets. Based on the finding that UBQLN2 increased 
FUS-RNA complex dynamics, we hypothesized that UBQLN2 addition would result in a decrease in 
FUS residence time in phase separated droplets and thus a decrease in the effective size of those 
droplets. To study the function of UBQLN2, we performed a FUS liquid droplet assay by mixing 
FUSR244C protein and partially Cy3-labelled pdU40 RNAs with or without UBQLN2. TEV protease 
was added to cleave off the MBP solubility tag from FUS to trigger the formation of liquid droplets 
and fluorescent images were taken at regular time intervals after protease digestion to monitor the size 
and number of the droplets. Within a period of 20 hrs, FUSR244C-RNA droplets formed and increased 
in both quantity and size. When UBQLN2 was present, the FUSR244C-RNA droplets formed were 
smaller in size but more numerous compared to those formed in the absence of UBQLN2 (Figure 
3-4A, B quantitated in (Figure 3-4C, D). Notably, the FUSR244C-RNA droplets in the absence of 
UBQLN2 displayed non-spherical irregular patterns whereas those in the presence of UBQLN2 
remained highly spherical over the entire time course. These non-spherical irregular droplets may 
represent the transition from the reversible liquid-like phase separated state of FUS to a more stable 
solid state of FUS. Taken together, these results suggest that UBQLN2 is able to prevent this liquid to 
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solid transition by increasing the FUS-RNA complex formation dynamics that underly FUS phase 
separation. This activity is consistent with the negative regulatory role that UBQLN2 plays in SG 
formation in suppressing large stress granule formation by increasing the dynamics of FUS recruitment 
into and out of SGs. 
 
DISCUSSION 
In this chapter, I demonstrate a previously unrecognized role for UBQLN2 in modulating the dynamics 
of SG formation. In the case of FUS highlighted here, UBQLN2 complexes with FUS, directly acts to 
promote the dynamics of FUS-RNA complexes and decrease the effective rate of FUS phase 
separation into liquid droplets thereby suppressing FUS SG formation. Mutations in UBQLN2 impair 
FUS binding, resulting in loss of UBQLN2’s ability to regulate the dynamics of FUS-RNA complexes 
and SG formation. These results expand understanding of UBQLN2 function and provide a direct link 
between protein and RNA homeostasis in normal stress responses and the pathogenesis of ALS/FTD. 
These findings reveal that UBQLN2 has the capacity to chaperone RBPs independently of its 
previously established roles in mediating protein clearance. UBQLN2 promotes the dynamics of FUS-
RNA complexes with the effect of maintaining FUS solubility.  This solubilizing effect results in the 
suppression FUS liquid droplet growth consistent with the role of UBQLN2 in negatively regulating 
SG formation and presumably the transition from a fluid to a solid, stable state. This function is 
reminiscent of the chaperone function of UBQLN2 in maintaining the solubility of transmembrane 
mitochondrial precursor proteins (Itakura et al., 2016) except that instead of interacting with the 
hydrophobic transmembrane domain of the mitochondrial precursor proteins, UBQLN2 may interact 
with the hydrophobic low complexity region of FUS that mediates its oligomerization. UBQLN2’s 
effect on FUS phase separation most resembles the recently described role of the small molecule ATP 
acting as a biological hydrotrope (Patel et al., 2017). Like the recently described karyopherin 
Transportin 1/Karyopherin β2 UBQLN2 also phase separates itself, which has been attributed to the 
74 
 
second set of Sti1-like repeats in UBQLN2 (Dao et al., 2018). However, as I have shown (Chapter 2), 
UBQLN2 itself does not drive SG formation like other proteins with PrD domains, but rather acts as 
a factor that antagonizes the recruitment of SG components to SGs. These observations represent a 
potentially unrecognized mode of action for low complexity PrD-like proteins in SG formation. 
Previously described SG regulation has focused on regulation of levels of individual SG components, 
posttranslational modifications of SG components, and SG disaggregation through PQC mechanisms 
(Buchan et al., 2013; Ganassi et al., 2016; Goulet et al., 2008; Jain et al., 2016; Jayabalan et al., 2016; 
Kedersha et al., 2016; Ohn et al., 2008; Seguin et al., 2014). Our proteomic analysis shows that 
UBQLN2 associates with many of the PQC factors including Ubiquitin, Hsp70, VCP, and TriC (Table 
S1), suggesting that UBQLN2 may cooperate with other PQC factors in SG regulation. However, in a 
mechanism that is not mutually exclusive, our present study has demonstrated a distinct way that 
UBQLN2 directly influences the dynamics of protein-RNA complexes in the early stages of SG 
formation (Figure 3-5). Together, these findings expand our understanding of different modes of SG 
regulation.  
The results indicating that ALS/FTD-linked mutations in UBQLN2 (P497H and P506T) dampen 
UBQLN2’s association with FUS and thus impair the ability of UBQLN2 to regulate FUS-RNA 
interaction dynamics and SG formation, suggest that these processes may underlie the pathogenesis of 
ALS/FTD. FUS is one of a number of heterogenous ribonucleoproteins (hnRNPs) including EWS, 
hnRNPA1 and hnRNPA2/B1 associated with ALS/FTD that I isolated in my proteomic screen that 
contain low complexity flexible regions which impart the ability to phase separate, but also to aggregate. 
FUS have been reported to increase the propensity of these hnRNPs to collect in SGs, disrupting SG 
function as an adaptive stress response (Patel et al., 2015). Increased residence of hnRNPs in SGs may 
be directly linked to formation of abnormal SGs prone to form the pathological inclusions found in 
ALS/FTD patients. UBQLN2’s function to maintain the fluidity of FUS-RNA interactions suggests 
that UBQLN2 is an intrinsic factor that protects against aberrant SG formation and subsequent disease 
pathology. I have shown that the relative level of UBQLN2 to SG components directly impacts the 
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rate of growth of large cytoplasmic SGs. Because ALS-linked mutations in UBQLN2 impair its 
interaction with hnRNPs or its function in maintaining hnRNP-RNA complex fluidity, the mutations 
could compromise the intrinsic ability of UBQLN2 to protect against aberrant SG formation and 
subsequent disease pathology. 
This protective effect is consistent with previous reports that increasing the expression of UBQLN2 
or its family members protects against the toxicity of a variety of neurodegeneration-related proteins, 
including amyloid-, polyQ repeats, and TDP-43 (Adegoke et al., 2017; Hanson et al., 2010; Safren et 
al., 2015). Collectively, the present study results reveal that UBQLN2 directly regulates the early stages 
of SG formation and suggest it has a critical cytoprotective role at the junction of protein and RNA 




UBQLN2 wild type, mutants, and fragments along with GUS, and FUS wild type and mutant were 
cloned into pENTR221 to introduce UBQLN2 into pcDNA3.1-CMV/TO-n3xFLAG-UBQLN2-
TetR-IRES-PuroR DEST, GUS into pcDNA3.1-CMV/TO-n3xFLAG and FUS into pcDNA6.2-
emGFP and pcDNA3.1_CMV_cV5 via Gateway cloning (ThermoFisher, Waltham, MA). For E. coli 
expression, UBQLN2 was cloned into the SspI cut pET-6xHis-GFP-LIC from Addgene via Gibson 
assembly.  
Cell Culture 
HeLa cells were cultured in DMEM with 10% Fetal Bovine Serum (FBS). at 37C in an atmosphere of 
5% CO2 in standard circular tissue culture dishes.  Cells were transfected with lipofectamine 2000 
(Thermo-Fisher) in Opti-MEM reduced serum media, halving the manufacturers recommended 
volumes and following the manufacturer’s protocol. Opti-MEM was replaced with DMEM with 10% 





Antibodies for Western blotting and Immunocytochemistry 
Rabbit anti-UBQLN2 (Sigma HPA0006431) was used to specifically detect UBQLN2 via 
immunofluorescence (Figure B-1). Goat anti-TIA-1 (Santa Cruz, C-20) was used to detect SGs. Mouse 
anti- DYKDDDDK (Sigma F3165) was used to detect FLAG constructs by Western blot.  FUS-V5 
was detected by mouse anti-GKPIPNPLLGLDST (Invitrogen R960-25) by Western blot and FUS-
GFP by mouse anti-GFP (Invitrogen A11120) by ICC. Mouse anti--actin (Santa Cruz, C4) was used 
as a loading control for Western blots. Secondary antibodies Donkey anti-goat IgG-Alexa fluor 647 
nm, Donkey anti-mouse IgG-Alexa flour 488 nm, and Donkey anti-rabbit IgG-Alexa fluor 555 nm 
(Invitrogen) were used for 3 color immunofluorescence staining. Secondary antibodies Goat/Donkey 
anti-mouse IgG and anti-rabbit IgG-800CW and 680LT pair were used for two color Odyssey Western 
blots (Licor). 
SDS-PAGE and Immunoblotting 
Cell lysates were collected in 1% CHAPSO [3-([3-Cholamidopropyl]dimethylammonio)-2-hydroxy-1-
propanesulfonate], 50 mM HEPES pH 7.9, 150 mM NaCl, 2 mM EDTA supplemented with 1x 
Protease Inhibitor Cocktail (Sigma P8340) and 0.2 mM Na3VO4 and sonicated using a Diagenode 
Bioruptor 5 min (high setting, 30 sec pulse, 5 min) prior to spinning at 20,000 x g at 4C. In our 
experience, ubiquilin protein separated well on an 8% isocratic Tris-Gly SDS-PAGE gel with 4% 
stacking gel at 65V or TGX Criterion 4-20% gradient gel at 85V (Bio-rad). Protein was transferred to 
0.2 μm nitrocellulose membrane via Bio-rad Turboblot transfer (25V, 1.3 Amp, 12-15 min), the 
membrane was blocked with 5% Milk/TBS-T (20 mM Tris pH 7.6  0.1, 150 mM NaCl, 0.1% Tween 
20), and then incubated with primary antibody in 5% BSA, TBS-T, 0.03% sodium azide solution at 
4C.  Secondary antibodies Donkey anti-Mouse IgG-680LT or 800CW and Donkey anti-Rabbit IgG-
680LT or 800CW (Licor Biosciences, Nebraska, USA) at 1:10,000-1:20,000 in milk were used to detect 
primary antibody. An Odyssey scanner (Licor Biosciences, Nebraska, USA) equipped with 700 nm and 





Cells grown on glass coverslips were simultaneously fixed and permeabilized to visualize UBQLN2 in 
SGs (Figure 2-5., Table S2). Coverslips were washed with PBS prior to blocking with 5% 
Donkey/Horse serum in 0.25% Triton X-100 for 1 hr at room temperature or overnight at 4C. 
Primary antibody was incubated 3 hrs at room temperature or overnight at 4C and secondary antibody, 
2 hrs at room temperature in the dark. DAPI (4′,6-diamidino-2-phenylindole) was diluted to 1 μg/mL 
with secondary antibody to label cell nuclei. Primary and secondary antibodies were diluted in a 3% 
BSA, 0.25% Triton X-100 solution.  Three washes for 5 min each were performed after primary and 
secondary antibody incubations at room temperature on an orbital shaker.  Coverslips were mounted 
with Prolong Gold mounting media and allowed to cure 24 hrs at room temperature in the dark prior 
to imaging on a Leica SP8 scanning confocal microscope.  All solutions were buffered with Phosphate 
buffered saline (PBS) (8 mM Na2HPO4, and 2 mM KH2PO4, 137 mM NaCl, 2.7 mM KCl, pH 7.4  
0.1). Live cell images of FUS-GFP were taken on a Nikon fluorescent microscope. 
FUS-UBQLN2 Coimmunoprecipitation 
A doxycycline-inducible FLAG-UBQLN2 and a FUS-V5 construct were co-transfected into 
HEK293T cells at a molar ration 1:1. 24 hrs later, cells were harvested in lysis buffer (50 mM Tris-HCl 
(pH 7.5), 150 mM NaCl, 0.4 mM EDTA, 1% NP-40, 0.05% sodium deoxycholate, and complete 
protease inhibitor cocktail (Roche 11836153001)) and 200 μL of the cell pellet was sonicated 5 min on 
high power in 30 second intervals in a Diagenode Bioruptor on ice. Cell debris was pelleted at 20000 
x g, 10 min at 4C and the supernatant was loaded onto anti-Protein A/G magnetic beads pre-
equilibrated with anti-FLAG (M2) antibody (Sigma F3165) and incubated overnight at 4C. The beads 
were washed five times with lysis buffer and protein eluted via low pH buffer (Pierce IgG Elution 




Native UBQLN2 Purification: UBQLN2 wild type and P497H, P506T mutants were purified from E. 
coli as 6xHis-GFP-TEV-UBQLN2 by NiNTA chromatography. TEV protease cleavage of the fusion 
protein resulted in two amino acid residues upstream of the initiator methionine residue (Ser-Ile). This 
product was further purified by collecting and concentrating the flow through passed back over freshly 
cleaned NiNTA beads.  This product was injected into a size exclusion column then spin concentrated 
in a 50 MWCO centrifugation column (Amicon) before flash freezing aliquots in liquid nitrogen.  This 
optimized purification method is described in detail in Appendix B (Figure B-4). 
FUS Purification: GST-FUS and GST-FUSR244C were purified for the EMSA assay as described in 
(Zhang et al., 2018b). FUSR244C was purified for the smFRET assay as a 6x-His-FUS monomer from 
E. coli [BL21DE3] also described in (Zhang et al., 2018b). Briefly, the His tagged protein was purified 
by NiNTA affinity chromatography (HisTrap) followed by size exclusion chromatography and stored 
in buffer containing 1 M KCl and 1 M urea to prevent aggregation.  MBP-TEV-FUS was purified for 
the liquid droplet assay as described in (Burke et al., 2015).  
Electromobility Shift Assay (EMSA) 
Sample was prepared by mixing 0.5-1 nM of Cy3-Cy5 dual-labelled RNA probe (used in smFRET 
experiments) with varying concentrations of proteins in a binding buffer containing 50 mM Tris-HCl 
pH 7.5, 150 mM KCl, 2 mM MgCl2, 100 mM β-mercaptoethanol, and 0.1 mg/mL BSA. Samples were 
mixed with loading dye and run on a 6% DNA retardation polyacrylamide gel (Invitrogen). RNA 
mobility was visualized using a Typhoon scanner in fluorescent mode. 
Single Molecule Fluorescence Resonance Energy Transfer (smFRET) via TIRF microscopy 
A biotinylated RNA probe was immobilized on the surface of a PEG-coated quartz slide pretreated 
with 0.05 mg/mL Neutravidin. Purified FUS and UBQLN2 were added to the slide in imaging buffer 
(100 mM KCl, 20 mM Tris-HCl pH 7.5 with an oxygen scavenging system containing 1 mg/mL glucose 
oxidase, 0.5% glucose, and 88 U/mL catalase in 10 mM Trolox).  Single molecule FRET signals were 
then measured using a home-built Total Internal Reflection Fluorescent (TIRF) microscope equipped 
with an EMCC Andor camera. Cy3 (donor) and Cy5 (acceptor) dyes were used as FRET pairs excited 
79 
 
by a solid state 532 nm laser (Coherent CUBE, 75mW). Quantification of individual fluorescent spots 
in multiple imaging fields was then performed using custom IDL and MATLAB codes. Codes can be 
found at the Center for Physics of Living Cells website (https://cplc.illinois.edu/software). 
Liquid Droplet Assay 
1 µM MBP-FUS, 1 µM unlabeled 40 nucleotide long polyU RNA (U40), 4 µM UBQLN2, and 10 nM 
Cy3-labeled U40 were prepared in 50mM Tris-HCl pH 7.4, 100mM NaCl, 1mM EDTA, 1mM DTT 
buffer. TEV protease was added to cleave the MBP tag off of FUS. To visualize droplets, this mixture 
was added to the surface of an 8-well chambered coverglass (Nunc Lab-Tek) and imaged using a Nikon 
Ti Eclipse microscope equipped with a 100x oil immersive objective, 555 nM laser, a Cy3 emission 
filter and an EMCCD Andor camera in a 133 m2 field. Myong lab used intensity thresholding in order 
to mask and quantify the number and shape of the droplets by ImageJ.  
RNA probe preparation 
The following pairs of RNA oligos were annealed to prepare the RNA probes for the EMSA and 
smFRET experiments (1 and 2), and the liquid droplet experiments (1 and 3): 
1) 18-mer: 5’-biotin-UGG CGA CGG CAG CGA GGC-3’-amino modified;  
2) U50-18mer: 5’-amino modified-polyU(50)-GCC UCG CUG CCG UCG CCA-3’;  
3) U40: 5’-polyU(40)- UGG CGA CGG CAG CGA GGC-3’-amino modified.  
Amino modified RNA strands were end-labeled with Cy5 or Cy3 via NHS-ester-amine chemistry. 
Statistical analysis 
All statistical analysis for cell data was performed in GraphPad Prism.  Column data was analyzed by a 
standard one-way ANOVA with Dunnett’s method of correction for multiple paired comparisons. 
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FIGURES & TABLES 
Table 3-1 Table of hnRNPs in the SG proteome that immunoprecipitate with UBQLN2 
Gene symbol Accession Peptides Intensity SILAC Ratio
FUS NP_001164408.1 3 21,808,551 1.6
HNRNPA2B1 NP_002128.1 22 21,405,728 1.9
HNRNPA3 NP_919223.1 6 20,659,907 1.8
KHDRBS1 NP_006550.1 3 19,275,127 1.7
HNRNPK NP_112552.1 3 15,379,763 1.8
HNRNPE2 NP_001122386.1 8 13,417,898 1.9
IGF2BP1 NP_006537.3 5 11,938,355 1.7
EWSR1 NP_001156758.1 2 5,309,022 *
FAM120A NP_055427.2 1 914,165 1.7  
Protein and peptide false discovery rates were set at 1% for the Proteome Discoverer database search. 
Identified proteins were cross-referenced with the SG proteome using the vlookup function in Excel 
and sorted by intensity. This list contains 9 hnRNPs. FUS had the highest total precursor ion intensity. 
Peptides are the peptide spectrum matched hits. Intensity is the total integrated precursor ion 
intensity. SILAC Ratio is the average HEAVY (UBQLN2)/LIGHT (Control) peptide ratio. * 






Figure 3-1 UBQLN2 forms a complex with FUS and suppresses its SG formation 
(A) FUS-V5 immunoprecipitates with FLAG-UBQLN2 in HEK293T cells. UBQLN2 ALS-linked 
missense mutations P497H and P506T partially disrupt UBQLN2’s interaction with FUS. The 
FLAG-tagged plant reporter protein β-Glucuronidase (GUS) was used as a control. 
(B) Quantitation of WB shown in (A). The experiment was repeated twice and the average results are 
presented here. Error bars represent SD. **p<0.01 by Dunnett’s multiple comparison test. 
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(C) IF images of fixed HeLa cells cotransfected with FLAG-UBQLN2 and FUS-GFP.  Cells 
overexpressing FLAG-UBQLN2 are outlined.  UBQLN2 overexpression suppresses FUS-GFP 
SG formation in response to heat stress.  TIA-1 marks SGs. 
(D) Quantitation of G3BP cytoplasmic signal in 13 pairs of cells expressing just FUS-GFP or FUS-
GFP in the presence of FLAG-UBQLN2. **p<0.01 by a two-tailed student’s t-test. FLAG-
UBQLN2 overexpression suppresses FUS-GFP SG formation (marked by TIA-1) in response to 
heat stress (30 min, 43.7C). 
(E) Coomassie blue stained native PAGE gel of FUS-RNA and FUS-RNA-UBQLN2 electromobility 
shift. The RNA probe is Cy3 labelled polyU40. 5 nM FUS results in monomer FUS-RNA complex. 
whereas 500 nM FUS results in a shifted mobility multimer FUS-RNA complex.  Addition of 







Figure 3-2 C-terminal FUS-GFP Construct forms SGs spontaneously 
(A) FUS domain structure showing the position of the GFP tag placed on the C-terminus separated 
by a 13 amino acid (aa) linker to avoid interfering with the oligomerization of low complexity 
QGSY-rich and Gly-rich regions that drive SG formation. 
(B) Live brightfield and widefield fluorescence images of HeLa cells transfected with FUS-GFP 24 hrs 






Figure 3-3 UBQLN2 increases FUSR244C RNA Interaction Dynamics 
(A) Polyuridine 50 RNA probe design and sample static and dynamic single molecule (sm) traces 
showing the dwell time constant τ.  
(B) Representative traces showing the fluctuation of the FRET ratio for single molecules over time 
(Panel 1-8). FUS-m is the FUS mutant FUSR244C. 
(C) Histograms of single molecule FRET ratios for FUS-m mixed with pdU50 RNA (red) (Panel 1-3), 
FUS-m mixed with PdU50 in the presence of wild type UBQLN2 (Panel 4-6), and mutant UBQLN2 
P497H and P506T (cyan) (Panel 7, 8).  The grey arrow points to the FRET peak broadened and 
flattened by UBQLN2 addition. 
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 (D) Percentage of single molecules with dynamic vs. static smFRET ratios. More than 1000 traces 
were surveyed for this analysis. UBQLN2 mutant traces were collected between 20 and 40 min. Wild 
type UBQLN2 addition alters FUSR244C-RNA complex dynamics, while mutant UBQLN2 does to a 
lesser extent. 
(E) Dwell time (τ) of FRET fluctuation taken at 5, 20 and 40 min after addition of wild type UBQLN2 
to FUSR244C. 5 to 20 min after UBQLN2 addition the FRET fluctuation rate dramatically increases for 






Figure 3-4 UBQLN2 suppresses mutant FUS recruitment into phase separated droplets.  
(A) Phase separated droplets of FUSR244C mutants formed over 20 hrs. 
(B) Droplets of FUSR244C with UBQLN2 formed over 20 hrs. 
(C) Area of droplets taken over 20 hrs. Red and light blue indicate FUSR244C without and with 
UBQLN2 added respectively.  UBQLN2 addition leads to an increase in liquid droplet area. 
(D) Number of droplets per imaging area. UBQLN2 addition leads to a decrease in droplet number. 
(E) Circularity of droplets over 20 hrs. UBQLN2 addition leads to an increase in droplet circularity. 
(F) More than 400 droplets in 3-4 fields of view were used for this analysis.  All error bars shown are 







Figure 3-5 Model of UBQLN2 function in SG formation 
Illustration of UBQLN2’s negative regulatory role in the early stages of SG formation.  Orange spheres 
represent hnRNPs including FUS that can be recruited to SGs.  Black and white spheres represent 
other SG components as shown in Fig. 1E.  Grey ribbons are RNA.  The fluid liquid granule and rigid 
solid granule forms of SG assemblies represent different levels of complex fluidity that may exist within 
a single SG.  I show UBQLN2 in both the liquid and solid forms, because both WT and ALS-linked 
mutant UBQLN2 collect in patient inclusions, for which solid forms may serve as precursors.  Our in 
vitro and cell data show that UBQLN2 may promote exchange of FUS-RNA complex out of SGs to 




Chapter 4 Conclusions & Future Directions 
In this study, I have shown a cytoprotective role of the ubiquilin 2 (UBQLN2) protein in regulating 
the cell’s adaptation to stress at stress granules (SGs).  From a proteomic screen for UBQLN2 
interactors I identified an enrichment of SG components. Staining of fixed cells using an 
unconventional staining technique revealed that UBQLN2 is universally recruited to SGs and the Sti1-
like linker region of UBQLN2 is sufficient for this recruitment.  This recruitment however was 
transient, and mediated by UBQLN2’s association with soluble hnRNP-RNA complexes. Effectively, 
UBQLN2 limited the growth of SGs in the cytoplasm by increasing the dynamics of hnRNP-RNA 
interactions.  I focused on FUS as an ALS-linked hnRNP known to localize to SGs, but I expect that 
this regulatory function will broadly apply to other RNA binding proteins (RBPs) that I isolated in my 
proteomic study that rely on low complexity intrinsically disordered regions to phase separate into SGs. 
This mode of regulating SG assembly at the level of liquid-liquid phase separation has not previously 
been described.  Further investigation into UBQLN2’s mechanism of action in SG formation might 
be addressed by answering the following questions: 
• Does UBQLN2 function with other PQC components in SG assembly? 
• Does UBQLN2 mediate phase separation of other membraneless compartments in the cell? 
• Is UBQLN’s function in SG formation applicable to motor and/or hippocampal neurons? 
 
Other potential partners and functions of UBQLN2 in SG formation? 
The mechanism by which UBQLN2 regulates hnRNP incorporation into SGs is distinct among PQC 
factors described, but does not preclude its cooperation with other known PQC factors in SG 
homeostasis.  The two major protein degradation systems in the cell: the proteasome and 
autophagosome/lysosome machinery both reportedly disassemble SG components (Buchan et al., 
2013; Ganassi et al., 2016). Both the proteasome inhibitor MG132 and ubiquilin 2 depletion lead to a 
build-up of polyubiquitinated proteins in the cells, but MG132 alone is sufficient to induce SG 
formation (Mazroui et al., 2007), whereas UBQLN2 only sensitizes cells to stress induced granule 
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formation. Inhibition of autophagy both inhibits SG assembly and disassembly, although one report 
estimated that only 30% of SGs are degraded by autophagy (Ganassi et al., 2016), indicating that 
proteasomal degradation may be the dominant means of SG protein degradation.  
SGs are dynamic particles whose rapid dissolution following stress ensures that the cell can resume 
normal homeostasis.  Protein disaggregases play an important role in this process. The Hsp70 HSPA1A 
with the small heat shock protein HSPB8 and nucleotide exchange cofactor BAG3 is able to extract 
prematurely terminated transcripts (termed defective ribosomal products or DRiPs) from SGs (Ganassi 
et al., 2016) to sequester them away from SGs.  However, Hsp70 only colocalizes with abnormal SGs 
anchored by HSPB8 once DRiPs have accumulated or SGs have simply morphed into aggresomes.  
UBQLN2’s exclusion from perinuclear aggregates and universal recruitment to large cytoplasmic 
aggregates suggests that UBQLN2 and Hsp70 may be present in separate SG related compartments at 
least upon the initial onset of an acute stress.  VCP with its cofactors Ufd1 and Npl4 reportedly 
functions in SG disassembly (Buchan et al., 2013).  However, inhibiting or knocking down VCP inhibits 
SG assembly (Seguin et al., 2014) counter to UBQLN2 depletion enhancing SG assembly.  The 
deubiquitinating enzyme USP10 reportedly competes with caprin 1 to inhibit G3BP incorporation into 
SGs (Kedersha et al., 2016).  This negative regulatory role is consistent with ubiquilin 2’s role, but 
UBQLN2 in contrast to USP10 is recruited to SGs and binds hnRNPs.  I did find evidence that 
UBQLN2’s close homolog UBQLN1 may associate with G3BP (Table A-2), but I did not investigate 
this further.  Jain et. al. also suggested that the actin/tubulin TriC complex may negatively regulate SG 
formation (Jain et al., 2016), but this functional role is yet to be investigated. Both ubiquitin and the 
E3 ubiquitin ligases Roquin or MNAB (membrane-associated nucleic acid binding protein) 
(Athanasopoulos et al., 2010) and TRAF2 (Kim et al., 2005), and the unconjugated autophagy marker 
LC3B (Seguin et al., 2014) have also been seen at SGs, but their role is as yet uncharacterized 
(Athanasopoulos et al., 2010; Kim et al., 2005; Seguin et al., 2014).  Notably UBQLN2 precipitated all 
of these factors except the G3BP complex. I decidedly focused here on the function of UBQLN2 
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alone, but this study does not preclude that UBQLN2 could work in concert with any of these PQC 
factors. 
In all other contexts in the cell in which UBQLN2 has been identified, ubiquitin and/or ubiquitin 
receptors containing UIM domains are important to its function.  The role for UBQLN2 in modulating 
hnRNP fluidity might thus also be explored in the context Ubl and Uba domain function.  It will be 
important to determine if the Ubl and Uba domains alone can localize to SGs.  The Ubl alone is highly 
stable. The Uba domain is rarely visible by Western blot.  Tagging the Uba domain with a larger tag or 
its own Ubl domain with a short linker might actively stabilize it.  It will also be interesting to see if the 
linker from UBQLN1 and UBQLN4 which lacks the unique PXX repeats in UBQLN2 is also able to 
localize to SGs.  I saw that UBQLN1 and 4 are able to localize to SGs, but not under all of the same 
conditions as UBQLN2.  UBQLN1 and 4 depletion, unlike UBQLN2 also strongly induced eIF2 
phosphorylation, a marker for stalled translation initiation complexes indicating that they may have a 
distinct function in SG formation.  Recently it was shown that the second set of mammalian specific 
Sti1-like repeats in UBQLN2, which contain the predicted PrD are sufficient for UBQLN2’s own 
phase separation required for its SG recruitment.  The PXX repeat in UBQLN2 was not essential for 
this oligomerization, but ALS/FTD-linked proline missense mutations did promote aggregation of 
UBQLN2 in cells and in model organisms in response to stress (Sharkey et al., 2018) suggesting that 
the PXX repeats play a role in tuning UBQLN2’s solubility within SGs. In vitro droplet aging 
experiments could be performed to assess whether prolonged residence of UBQLN2 in liquid droplets 
leads to its aggregation as previously observed for hnRNPA1 and A2/B1 mutants (Kim et al., 2013).  
FRAP measurements of fluorescently labeled UBQLN2 and/or hnRNP could be performed in cells 
to assess UBQLN2’s mobility. 
The fact that both mono- and polyubiquitin chains dispersed UBQLN2 liquid droplets in trans suggests 
that ubiquitin-binding may play an important role in UBQLN2 dissociation from SGs that I observed 
in our heat stress time course analysis.  Expression of a ubiquitin-binding mutant could be used to test 
this hypothesis coupled with ubiquitin staining during the timecourse.  It would also be informative to 
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test if the large cytoplasmic SGs with which UBQLN2 stably associates differ in their ubiquitin content 
because SGs that misincorporate misfolded ubiquitinated proteins may be inherently more prone to 
contain protein aggregates.  These experiments would address whether UBQLN2’s association with 
ubiquitin in SGs is important to its regulatory function or stable integration into SGs. 
ILVBL: a promising UBQLN2 interactor at SGs 
Other, unexplored UBQLN2 interactors may also play a role in UBQLN2’s function at SGs. Among 
the strong interactors that I validated from our SILAC nLC-MS/MS analysis, the protein ILVBL 
showed a clear localization to SGs (Figure 4-1 B, C, D).  ILVBL is a single-pass transmembrane protein 
of unknown function, most similar to the bacterial acetolactate synthase-like gene. ILVBL contains 3 
predicted TPP binding domains preceded by a signal peptide (Figure 4-1A). Interestingly, acetolactate 
synthase is a thiamine pyrophosphate (TPP) dependent enzyme that catalyzes the first step in branched 
chain amino-acid synthesis.  These enzymes have been characterized as potential evolutionary 
precursors of the E1/E2 ubiquitin activating and conjugating enzymes because they also use activation 
of their substrates by formation of a thioester bond (Hochstrasser, 2009).  Whether this association is 
relevant to ILVBL’s strong interaction with UBQLN2 remains to be determined. 
ILVBL immunoprecipitated with UBQLN1 and 2 equally well (Figure 4-1C) but appeared to require 
the UBQLN Ubl domain for its interaction with UBQLN1. Unlike UBQLN2, ILVBL SG staining was 
not sensitive to the fixation and permeabilization method used similar to core SG components TIA-1 
and G3BP, and was visible with heat and sodium arsenite stress in HeLa and U2OS cells (Figure 4-1D, 
E). This preliminary data suggests that ILVBL and UBQLN2 could function together at SGs. 
 
UBQLN2 function in the LLPS of other membraneless compartments? 
Liquid-liquid phase separation has recently been recognized as a critical step in the formation of 
membraneless organelles in the cell. This work focuses on the association and regulatory function of 
UBQLN2 in SG formation.  However, other phase separated compartments in the cell such as nucleoli, 
Cajal bodies, gems, paraspeckles, and promyelocytic leukemia (PML) bodies in the nucleus, and 
processing bodies (P-bodies) in the cytoplasm also contain phase separated RBPs bound to RNA 
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(Brangwynne et al., 2011).  Our preliminary data shows at least one instance in which UBQLN2 
localizes to another phase separated compartment, the nucleolus (Figure 4-2A, B).  In response to 
prolonged puromycin treatment UBQLN2 concentrated in large nuclear granules that colocalized with 
the nucleolar marker fibrillarin.  I also saw the concentration of UBQLN2 in the nucleolus, another 
phase separated nuclear compartment (Brangwynne et al., 2011), following prolonged, low dose 
puromycin treatment.  Puromycin, an aminoglycoside antibiotic leads to the accumulation of 
prematurely terminated translation products.  Seguin et. al. also saw a similar concentration of 
puromycin-labelled prematurely terminated transcript in these large circular nuclear structures.  The 
60S ribosomal subunit Rpl19 in large round nuclear structures also concentrated here in Atg5-/- MEFs.  
Both are components of DRiPs (Defective Ribosomal Products).  This effect might be linked to a 
nuclear to cytoplasmic trafficking defect (Mahboubi and Stochaj, 2014) because both compartments 
contain ribosomal components, although the functional consequences of this effect are as yet 
unknown. It will be interesting to investigate if UBQLN2’s effect on the LLPS of SG components can 
be generalized to other compartments in the cell. 
 
UBQLN2’s effect on SG formation in neurons? 
While the major part of this study focused on the cell biology of UBQLN2 function in SG formation, 
the partial loss of function of the ALS/FTD linked mutants suggests that the UBQLN2 mutants might 
function in a dominant negative manner in SGs in neurons by interacting with hnRNPs but failing to 
efficiently modulate complex formation.  To assess the biological relevance of UBQLN2’s action in 
SG formation, experiments might be done both in induced pluripotent stem cells that have been 
differentiated into motor neurons and in a worm model of ALS pathology.  Unfortunately, I was unable 
to obtain patient cells and/or use CRISPR to alter the gene sequence in the time scale of this study.  
However, study of UBQLN2 mutants expressed at endogenous levels might help to better dissect the 
mechanism of the UBQLN2 mutant pathology.  
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Figure 4-1 ILVBL is a strong interactor for UBQLN2 that localizes to SGs 
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(A) Pfam generated domain map of ILVBL drawn to scale. Human ILVBL is a 632 amino acid protein. 
SP=signal peptide. TPP=thiamine pyrophosphate binding domain. Blue dots represent sites of 
Mg ion binding. ILVBL was recently renamed 2-hydroxyacyl-CoA lyase 2 (HACL2) for its function 
in a novel fatty acid oxidation pathway in the ER. 
(B) SILAC nLC-MS/MS data for ILBVL bound to UBQLN2 relative to UBQLN1 (top box) and 
UBQLN1 relative to UBQLN2 
(C) Western blot validation of endogenous ILVBL immunoprecipitation (IP) with FLAG-UBQLN1 
and FLAG-UBQLN2. FLAG-β-glucuronidase was used as a control. Β-actin was used as a loading 
control. 
(D) Confocal immunofluorescence (IF) images of HeLa cells under normal conditions or exposed to 
45 min heat stress (43.7C). ILVBL colocalization with UBQLN2 and SG marker TIA-1 in 
response to heat stress is clearly visible.  Cells were simultaneously fixed and permeabilized as 
described in Chapter 2. Antibodies used were mouse anti-ILVBL (Sigma, A262) 1:1000, rabbit 
anti-UBQLN2 (Sigma, HPA006431) 1:250, and goat anti-TIA-1 (Santa Cruz, C-20) 1:50. 
(E) IF images of U2OS cells under normal and sodium arsenite stress (1 hr 0.5 mM NaAsO2). Rabbit 







Figure 4-2 UBQLN2 localizes to nucleoli with prolonged puromycin treatment 
(A) Immunofluorescence (IF) images of UBQLN2 localization relative to nuclei stained with DAPI 
before and after puromycin treatment in HEK293T cells.  Cells were plated directly on glass 
coverslips and fixative was applied directly to retain cell structure. Rabbit anti-UBQLN2 (Sigma, 
HPA006431) marks the endogenous protein. 
(B) IF image of HEK293T cells expressing PuroR treated with 3 μg/mL puromycin for more than 72 
hr and stained with mouse anti-fibrillarin (Abcam, ab4566), a nucleolar marker. 
(C) Chemical structure of puromycin, an aminonucleoside antibiotic from Streptomyces alboniger that 
results in premature chain termination on translating ribosomes. The resulting protein is 







Appendix A: Building a UBQLN interactome via quantitative proteomic 
analysis 
INTRODUCTION 
ubiquilin 2 (UBQLN2) is one of 4 conserved UBQLNs in mammals. To identify interactors for the 
UBQLN proteins UBQLN1, 2 and 4, I optimized a FLAG-UBQLN immunoprecipitation protocol 
and analyzed the interactors by nano-liquid chromatography tandem mass spectrometry (nLC-
MS/MS).  This work was performed in collaboration with Akhilesh Pandey’s lab. From this analysis I 
identified a number of common and unique interactors for the UBQLNs (Figure A-2B).  Analysis of 
these interactors with respect to their interaction with individual UBQLN homologs was in part 
confounded by the strong interaction of UBQLN1, 2, and 4 with one another.  However, several 
unique interactors were identified for UBQLN2. For example, I immunoprecipitated the Hsp70 
HSPA1A with UBQLN1, 2, and 4, but only detected it by FLAG IP of UBQLN2 by Western blot. 
This observation is consistent with reports that UBQLNs homo- and heterodimerize. I was surprised 
to find that UBQLN2, but not UBQLN1 or 4 immunoprecipitated SG components, especially 
hnRNPs. 
Interestingly, UBQLN2 itself has never been identified as a component of SGs in any of the SG 
proteome studies.  The first reason for this absence may be related to the amino acid sequence and 
structure of UBQLN2. UBQLN2 contains no cysteines and its lysines are all clustered in its amino-
terminal Ubl domain and may be buried in the interface between Ubl and Uba domain or Ubl and 
UIM domain of an interacting partner.  iTRAQ tagging requires the presence of cysteine residues and 
both bioID and apex tagging strategies rely on the conjugation of biotin to protein lysine residues.  
Based on our staining results, I also might predict that UBQLN2 resides in the SG “shell” rather than 






FIGURES & TABLES 
 
Figure A-1 CHAPSO enhances coimmunoprecipitation of UBQLN2 binding partners 
(A) Table of lysis buffer compositions for each of the test immunoprecipitations (IP).  
(B) Silver stained SDS-PAGE gel of proteins that coimmunoprecipitate with FLAG-UBQLN2 under 
different lysis/IP conditions. The zwitterionic detergent CHAPSO enhanced FLAG-UBQLN2 






Figure A-2 UBQLN2 binds a set of unique and common UBQLN interactors 
(A) Silver stained Tris-Gly SDS-PAGE gels of FLAG-UBQLN immunoprecipitation (IP) eluant. 
(B) Venn diagram showing numbers of unique and common UBQLN1, 2 and 4 interactors 
(C) Cumulative frequency distribution histograms for UBQLN interactors. Fold enrichment indicates 





Table A-1 Table of UBQLN2 associated proteins identified by SILAC nLC-MS/MS 
Gene Accession Protein name Peptides Intensity Ratio
UBQLN1 NP_444295.1 ubiquilin-1 isoform 2 59 1,331,669,710 *
HSPA1A NP_005336.3 heat shock 70 kDa protein 1A/1B 120 440,917,747 20.3
HSPA8 NP_006588.1
heat shock cognate 71 kDa protein 
isoform 1 138 369,392,192 13.8
CEP170 NP_001035864.1
centrosomal protein of 170 kDa 
isoform gamma 6 327,327,700 *
ALDH3A2 NP_000373.1
fatty aldehyde dehydrogenase 
isoform 2 40 275,359,967 32.0
TRIM5 NP_149084.2
tripartite motif-containing protein 5 
isoform delta 14 190,548,370 *
LAMP1 NP_005552.3
lysosome-associated membrane 
glycoprotein 1 precursor 6 186,577,980 1.5
UBB NP_061828.1 polyubiquitin-B precursor 23 168,367,867 20.6
UBQLN2 NP_038472.2 ubiquilin-2 73 159,943,535 33.3
UBQLN4 NP_064516.2 ubiquilin-4 36 159,813,723 *
ATP5B NP_001677.2
ATP synthase subunit beta, 
mitochondrial precursor 89 158,634,225 1.8
TUBB4B NP_006079.1 tubulin beta-4B chain 188 127,885,308 3.0
TUBA1B NP_006073.2 tubulin alpha-1B chain 81 122,016,582 2.8
CDKN2C NP_001253.1
cyclin-dependent kinase 4 inhibitor 
C 2 106,978,486 30.3
PPM1B NP_002697.1 protein phosphatase 1B isoform 1 94 101,227,769 2.8
HNRNPC NP_004491.2
heterogeneous nuclear 
ribonucleoproteins C1/C2 isoform 
b 12 74,603,245 1.7
ATP5A1 NP_001001937.1
ATP synthase subunit alpha, 
mitochondrial isoform a precursor 38 66,095,125 3.6
HNRNPH1 NP_005511.1
heterogeneous nuclear 
ribonucleoprotein H 51 64,510,490 1.5
ILVBL NP_006835.2 acetolactate synthase-like protein 23 61,191,206 51.6
C10orf68 NP_078964.2 uncharacterized protein C10orf68 2 53,256,061 *
CCT3 NP_001008800.1
T-complex protein 1 subunit 
gamma isoform c 6 53,172,495 5.3
HSPA9 NP_004125.3
stress-70 protein, mitochondrial 
precursor 16 52,853,822 3.0
TUBB6 NP_115914.1 tubulin beta-6 chain 61 50,165,913 2.2
CANX NP_001737.1 calnexin precursor 12 47,415,913 9.6
CCT4 NP_006421.2
T-complex protein 1 subunit delta 
isoform a 18 47,194,615 4.3
HSPD1 NP_002147.2
60 kDa heat shock protein, 
mitochondrial 15 46,600,293 3.2
ENO1 NP_001419.1 alpha-enolase isoform 1 38 46,116,335 3.7
NPM1 NP_001032827.1 nucleophosmin isoform 3 11 45,876,610 1.5
PRKDC NP_001075109.1
DNA-dependent protein kinase 








Gene Accession Protein name Peptides Intensity Ratio
TRAP1 NP_001258978.1
heat shock protein 75 kDa, 
mitochondrial isoform 2 2 39,861,870 1.6
HNRNPU NP_004492.2
heterogeneous nuclear 
ribonucleoprotein U isoform b 58 38,523,831 2.1
PHGDH NP_006614.2
D-3-phosphoglycerate 
dehydrogenase 19 37,493,615 3.6
KIF11 NP_004514.2 kinesin-like protein KIF11 69 33,048,167 1.5
PSMD4 NP_002801.1
26S proteasome non-ATPase 
regulatory subunit 4 2 32,753,364 5.1
RTN4 NP_722550.1 reticulon-4 isoform B 6 32,516,827 13.8
PABPC1 NP_002559.2 polyadenylate-binding protein 1 31 31,570,195 1.5
XRCC6 NP_001460.1
X-ray repair cross-complementing 
protein 6 13 28,749,508 2.5
LSM14A NP_056393.2
protein LSM14 homolog A isoform 
b 10 27,758,521 1.7
VKORC1 NP_996560.1
vitamin K epoxide reductase 
complex subunit 1 isoform 2 
precursor 2 26,859,753 *
ESYT1 NP_056107.1
extended synaptotagmin-1 isoform 
2 3 26,026,293 19.0
ESYT2 NP_065779.1 extended synaptotagmin-2 17 25,724,668 21.4
RIOK1 NP_113668.2
serine/threonine-protein kinase 
RIO1 isoform 1 26 25,666,483 1.6
PABPC4 NP_001129126.1
polyadenylate-binding protein 4 
isoform 3 9 24,977,593 1.6
DDX3X NP_001180346.1
ATP-dependent RNA helicase 
DDX3X isoform 3 65 24,238,144 2.0
EEF1D NP_001123528.1 elongation factor 1-delta isoform 4 4 23,443,019 3.2
VIM NP_003371.2 vimentin 22 21,906,105 1.6
FUS NP_001164408.1
RNA-binding protein FUS 
isoform 3 3 21,808,551 1.6
HNRNPA2B1 NP_002128.1
heterogeneous nuclear 
ribonucleoproteins A2/B1 isoform 
A2 22 21,405,728 1.9
HNRNPA3 NP_919223.1
heterogeneous nuclear 
ribonucleoprotein A3 6 20,659,907 1.8
ATP1B3 NP_001670.1
sodium/potassium-transporting 
ATPase subunit beta-3 3 20,258,257 6.7
ATAD2 NP_054828.2
ATPase family AAA domain-




associated protein 1 isoform 1 3 19,275,127 1.7
BSG NP_940991.1 basigin isoform 2 17 19,042,000 11.6
RUVBL2 NP_006657.1 ruvB-like 2 19 18,526,328 2.9
IMPDH2 NP_000875.2
inosine-5'-monophosphate 
dehydrogenase 2 4 18,378,716 1.5
HSPA13 NP_008879.3
heat shock 70 kDa protein 13 
precursor 3 18,248,766 30.0
TGM3 NP_003236.3
protein-glutamine gamma-
glutamyltransferase E 4 18,235,616 *
DDX1 NP_004930.1
ATP-dependent RNA helicase 











protein glycosyltransferase 48 kDa 
subunit precursor 13 18,065,095 2.2
GLUL NP_002056.2 glutamine synthetase 3 17,989,823 1.6
ACSL3 NP_004448.2 long-chain-fatty-acid--CoA ligase 3 3 17,963,774 7.5
H2AFV NP_619541.1 histone H2A.V isoform 2 2 17,897,943 *
CCT5 NP_036205.1
T-complex protein 1 subunit 
epsilon 2 17,212,181 3.1
KPNB1 NP_002256.2 importin subunit beta-1 isoform 1 7 17,187,882 1.9
HIST1H2BD NP_066407.1 histone H2B type 1-D 4 16,972,105 2.0
NSDHL NP_001123237.1
sterol-4-alpha-carboxylate 3-




exchanger 1 protein 2 15,630,087 2.2
SGK196 NP_115613.1
probable inactive protein kinase-
like protein SgK196 4 15,502,103 30.2
HSP90AB1 NP_001258901.1
heat shock protein HSP 90-beta 
isoform c 12 15,481,520 1.7
HNRNPK NP_112552.1
heterogeneous nuclear 
ribonucleoprotein K isoform b 3 15,379,763 1.8
VRK3 NP_001020949.1
inactive serine/threonine-protein 
kinase VRK3 isoform 2 4 15,111,551 1.6
TUFM NP_003312.3
elongation factor Tu, mitochondrial 
precursor 10 15,046,192 2.5
LETM1 NP_036450.1
LETM1 and EF-hand domain-
containing protein 1, mitochondrial 
precursor 3 14,751,288 10.7
CCT7 NP_001159756.1
T-complex protein 1 subunit eta 
isoform c 11 14,473,214 5.0
MCM3 NP_001257401.1
DNA replication licensing factor 
MCM3 isoform 2 (putative 
replicative helicase essential for 
'once per cell cycle' DNA 
replication initiation and 
elongation in eukaryotic cells. O-
glycosylated (O-GlcNAcylated), in a 
cell cycle-dependent manner.) 6 14,293,457 2.5
PSMD2 NP_002799.3
26S proteasome non-ATPase 
regulatory subunit 2=RPN1 4 14,121,080 5.6
HNRNPM NP_112480.2
heterogeneous nuclear 
ribonucleoprotein M isoform b 7 13,986,205 1.5
CCT6A NP_001009186.1
T-complex protein 1 subunit zeta 
isoform b 4 13,753,259 3.7
PCBP2 NP_001122386.1
poly(rC)-binding protein 2 isoform 
g 8 13,417,898 1.9
HSPA5 NP_005338.1
78 kDa glucose-regulated protein 
precursor 8 13,336,933 *
PFKFB3 NP_001138915.1
6-phosphofructo-2-kinase/fructose-
2, 6-bisphosphatase 3 isoform 2 7 13,236,204 1.9







Gene Accession Protein name Peptides Intensity Ratio
PAICS NP_006443.1
multifunctional protein ADE2 
isoform 2 6 12,859,321 2.8
HIST1H1C NP_005310.1 histone H1.2 5 12,730,924 1.6
TMPO NP_003267.1
thymopoietin isoform 
alpha=LAP2a 10 12,554,996 3.8
CSE1L NP_001243064.1 exportin-2 isoform 2 3 12,493,809 4.3
IDH2 NP_002159.2
isocitrate dehydrogenase [NADP], 
mitochondrial precursor 4 12,468,623 3.4
IGF2BP1 NP_006537.3
insulin-like growth factor 2 mRNA-
binding protein 1 isoform 1 5 11,938,355 1.7
CCT8 NP_006576.2 T-complex protein 1 subunit theta 2 11,924,921 3.1
RBMX NP_002130.2
RNA-binding motif protein, X 
chromosome isoform 1 4 11,898,714 1.9
HSPA1L NP_005518.3 heat shock 70 kDa protein 1-like 12 11,767,756 *
PDHB NP_001166939.1
pyruvate dehydrogenase E1 
component subunit beta, 
mitochondrial isoform 2 precursor 2 11,633,152 7.0
CCT2 NP_001185771.1
T-complex protein 1 subunit beta 
isoform 2 4 11,546,933 1.8
EIF3G NP_003746.2
eukaryotic translation initiation 
factor 3 subunit G 6 11,416,464 2.1
PSMD13 NP_002808.3
26S proteasome non-ATPase 
regulatory subunit 13 isoform 1 2 11,415,492 5.1





subunit 1 precursor 3 11,333,358 1.5
MOGS NP_001139630.1
mannosyl-oligosaccharide 
glucosidase isoform 2 5 11,305,935 7.9
RUVBL1 NP_003698.1 ruvB-like 1 11 11,114,101 3.8
BAG6 NP_001186626.1
large proline-rich protein BAG6 
isoform c (Bat3) 5 11,031,790 4.9
TIMM50 NP_001001563.1
mitochondrial import inner 
membrane translocase subunit 




ase family member 1 2 10,793,518 *
PSMD7 NP_002802.2
26S proteasome non-ATPase 
regulatory subunit 7 5 10,736,805 5.2
DDX39A NP_005795.2
ATP-dependent RNA helicase 
DDX39A 2 10,559,015 3.1
RPS9 NP_001004.2 40S ribosomal protein S9 3 10,518,235 1.6
EPRS NP_004437.2
bifunctional glutamate/proline--
tRNA ligase 5 10,447,513 2.0
XRCC5 NP_066964.1
X-ray repair cross-complementing 
protein 5=Ku80 13 10,399,345 2.8
COPRS NP_060875.2
coordinator of PRMT5 and 
differentiation stimulator 8 10,379,302 1.6







Gene Accession Protein name Peptides Intensity Ratio
TIMM44 NP_006342.2
mitochondrial import inner 
membrane translocase subunit 
TIM44 7 10,155,998 9.4
SRPR NP_001171313.1
signal recognition particle receptor 
subunit alpha isoform 2 2 9,891,992 *
PTBP1 NP_114368.1
polypyrimidine tract-binding 
protein 1 isoform c 5 9,888,787 2.0
SF3B1 NP_036565.2
splicing factor 3B subunit 1 
isoform 1 4 9,664,201 1.9
PSMC4 NP_694546.1
26S protease regulatory subunit 
6B isoform 2 6 9,564,581 5.9
PSMD12 NP_002807.1
26S proteasome non-ATPase 
regulatory subunit 12 isoform 1 6 9,551,526 5.9
RNF126 NP_919442.1 RING finger protein 126 3 9,467,761 7.7
PRSS3 NP_001184027.1 trypsin-3 isoform 4 preproprotein 4 9,400,564 *
SF3B2 NP_006833.2 splicing factor 3B subunit 2 4 9,391,733 1.9
ACADM NP_000007.1
medium-chain specific acyl-CoA 
dehydrogenase, mitochondrial 
isoform a precursor 8 8,996,741 5.7
HIST1H4A NP_003529.1 histone H4 22 8,900,738 1.7
PSMC3 NP_002795.2
26S protease regulatory subunit 
6A 5 8,848,862 5.9
PSMD11 NP_001257411.1
26S proteasome non-ATPase 
regulatory subunit 11 7 8,728,764 5.9
EIF3E NP_001559.1
eukaryotic translation initiation 
factor 3 subunit E 3 8,673,657 2.1
TUBA1A NP_001257329.1 tubulin alpha-1A chain isoform 2 12 8,673,036 3.5
B3GNT1 NP_006867.1
N-acetyllactosaminide beta-1,3-N-
acetylglucosaminyltransferase 4 8,672,567 8.0
RBM10 NP_001191396.1 RNA-binding protein 10 isoform 4 4 8,672,140 2.2
VCP NP_009057.1
transitional endoplasmic reticulum 
ATPase=VCP 5 8,607,121 3.5
CERS2 NP_071358.1 ceramide synthase 2 3 8,600,777 5.9
RPL3 NP_001029025.1
60S ribosomal protein L3 isoform 
b 2 8,418,979 2.0
EIF3F NP_003745.1
eukaryotic translation initiation 
factor 3 subunit F 16 8,270,952 2.5
DDX6 NP_004388.2
probable ATP-dependent RNA 
helicase DDX6 3 8,270,045 1.7
VAT1 NP_006364.2
synaptic vesicle membrane 
protein VAT-1 homolog 4 8,201,372 *
DHX9 NP_001348.2 ATP-dependent RNA helicase A 14 8,151,662 1.8
SPTLC1 NP_006406.1
serine palmitoyltransferase 1 
isoform a 2 8,076,527 *
DCTN2 NP_001248342.1 dynactin subunit 2 isoform 3 2 8,074,018 1.6
MTHFD1 NP_005947.3
C-1-tetrahydrofolate synthase, 
cytoplasmic 5 8,041,608 2.5
ST13 NP_003923.2 hsc70-interacting protein 2 8,013,742 4.0
PSMC6 NP_002797.3
26S protease regulatory subunit 
10B 3 7,915,075 5.8
COPB1 NP_057535.1 coatomer subunit beta 3 7,911,623 3.1
LRPPRC NP_573566.2
leucine-rich PPR motif-containing 






Gene Accession Protein name Peptides Intensity Ratio
MYH9 NP_002464.1 myosin-9 4 7,801,507 2.1
PDZ8 NP_776152.1 PDZ domain-containing protein 8 4 7,794,565 *
CD63 NP_001244329.1 CD63 antigen isoform D precursor 2 7,726,939 5.6
MCM5 NP_006730.2
DNA replication licensing factor 
MCM5 4 7,695,032 2.5
POR NP_000932.3
NADPH--cytochrome P450 
reductase 9 7,489,233 7.7
APMAP NP_065392.1
adipocyte plasma membrane-
associated protein 6 7,315,428 *
MCM4 NP_877423.1
DNA replication licensing factor 
MCM4 1 7,275,650 3.41
BLMH NP_000377.1 bleomycin hydrolase 2 7,123,152 *
RPL18 NP_001257419.1
60S ribosomal protein L18 




protein alpha 9 6,889,927 6.9
SLC25A6 NP_001627.2 ADP/ATP translocase 3 8 6,664,595 *
GNB4 NP_067642.1
guanine nucleotide-binding 




dehydrogenase precursor 2 6,438,496 *
TMX4 NP_066979.2
thioredoxin-related 
transmembrane protein 4 
precursor 2 6,433,585 8.5
ATP1A1 NP_001153706.1
sodium/potassium-transporting 
ATPase subunit alpha-1 isoform d 12 6,410,775 5.4
MARCKS NP_002347.5
myristoylated alanine-rich C-
kinase substrate 3 6,375,584 1.8
AP2M1 NP_001020376.1
AP-2 complex subunit mu isoform 
b 2 6,321,212 2.2
INSR NP_001073285.1
insulin receptor isoform Short 
preproprotein 6 6,285,701 10.2
MARS NP_004981.2
methionine--tRNA ligase, 
cytoplasmic 2 6,250,868 5.0
GAPDH NP_002037.2
glyceraldehyde-3-phosphate 
dehydrogenase isoform 1 8 6,188,879 *
ERGIC3 NP_057050.1
endoplasmic reticulum-Golgi 
intermediate compartment protein 
3 isoform b 4 6,164,440 5.5
ATP2A2 NP_001672.1
sarcoplasmic/endoplasmic 
reticulum calcium ATPase 2 
isoform a 3 6,083,691 5.5
SLC3A2 NP_001013269.1
4F2 cell-surface antigen heavy 
chain isoform f 7 5,970,870 2.8
FAF2 NP_055428.1 FAS-associated factor 2 4 5,911,616 *
IDH3A NP_005521.1
isocitrate dehydrogenase [NAD] 
subunit alpha, mitochondrial 
precursor 3 5,903,767 *








Gene Accession Protein name Peptides Intensity Ratio
EIF3A NP_003741.1
eukaryotic translation initiation 
factor 3 subunit A 12 5,825,481 3.4
PSMC5 NP_001186092.1
26S protease regulatory subunit 8 
isoform 2 14 5,692,381 5.9
SAFB NP_001188269.1
scaffold attachment factor B1 
isoform 4 2 5,504,130 3.8
B3GAT3 NP_036332.2
galactosylgalactosylxylosylprotein 
3-beta-glucuronosyltransferase 3 2 5,501,462 3.6
KPNA2 NP_002257.1 importin subunit alpha-2 2 5,482,660 2.1
NDUFS2 NP_001159631.1
NADH dehydrogenase 
[ubiquinone] iron-sulfur protein 2, 
mitochondrial isoform 2 precursor 5 5,359,528 1.6
CASP14 NP_036246.1 caspase-14 precursor 3 5,339,378 *
SLC25A5 NP_001143.2 ADP/ATP translocase 2 10 5,337,110 2.2
PSMD6 NP_001258710.1
26S proteasome non-ATPase 
regulatory subunit 6 isoform 4 3 5,323,490 4.2
EWSR1 NP_001156758.1
RNA-binding protein EWS isoform 
4 (Ewing sarcoma breakpoint 
region 1) 2 5,309,022 *
RPLP0 NP_444505.1 60S acidic ribosomal protein P0 6 5,258,556 2.0
CYP20A1 NP_803882.1 cytochrome P450 20A1 5 5,223,075 31.5
GNAS NP_001070957.1 protein GNAS isoform g 2 5,195,619 3.9
MCM7 NP_005907.3
DNA replication licensing factor 
MCM7 isoform 1 4 5,141,775 3.0
PCYT1B NP_001156737.1
choline-phosphate 
cytidylyltransferase B isoform 3 2 5,095,267 *
ANXA2 NP_001129487.1 annexin A2 isoform 2 8 5,026,577 *
RAD50 NP_005723.2 DNA repair protein RAD50 2 4,971,819 2.7
SRP54 NP_003127.1
signal recognition particle 54 kDa 
protein isoform 1 2 4,929,038 4.4
CTSD NP_001900.1 cathepsin D preproprotein 3 4,916,716 *
HNRNPR NP_001095867.1
heterogeneous nuclear 
ribonucleoprotein R isoform 4 3 4,914,800 1.6
PSMC2 NP_002794.1
26S protease regulatory subunit 7 
isoform 1 7 4,886,364 5.7
HSP90AA1 NP_005339.3
heat shock protein HSP 90-alpha 
isoform 2 3 4,846,809 1.5
SEC62 NP_003253.1 translocation protein SEC62 4 4,838,024 2.4
AZGP1 NP_001176.1
zinc-alpha-2-glycoprotein 
precursor 2 4,836,685 *
TXN NP_001231867.1 thioredoxin isoform 2 5 4,835,216 *
TCP1 NP_001008897.1
T-complex protein 1 subunit alpha 
isoform b 1 4,817,514 *
DHODH NP_001352.2
dihydroorotate dehydrogenase 
(quinone), mitochondrial 4 4,817,013 6.6
MARCKSL1 NP_075385.1 MARCKS-related protein 7 4,813,216 1.7
GCN1L1 NP_006827.1 translational activator GCN1 2 4,796,380 1.7
OAT NP_000265.1
ornithine aminotransferase, 
mitochondrial isoform 1 precursor 2 4,745,463 *







Gene Accession Protein name Peptides Intensity Ratio
PSMC1 NP_002793.2 26S protease regulatory subunit 4 5 4,616,331 5.8
KCTD5 NP_061865.1
BTB/POZ domain-containing 
protein KCTD5 9 4,610,457 1.9
HNRNPUL2 NP_001073027.1
heterogeneous nuclear 
ribonucleoprotein U-like protein 2 4 4,589,802 1.8
BUB3 NP_001007794.1
mitotic checkpoint protein BUB3 
isoform b 4 4,568,556 1.6
GTF2I NP_001509.3
general transcription factor II-I 
isoform 4 8 4,562,355 2.3
COPG2 NP_036265.3 coatomer subunit gamma-2 3 4,549,606 2.1
SERBP1 NP_056455.3
plasminogen activator inhibitor 1 
RNA-binding protein isoform 4 11 4,549,331 1.8
ALDH1L1 NP_001257294.1
cytosolic 10-formyltetrahydrofolate 
dehydrogenase isoform 3 2 4,544,022 *
PDHA1 NP_001166927.1
pyruvate dehydrogenase E1 
component subunit alpha, somatic 
form, mitochondrial isoform 4 
precursor 2 4,511,293 4.5
PFKFB1 NP_001258734.1
6-phosphofructo-2-kinase/fructose-
2, 6-bisphosphatase 1 isoform 3 2 4,504,574 1.5
MCM6 NP_005906.2
DNA replication licensing factor 
MCM6 2 4,470,070 1.9
NSF NP_006169.2 vesicle-fusing ATPase=NSF 2 4,414,065 3.2
TUBB NP_821133.1 tubulin beta chain 3 4,338,050 6.8
NUP205 NP_055950.1
nuclear pore complex protein 
Nup205 1 4,312,302 4.31
KCTD17 NP_078957.2
BTB/POZ domain-containing 
protein KCTD17 5 4,151,795 1.8
PRDX2 NP_005800.3 peroxiredoxin-2 2 4,127,660 *
HADHB NP_000174.1
trifunctional enzyme subunit beta, 
mitochondrial precursor 4 4,126,117 *
IARS NP_002152.2
isoleucine--tRNA ligase, 
cytoplasmic 5 4,049,162 1.8
RPL27A NP_000981.1 60S ribosomal protein L27a 5 4,031,316 1.6
AFG3L2 NP_006787.2 AFG3-like protein 2= AAA ATPase 7 4,007,768 2.3
STX12 NP_803173.1 syntaxin-12 2 3,933,053 1.9
GSDMA NP_835465.2 gasdermin-A 2 3,925,754 *
THOC3 NP_115737.1 THO complex subunit 3 2 3,905,055 1.5
DSC1 NP_004939.1
desmocollin-1 isoform Dsc1b 
preproprotein 2 3,839,581 *
FAM162A NP_055182.3 protein FAM162A 2 3,816,340 *
DHRS7 NP_057113.1
dehydrogenase/reductase SDR 
family member 7 precursor 4 3,750,267 9.7
RFC4 NP_002907.1 replication factor C subunit 4 2 3,725,522 2.9
TOR1AIP1 NP_056417.2
torsin-1A-interacting protein 1 
isoform 2 4 3,632,993 6.8
MMS19 NP_071757.4
MMS19 nucleotide excision repair 
protein homolog 2 3,593,040 *
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COL1A2 NP_000080.2
collagen alpha-2(I) chain 
precursor 2 3,569,111 *
CD320 NP_057663.1
CD320 antigen isoform 1 
precursor 2 3,506,057 5.0
EIF2S2 NP_003899.2
eukaryotic translation initiation 
factor 2 subunit 2 2 3,436,968 2.0
TFRC NP_003225.2 transferrin receptor protein 1 3 3,402,082 2.6
PRRC2B NP_037450.2
proline-rich and coiled coil-
containing protein 1 2 3,395,652 2.1
AMY2B NP_066188.1 alpha-amylase 2B precursor 2 3,306,609 *
MRE11A NP_005581.2
double-strand break repair protein 
MRE11A isoform 2 2 3,182,981 2.3
EIF4G1
NP_004944.3 eukaryotic translation initiation 




binding protein 4 (RING-type Zn-
finger) 2 2,963,874 *
IDH1 NP_005887.2
isocitrate dehydrogenase [NADP] 
cytoplasmic 5 2,865,597 1.5
ARG1 NP_000036.2 arginase-1 isoform 2 4 2,860,871 2.7
EIF4G2
NP_001036024.3 eukaryotic translation initiation 




transmembrane protein 1 
precursor 2 2,709,795 7.7
CREM NP_874392.1
cAMP-responsive element 
modulator isoform 10 2 2,697,191 1.7
CXADR NP_001329.1
coxsackievirus and adenovirus 
receptor isoform 1 precursor 3 2,617,719 *
MATR3 NP_954659.1 matrin-3 isoform a 3 2,613,955 1.5
ADPGK NP_112574.3
ADP-dependent glucokinase 
precursor 2 2,611,902 *
ARMC6 NP_219483.1
armadillo repeat-containing 
protein 6 isoform 2 3 2,539,466 2.5
PLIN3 NP_001157666.1 perilipin-3 isoform 3 5 2,479,809 4.3
DNAJA1 NP_001530.1
dnaJ homolog subfamily A 
member 1 4 2,435,478 3.0




ubiquitin-like domain member 1 
protein isoform 4 2 2,299,287 15.7
APOL2 NP_663612.1 apolipoprotein L2 2 2,206,650 9.3
NACA NP_001106673.1
nascent polypeptide-associated 
complex subunit alpha isoform b 2 2,127,874 *
RPS3 NP_001243731.1
40S ribosomal protein S3 isoform 
1 6 2,113,738 1.9
SLC25A11 NP_001158890.1
mitochondrial 2-
oxoglutarate/malate carrier protein 
isoform 3 2 2,089,062 1.8
MDC1 NP_055456.2
mediator of DNA damage 
checkpoint protein 1 2 2,005,412 *
LDHB NP_002291.1 L-lactate dehydrogenase B chain 3 1,722,938 1.5







Gene Accession Protein name Peptides Intensity Ratio
GNAQ NP_002063.2
guanine nucleotide-binding 
protein G(q) subunit alpha 4 1,468,824 10.1
ALDH18A1 NP_001017423.1
delta-1-pyrroline-5-carboxylate 





mitochondrial precursor 2 1,266,779 *
CDK1 NP_203698.1
cyclin-dependent kinase 1 isoform 
2 1 1,153,981 3.05
SAE1 NP_001139186.1
SUMO-activating enzyme subunit 1 
isoform c 2 976,832 2.8
FAM120A NP_055427.2
constitutive coactivator of PPAR-
gamma-like protein 1 1 914,165 1.72
RPS3A NP_000997.1
40S ribosomal protein S3a 
isoform 1 4 898,373 1.5
LRRC59 NP_060979.2
leucine-rich repeat-containing 
protein 59 2 695,178 1.8
PELO NP_057030.3 protein pelota homolog 2 643,773 2.7
HSD17B12 NP_057226.1
estradiol 17-beta-dehydrogenase 
12 2 594,787 18.2  
Only proteins with more than 1 peptide were included unless the protein was clearly part of a marked complex. Protein and 
peptide false discovery rates were set at 1% for the Proteome Discoverer database search. Proteins were sorted by intensity. 
Gene is the gene name. Blue text indicates proteins identified in the SG proteome. Orange text indicates SG proteome 
proteins that are hnRNPs. Peptides are the peptide spectrum matched hits. Intensity is the total integrated precursor ion peak 
density. SILAC ratio is the average HEAVY (UBQLN2)/LIGHT (Control) peptide ratio. * indicates a corresponding light 
peptide was not automatically identified by the search software. Red bars indicate proteins identified in this study.  Orange 







Table A-2 Table of UBQLN1 associated proteins identified by SILAC nLC-MS/MS
Gene Accession Protein name Peptides Intensity SILAC Ratio
UBQLN1 NP_444295.1 ubiquilin-1 isoform 2 171 14,721,415,075 34.5
UBQLN4 NP_064516.2 ubiquilin-4 44 13,267,180,406 58.7
UBQLN2 NP_038472.2 ubiquilin-2 49 2,658,591,558 33.4
PDE4D NP_001184147.1
cAMP-specific 3',5'-cyclic 
phosphodiesterase 4D 8 1,132,278,447 *
HSPA1A NP_005336.3 heat shock 70 kDa protein 1A/1B 67 972,807,788 25.1
HSPA8 NP_006588.1
heat shock cognate 71 kDa protein 
isoform 1 81 921,427,447 20.8
ILVBL NP_006835.2 acetolactate synthase-like protein 58 398,193,490 42.3
HSPA5 NP_005338.1
78 kDa glucose-regulated protein 
precursor 15 390,324,054 8.3
PRMT5 NP_006100.2
protein arginine N-
methyltransferase 5 51 337,541,450 1.5
HSD17B12 NP_057226.1
estradiol 17-beta-dehydrogenase 
12 4 290,551,062 34.7
ALDH3A2 NP_000373.1
fatty aldehyde dehydrogenase 
isoform 2 75 285,584,192 37.9
UBB NP_061828.1 polyubiquitin-B precursor 206 197,312,983 27.6
FAM162A NP_055182.3 protein FAM162A 6 131,914,564 42.3
XRCC6 NP_001460.1
X-ray repair cross-complementing 
protein 6 24 129,200,022 14.5
TUBA1A NP_001257329.1 tubulin alpha-1A chain isoform 2 48 89,199,661 20.9
HIST1H2BD NP_066407.1 histone H2B type 1-D 20 80,182,497 13.6
TUBB NP_821133.1 tubulin beta chain 49 75,036,885 17.1
UBXN4 NP_055422.1
UBX domain-containing protein 4 
(erasin) 12 73,457,198 46.5




amidase 23 68,154,000 40.2
TMEM209 NP_116231.2 transmembrane protein 209 21 56,992,809 39.3
RTN4 NP_722550.1 reticulon-4 isoform B 9 52,343,609 41.9
BSG NP_940991.1 basigin isoform 2 23 51,938,257 34.8
ACSL3 NP_004448.2 long-chain-fatty-acid--CoA ligase 3 3 50,284,689 *
LMNB1 NP_005564.1 lamin-B1 isoform 1 18 46,275,504 4.2
TUBB4B NP_006079.1 tubulin beta-4B chain 38 45,393,234 14.5





subunit 2 isoform 2 precursor 10 43,276,689 *
GPX8 NP_001008398.2 probable glutathione peroxidase 8 11 41,911,870 35.7
HSPA9 NP_004125.3
stress-70 protein, mitochondrial 
precursor 10 39,047,336 19.8
SYNGR1 NP_663783.1 synaptogyrin-1 isoform 1b 5 27,295,445 35.6
XRCC5 NP_066964.1
X-ray repair cross-complementing 








Gene Accession Protein name Peptides Intensity SILAC Ratio
MOGS NP_006293.2
mannosyl-oligosaccharide 
glucosidase isoform 1 24 26,658,414 23.3
C9orf72 NP_060795.1 protein C9orf72 isoform a 50 24,985,100 *
COL14A1 NP_066933.1
collagen alpha-1(XIV) chain 
precursor 3 21,264,540 *
PRKDC NP_001075109.1
DNA-dependent protein kinase 
catalytic subunit isoform 2 93 21,140,063 15.0
HSPA13 NP_008879.3
heat shock 70 kDa protein 13 
precursor 14 21,083,267 39.4
MAN1A1 NP_005898.2
mannosyl-oligosaccharide 1,2-
alpha-mannosidase IA 5 20,620,511 *
LMAN1 NP_005561.1 protein ERGIC-53 precursor 4 19,648,002 19.8
PPM1B NP_002697.1 protein phosphatase 1B isoform 1 38 19,162,929 2.9
SRPR NP_001171313.1
signal recognition particle receptor 
subunit alpha isoform 2 2 18,990,472 *
CD320 NP_001159367.1
CD320 antigen isoform 2 
precursor 9 18,077,655 14.1
TMPO NP_001027454.1 thymopoietin isoform beta 19 17,651,183 12.1
ADAM9 NP_003807.1
disintegrin and metalloproteinase 
domain-containing protein 9 
precursor 9 17,424,092 *
NBAS NP_056993.2
neuroblastoma-amplified 
sequence 13 16,558,854 *
HNRNPU NP_004492.2
heterogeneous nuclear 
ribonucleoprotein U isoform b 33 16,235,839 12.5
SEC22B NP_004883.3
vesicle-trafficking protein SEC22b 
precursor 10 15,807,353 34.1
PARP1 NP_001609.2 poly [ADP-ribose] polymerase 1 25 15,472,135 18.8
PLD3 NP_001026866.1 phospholipase D3 8 15,187,458 *
SUPT16H NP_009123.1 FACT complex subunit SPT16 10 14,465,756 18.9
DDX1 NP_004930.1
ATP-dependent RNA helicase 
DDX1 15 13,982,498 12.9
COX4I1 NP_001852.1
cytochrome c oxidase subunit 4 
isoform 1, mitochondrial precursor 2 13,954,344 *
LMNB2 NP_116126.3 lamin-B2 12 13,412,652 *
PSMB6 NP_001257410.1
proteasome subunit beta type-6 
isoform 2 proprotein 2 13,207,610 4.6
RAB1B NP_112243.1 ras-related protein Rab-1B 4 12,866,705 11.6
LBR NP_919424.1 lamin-B receptor 7 12,815,332 9.7
SCFD1 NP_057190.2
sec1 family domain-containing 
protein 1 isoform a 3 12,574,665 *
FAF2 NP_055428.1 FAS-associated factor 2 4 12,488,410 26.7
EMD NP_000108.1 emerin 6 12,337,194 9.0
PSMD3 NP_002800.2
26S proteasome non-ATPase 
regulatory subunit 3 9 11,866,075 14.8
HSPD1 NP_002147.2
60 kDa heat shock protein, 
mitochondrial 21 11,828,104 4.1
PUF60 NP_001258029.1
poly(U)-binding-splicing factor 
PUF60 isoform h 3 11,656,364 5.1







Gene Accession Protein name Peptides Intensity SILAC Ratio
RTCB NP_055121.1
tRNA-splicing ligase RtcB 
homolog 2 11,535,357 16.3
BCLAF1 NP_001070908.1
bcl-2-associated transcription 
factor 1 isoform 2 14 11,089,899 2.8
RAB5C NP_958842.1
ras-related protein Rab-5C 
isoform a 2 11,069,816 17.1
TCP1 NP_110379.2
T-complex protein 1 subunit alpha 
isoform a 13 10,960,022 11.2
TOR1AIP2 NP_659471.1
torsin-1A-interacting protein 2 
isoform b 3 10,864,164 *
SLC25A5 NP_001143.2 ADP/ATP translocase 2 9 10,730,095 11.6
LAMP1 NP_005552.3
lysosome-associated membrane 
glycoprotein 1 precursor 6 10,367,247 23.7
SGK196 NP_115613.1
probable inactive protein kinase-
like protein SgK196 4 10,309,237 30.5
RBMX NP_002130.2
RNA-binding motif protein, X 
chromosome isoform 1 13 10,129,200 10.7
VKORC1 NP_076869.1
vitamin K epoxide reductase 
complex subunit 1 isoform 1 6 9,893,978 *
FDFT1 NP_004453.3 squalene synthase 9 9,669,719 29.8
KPNB1 NP_002256.2 importin subunit beta-1 isoform 1 5 9,624,470 12.8
CCT3 NP_001008800.1
T-complex protein 1 subunit 
gamma isoform c 7 9,572,790 11.1
SSR3 NP_009038.1
translocon-associated protein 
subunit gamma 7 9,272,382 7.9
BAK1 NP_001179.1 bcl-2 homologous antagonist/killer 6 9,255,646 60.8
RAB21 NP_055814.1 ras-related protein Rab-21 2 9,235,926 27.7
DHCR24 NP_055577.1
delta(24)-sterol reductase 




ubiquitin-like domain member 1 
protein isoform 4 4 9,104,671 32.9
VIM NP_003371.2 vimentin 24 9,089,854 6.8
RTN3 NP_001252520.1 reticulon-3 isoform g 2 8,764,348 32.9
FAM3C NP_055703.1 protein FAM3C precursor 4 8,704,339 12.7
CDK1 NP_203698.1
cyclin-dependent kinase 1 isoform 
2 2 8,691,291 6.5
IMMT NP_001093640.1
mitochondrial inner membrane 
protein isoform 3 21 8,541,705 8.8
PHB2 NP_001138303.1 prohibitin-2 isoform 1 7 7,829,977 6.7
RTN2 NP_996784.1 reticulon-2 isoform C 2 7,744,218 24.3
PABPC1L2A NP_001012995.1
polyadenylate-binding protein 1-
like 2 2 7,522,217 *
RPS18 NP_072045.1 40S ribosomal protein S18 16 7,478,679 6.0
PSMC5 NP_001186092.1
26S protease regulatory subunit 8 
isoform 2 2 7,358,341 24.2
TIMM21 NP_054896.2
mitochondrial import inner 
membrane translocase subunit 








Gene Accession Protein name Peptides Intensity SILAC Ratio
MCM7 NP_877577.1
DNA replication licensing factor 
MCM7 isoform 2 6 7,192,703 19.6
LSM14A NP_056393.2
protein LSM14 homolog A isoform 
b 7 6,770,277 4.0
ABCE1 NP_002931.2
ATP-binding cassette sub-family E 
member 1 7 6,742,306 36.1
LPCAT1 NP_079106.3
lysophosphatidylcholine 
acyltransferase 1 4 6,700,632 24.7
ATP1A1 NP_001153706.1
sodium/potassium-transporting 
ATPase subunit alpha-1 isoform d 19 6,252,723 11.9
SNRPD3 NP_004166.1
small nuclear ribonucleoprotein 
Sm D3 4 6,109,595 1.9
CCT5 NP_036205.1
T-complex protein 1 subunit 
epsilon 6 6,103,297 8.0
ARL6IP1 NP_055976.1
ADP-ribosylation factor-like protein 
6-interacting protein 1 2 6,030,608 *
NDUFB11 NP_001129470.1
NADH dehydrogenase 
[ubiquinone] 1 beta subcomplex 
subunit 11, mitochondrial isoform 
2 2 5,956,941 *
SSR4 NP_006271.1
translocon-associated protein 
subunit delta isoform 2 precursor 4 5,842,621 *
RAB11A NP_001193765.1
ras-related protein Rab-11A 
isoform 2 2 5,787,289 21.7
HDAC1 NP_004955.2 histone deacetylase 1 3 5,568,393 7.6
POR NP_000932.3
NADPH--cytochrome P450 
reductase 8 5,252,538 22.3
LOC402160 NP_001180211.1
uncharacterized protein 
LOC402160 2 5,125,185 *
NDUFS2 NP_001159631.1
NADH dehydrogenase 
[ubiquinone] iron-sulfur protein 2, 
mitochondrial isoform 2 precursor 2 4,982,818 *
RNF139 NP_009149.2
E3 ubiquitin-protein ligase 
RNF139 2 4,845,334 *
PARP2 NP_001036083.1
poly [ADP-ribose] polymerase 2 
isoform 2 12 4,779,634 *
CHPT1 NP_064629.2 cholinephosphotransferase 1 2 4,705,410 *
EXT2 NP_997005.1 exostosin-2 isoform 2 4 4,692,735 *
BZW1 NP_055485.2
basic leucine zipper and W2 
domain-containing protein 1 
isoform 4 3 4,684,238 *
NOMO2 NP_775885.1
nodal modulator 2 isoform 2 
precursor 7 4,659,817 4.5
UQCRC2 NP_003357.2
cytochrome b-c1 complex subunit 
2, mitochondrial precursor 7 4,563,833 6.5
BAG6 NP_001186626.1
large proline-rich protein BAG6 
isoform c 4 4,530,726 *
LIG3 NP_002302.2
DNA ligase 3 isoform beta 
precursor 3 4,529,935 22.1
INSR NP_001073285.1
insulin receptor isoform Short 












ase family member 1 2 4,497,209 *
LETM1 NP_036450.1
LETM1 and EF-hand domain-
containing protein 1, mitochondrial 
precursor 10 4,483,550 9.3
RPS5 NP_001000.2 40S ribosomal protein S5 4 4,470,749 6.2
SPNS1 NP_001135921.1
protein spinster homolog 1 
isoform 4 2 4,458,979 *
TMX1 NP_110382.3
thioredoxin-related 
transmembrane protein 1 
precursor 2 4,454,310 *
PRDX1 NP_859048.1 peroxiredoxin-1 5 4,432,328 4.4
HNRNPK NP_112552.1
heterogeneous nuclear 
ribonucleoprotein K isoform b 4 4,422,722 3.0
STK38 NP_009202.1 serine/threonine-protein kinase 38 8 4,377,778 4.3
ATL2 NP_001129145.1 atlastin-2 isoform 2 3 4,357,875 *
CLPTM1 NP_001285.1
cleft lip and palate 
transmembrane protein 1 2 4,319,688 20.4
LEMD2 NP_851853.1
LEM domain-containing protein 2 
isoform 1 9 4,236,496 *
SLC3A2 NP_001013269.1
4F2 cell-surface antigen heavy 
chain isoform f 4 4,088,435 11.4
RPS3 NP_001243731.1
40S ribosomal protein S3 isoform 
1 6 4,061,068 5.4
GBA NP_001165282.1 glucosylceramidase isoform 2 6 4,024,721 *
RAB3D NP_004274.1 ras-related protein Rab-3D 4 3,893,542 8.9
ROBO1 NP_001139317.1 roundabout homolog 1 isoform d 6 3,887,633 14.5
ERGIC3 NP_057050.1
endoplasmic reticulum-Golgi 
intermediate compartment protein 
3 isoform b 3 3,868,735 *
ATP5B NP_001677.2
ATP synthase subunit beta, 
mitochondrial precursor 3 3,771,714 8.7
RHOT2 NP_620124.1 mitochondrial Rho GTPase 2 2 3,724,280 35.5
PSMC1 NP_002793.2 26S protease regulatory subunit 4 8 3,647,153 20.7
IMPDH1 NP_001136047.1
inosine-5'-monophosphate 
dehydrogenase 1 isoform g 2 3,626,984 *
NCLN NP_064555.2 nicalin precursor 4 3,624,052 24.2
CCT6A NP_001009186.1
T-complex protein 1 subunit zeta 
isoform b 7 3,624,001 1.7
THRAP3 NP_005110.2
thyroid hormone receptor-
associated protein 3 6 3,613,884 2.0





subunit STT3A isoform b 2 3,580,514 *








Gene Accession Protein name Peptides Intensity SILAC Ratio
ADRM1 NP_008933.2
proteasomal ubiquitin receptor 
ADRM1 precursor 4 3,535,221 23.3
ENO1 NP_001188412.1
c-myc promoter-binding protein-1 
isoform MBP-1 4 3,522,824 *
YWHAQ NP_006817.1 14-3-3 protein theta 2 3,522,785 *
TMX2 NP_001137484.1
thioredoxin-related 
transmembrane protein 2 isoform 
2 4 3,476,529 *
CANX NP_001737.1 calnexin precursor 6 3,459,558 20.1
HIST1H1C NP_005310.1 histone H1.2 25 3,422,421 20.2
ATP5A1 NP_001001935.1
ATP synthase subunit alpha, 
mitochondrial isoform c 7 3,420,303 10.9
PRKCA NP_002728.1 protein kinase C alpha type 2 3,382,576 *
VIMP NP_060915.2 selenoprotein S 6 3,330,068 4.6
CYP20A1 NP_803882.1 cytochrome P450 20A1 4 3,275,417 *
DHX9 NP_001348.2 ATP-dependent RNA helicase A 2 3,250,180 3.7
HNRNPM NP_112480.2
heterogeneous nuclear 
ribonucleoprotein M isoform b 4 3,225,375 7.0
ATL3 NP_056274.3 atlastin-3 3 3,178,275 *
SIRPA NP_001035111.1
tyrosine-protein phosphatase non-
receptor type substrate 1 
precursor 6 3,125,140 *
PFKM NP_000280.1
6-phosphofructokinase, muscle 
type isoform 2 2 3,095,423 3.7
SEC62 NP_003253.1 translocation protein SEC62 2 3,092,926 8.6
SSRP1 NP_003137.1 FACT complex subunit SSRP1 3 3,053,331 28.7
VDAC1 NP_003365.1
voltage-dependent anion-selective 
channel protein 1 2 2,964,632 5.8
CLCC1 NP_001041675.1
chloride channel CLIC-like protein 
1 isoform 1 precursor 4 2,929,227 *
AIFM1 NP_001124318.1
apoptosis-inducing factor 1, 
mitochondrial isoform 4 2 2,877,486 *
TUFM NP_003312.3
elongation factor Tu, mitochondrial 
precursor 2 2,872,347 16.6
VRK3 NP_001020949.1
inactive serine/threonine-protein 
kinase VRK3 isoform 2 2 2,871,228 *
AAAS NP_001166937.1 aladin isoform 2 2 2,866,466 *
PSMC4 NP_694546.1
26S protease regulatory subunit 
6B isoform 2 2 2,795,461 *
ATP2A2 NP_001672.1
sarcoplasmic/endoplasmic 
reticulum calcium ATPase 2 
isoform a 5 2,792,595 9.5
RPS9 NP_001004.2 40S ribosomal protein S9 5 2,762,188 6.9
CCT7 NP_001159757.1
T-complex protein 1 subunit eta 
isoform d 16 2,752,959 7.4
SLC25A24 NP_998816.1
calcium-binding mitochondrial 
carrier protein SCaMC-1 isoform 2 8 2,716,012 11.3
PVRL1 NP_976031.1
poliovirus receptor-related protein 
1 isoform 3 precursor 4 2,714,888 *
WNK1 NP_055638.2
serine/threonine-protein kinase 
WNK1 isoform 2 3 2,683,209 *







Gene Accession Protein name Peptides Intensity SILAC Ratio
RPA1 NP_002936.1
replication protein A 70 kDa DNA-
binding subunit 3 2,578,917 *
PSMB5 NP_002788.1
proteasome subunit beta type-5 
isoform 1 6 2,567,246 *
PNKP NP_009185.2
bifunctional polynucleotide 
phosphatase/kinase 2 2,496,633 *
CCT8 NP_006576.2 T-complex protein 1 subunit theta 5 2,481,252 9.1
ATP6AP1 NP_001174.2
V-type proton ATPase subunit S1 
precursor 2 2,463,018 *
CACHD1 NP_065976.2
VWFA and cache domain-
containing protein 1 3 2,458,657 *
RUVBL1 NP_003698.1 ruvB-like 1 2 2,443,132 *
CYP51A1 NP_001139624.1
lanosterol 14-alpha demethylase 
isoform 2 2 2,438,310 *
VCP NP_009057.1
transitional endoplasmic reticulum 
ATPase 3 2,434,812 12.8
PRPF31 NP_056444.3
U4/U6 small nuclear 
ribonucleoprotein Prp31 4 2,415,665 2.2
ANXA2 NP_001129487.1 annexin A2 isoform 2 7 2,357,481 *
CREM NP_874392.1
cAMP-responsive element 
modulator isoform 10 2 2,307,291 14.6
BTRC NP_003930.1
F-box/WD repeat-containing 




precursor 2 2,289,136 *
SATB2 NP_056080.1 DNA-binding protein SATB2 4 2,272,279 8.0
B3GNT1 NP_006867.1
N-acetyllactosaminide beta-1,3-N-
acetylglucosaminyltransferase 8 2,217,659 *
MRE11A NP_005581.2
double-strand break repair protein 
MRE11A isoform 2 4 2,200,252 *
ATAD3A NP_001164007.1
ATPase family AAA domain-
containing protein 3A isoform 3 5 2,165,529 5.1
RHOT1 NP_060777.3
mitochondrial Rho GTPase 1 
isoform 3 3 2,142,103 *
RAP1B NP_001238851.1
ras-related protein Rap-1b isoform 
4 7 2,138,538 12.0
ESYT1 NP_056107.1
extended synaptotagmin-1 isoform 
2 6 2,105,947 *
NUP210 NP_079199.2
nuclear pore membrane 
glycoprotein 210 precursor 11 2,095,570 18.1




precursor 2 2,051,363 22.4
TIMM17B NP_005825.1
mitochondrial import inner 
membrane translocase subunit 
Tim17-B isoform 2 2 1,970,908 3.3
OAT NP_001165285.1
ornithine aminotransferase, 
mitochondrial isoform 2 2 1,928,706 30.9
BAZ1A NP_872589.1
bromodomain adjacent to zinc 







Gene Accession Protein name Peptides Intensity SILAC Ratio
G3BP1 NP_005745.1
ras GTPase-activating protein-
binding protein 1 2 1,888,348 *
ALDH18A1 NP_001017423.1
delta-1-pyrroline-5-carboxylate 
synthase isoform 2 4 1,884,114 11.2
EPRS NP_004437.2
bifunctional glutamate/proline--
tRNA ligase 4 1,868,883 5.8
DNAJB2 NP_001034639.1
dnaJ homolog subfamily B 
member 2 isoform a 2 1,842,418 *
HEATR2 NP_060272.3 HEAT repeat-containing protein 2 6 1,813,741 22.4
PHGDH NP_006614.2
D-3-phosphoglycerate 
dehydrogenase 2 1,810,417 2.8
FBXW11 NP_387449.2
F-box/WD repeat-containing 
protein 11 isoform A 8 1,795,805 *
EIF3L NP_057175.1
eukaryotic translation initiation 
factor 3 subunit L isoform 1 8 1,787,067 2.3
COL1A2 NP_000080.2
collagen alpha-2(I) chain 
precursor 11 1,758,989 *
DDX3X NP_001180346.1
ATP-dependent RNA helicase 
DDX3X isoform 3 4 1,687,881 4.6
CCT4 NP_001243650.1
T-complex protein 1 subunit delta 
isoform b 7 1,658,264 5.0
ITGB1 NP_596867.1
integrin beta-1 isoform 1A 
precursor 3 1,584,995 *
ACTR1B NP_005726.1 beta-centractin 2 1,573,546 6.3
RAD50 NP_005723.2 DNA repair protein RAD50 2 1,560,071 3.8
NONO NP_001138882.1
non-POU domain-containing 
octamer-binding protein isoform 2 2 1,472,456 4.0
TIMM44 NP_006342.2
mitochondrial import inner 
membrane translocase subunit 
TIM44 2 1,452,132 3.1
EIF4B NP_001408.2
eukaryotic translation initiation 
factor 4B 2 1,379,524 1.7
ACADM NP_000007.1
medium-chain specific acyl-CoA 
dehydrogenase, mitochondrial 
isoform a precursor 6 1,359,632 32.2
DDX5 NP_004387.1
probable ATP-dependent RNA 
helicase DDX5 3 1,358,560 4.2
ATP1B3 NP_001670.1
sodium/potassium-transporting 
ATPase subunit beta-3 2 1,289,924 8.0
HNRNPC NP_004491.2
heterogeneous nuclear 
ribonucleoproteins C1/C2 isoform 
b 2 1,286,731 *
PFKFB3 NP_001138915.1
6-phosphofructo-2-kinase/fructose-
2, 6-bisphosphatase 3 isoform 2 4 1,282,344 1.9
MFN1 NP_284941.2 mitofusin-1 2 1,249,701 *
PSMD2 NP_002799.3
26S proteasome non-ATPase 
regulatory subunit 2 2 1,082,536 *
GCN1L1 NP_006827.1 translational activator GCN1 10 1,068,272 14.2
FAM127B NP_001071640.1 protein FAM127B isoform 1 2 976,285 *
MDC1 NP_055456.2
mediator of DNA damage 








Gene Accession Protein name Peptides Intensity SILAC Ratio
EIF3G NP_003746.2
eukaryotic translation initiation 
factor 3 subunit G 2 950,124 7.8
SERBP1 NP_056455.3
plasminogen activator inhibitor 1 
RNA-binding protein isoform 4 2 904,494 *
MCM6 NP_005906.2
DNA replication licensing factor 
MCM6 2 884,125 *
DNAJA1 NP_001530.1
dnaJ homolog subfamily A 
member 1 3 708,480 *
ZMYM4 NP_005086.2 zinc finger MYM-type protein 4 2 669,707 *
CDC5L NP_001244.1 cell division cycle 5-like protein 2 741,057 *
IGF2R NP_000867.2
cation-independent mannose-6-
phosphate receptor precursor 2 693,877 *
AGPAT2 NP_001012745.1
1-acyl-sn-glycerol-3-phosphate 
acyltransferase beta isoform b 
precursor 2 637,216 *
IBTK NP_056340.2 inhibitor of Bruton tyrosine kinase 2 555,839 *
NCL NP_005372.2 nucleolin 2 405,056 *
ACIN1 NP_001158289.1
apoptotic chromatin condensation 
inducer in the nucleus isoform 5 2 346,494 *
MARS NP_004981.2
methionine--tRNA ligase, 
cytoplasmic 2 272,846 *
CXADR NP_001329.1
coxsackievirus and adenovirus 
receptor isoform 1 precursor 2 262,475 *
RPL31 NP_001093163.1
60S ribosomal protein L31 
isoform 3 2 230,987 *
PLXNA1 NP_115618.3 plexin-A1 precursor 2 797,911 *
FASN NP_004095.4 fatty acid synthase 2 794,076 1.9
PIGR NP_002635.2
polymeric immunoglobulin 
receptor precursor 2 1,034,165 *
TMEM132A NP_821174.1
transmembrane protein 132A 
isoform b precursor 2 1,019,924 *
TGFBR1 NP_001124388.1
TGF-beta receptor type-1 isoform 2 
precursor 3 1,236,160 *
LOC1002875
15 XP_003846501.1 zinc finger protein 26-like 2 1,234,118 *
BBC3 NP_001120713.1
bcl-2-binding component 3 
isoform 2 2 1,178,025 *
CHST14 NP_569735.1 carbohydrate sulfotransferase 14 2 1,163,866 *
SLC30A7 NP_598003.2 zinc transporter 7 2 1,153,897 *
GMPS NP_003866.1
GMP synthase [glutamine-
hydrolyzing] 2 1,790,316 *
RPL18A NP_000971.1 60S ribosomal protein L18a 2 1,738,743 *
PTPLAD1 NP_057479.2
very-long-chain (3R)-3-hydroxyacyl-
[acyl-carrier protein] dehydratase 3 2 1,698,420 *
CDKAL1 NP_060244.2
threonylcarbamoyladenosine tRNA 
methylthiotransferase 2 1,695,050 *
SERPINE2 NP_001130000.1
glia-derived nexin isoform b 
precursor 5 1,689,542 *
MAGOH NP_002361.1 protein mago nashi homolog 2 1,684,867 *







Gene Accession Protein name Peptides Intensity SILAC Ratio
SPTLC1 NP_847894.1
serine palmitoyltransferase 1 
isoform b 2 1,677,314 *
TOP2A NP_001058.2 DNA topoisomerase 2-alpha 2 1,650,326 *
HRAS NP_789765.1 GTPase HRas isoform 2 2 1,616,774 *
SAAL1 NP_612430.2 protein SAAL1 2 1,615,444 *
GPAA1 NP_003792.1
glycosylphosphatidylinositol 
anchor attachment 1 protein 2 1,613,078 *
BPIFB1 NP_149974.2
BPI fold-containing family B 
member 1 precursor 4 1,605,502 *
FANCD2 NP_001018125.1
Fanconi anemia group D2 protein 




mitochondrial precursor 2 1,526,835 *
ADPGK NP_112574.3
ADP-dependent glucokinase 
precursor 2 1,511,138 *
PPP2R1A NP_055040.2
serine/threonine-protein 
phosphatase 2A 65 kDa regulatory 
subunit A alpha isoform 2 1,501,161 *
RIOK1 NP_694550.1
serine/threonine-protein kinase 
RIO1 isoform 2 2 1,484,595 *
CLMN NP_079010.2 calmin 2 1,475,600 *
BAZ1B NP_115784.1 tyrosine-protein kinase BAZ1B 2 1,993,228 *
COL1A1 NP_000079.2
collagen alpha-1(I) chain 
preproprotein 2 1,968,663 *
FNDC3A NP_055738.3
fibronectin type-III domain-
containing protein 3A isoform 2 2 1,945,676 *
POLR2B NP_000929.1
DNA-directed RNA polymerase II 
subunit RPB2 2 1,350,490 *
THEM6 NP_057731.1 protein THEM6 precursor 3 1,346,081 *
RPL27 NP_000979.1 60S ribosomal protein L27 2 1,334,148 *
TOR1AIP1 NP_056417.2
torsin-1A-interacting protein 1 
isoform 2 2 1,298,814 *
H1F0 NP_005309.1 histone H1.0 2 1,293,987 *
CCDC47 NP_064583.2
coiled-coil domain-containing 
protein 47 precursor 4 1,447,419 *
TBX2 NP_005985.3 T-box transcription factor TBX2 4 1,419,992 *
KTN1 NP_004977.2 kinectin isoform c 3 1,406,440 *
UBAC2 NP_808882.1
ubiquitin-associated domain-
containing protein 2 isoform 2 2 1,398,200 *  
Only proteins with more than 1 peptide were included unless the protein was clearly part of a marked complex. Protein and 
peptide false discovery rates were set at 1% for the Proteome Discoverer database search. Proteins were sorted by intensity. 
Gene is the gene name. Blue text indicates proteins identified in the SG proteome. Orange text indicates SG proteome 
proteins that are hnRNPs. Peptides are the peptide spectrum matched hits. Intensity is the total integrated precursor ion 
peak density. SILAC ratio is the average HEAVY (UBQLN2)/LIGHT (Control) peptide ratio. * indicates a corresponding 
light peptide was not automatically identified by the search software. Red bars indicate proteins identified in this study.  
Orange bars indicate proteins identified in previous studies. A total of 289 proteins were identified in this analysis.  
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Table A-3 Table of UBQLN4 associated proteins identified by SILAC nLC-MS/MS
Gene Accession Protein name Peptides Intensity Ratio
UBQLN4 NP_064516.2 ubiquilin-4 999 12,265,099,179 33.8
UBQLN1 NP_444295.1 ubiquilin-1 isoform 2 249 9,236,254,576 *
ALDH3A2 NP_000373.1
fatty aldehyde dehydrogenase 
isoform 2 211 878,564,638 44.6
PRMT5 NP_006100.2
protein arginine N-
methyltransferase 5 isoform a 261 696,653,112 2.3
TUBA1A NP_001257329.1 tubulin alpha-1A chain isoform 2 124 600,033,598 29.9
TUBB NP_821133.1 tubulin beta chain 249 510,530,537 12.4
TUBB4B NP_006079.1 tubulin beta-4B chain 221 427,364,998 24.0
TUBB4A NP_006078.2 tubulin beta-4A chain 173 410,949,268 *
TUBB2A NP_001060.1 tubulin beta-2A chain 193 348,209,029 *
TUBB2B NP_821080.1 tubulin beta-2B chain 193 348,209,029 *
HSPA8 NP_006588.1
heat shock cognate 71 kDa protein 
isoform 1 184 253,487,412 22.8
ATP5B NP_001677.2
ATP synthase subunit beta, 
mitochondrial precursor 112 244,634,339 20.6
EEF1A1 NP_001393.1 elongation factor 1-alpha 1 106 240,822,394 12.0
BSG NP_940991.1 basigin isoform 2 27 224,158,719 33.0
SLC25A5 NP_001143.2 ADP/ATP translocase 2 103 203,386,835 21.2
SGK196 NP_115613.1
probable inactive protein kinase-
like protein SgK196 54 195,969,868 42.3
TUBB6 NP_115914.1 tubulin beta-6 chain 92 187,617,808 36.4
HSPA1A NP_005336.3 heat shock 70 kDa protein 1A/1B 110 180,826,337 17.9
SLC25A6 NP_001627.2 ADP/ATP translocase 3 79 165,436,666 17.7
ATP5A1 NP_001001937.1
ATP synthase subunit alpha, 
mitochondrial isoform a precursor 109 161,845,193 24.2
SLC25A4 NP_001142.2 ADP/ATP translocase 1 70 159,781,335 *
ILVBL NP_006835.2 acetolactate synthase-like protein 80 130,893,848 42.0
RTN4 NP_722550.1 reticulon-4 isoform B 15 104,776,292 27.4
RPS27A NP_001129064.1
ubiquitin-40S ribosomal protein 
S27a precursor=UBA52 320 97,095,355 25.1
SSBP1 NP_001243439.1
single-stranded DNA-binding 




protein glycosyltransferase 48 kDa 
subunit precursor 38 85,088,366 26.0
CROCC NP_055490.3 rootletin 3 77,784,882 *
COX5A NP_004246.2
cytochrome c oxidase subunit 5A, 
mitochondrial precursor 32 74,552,837 34.2
PGRMC2 NP_006311.2
membrane-associated 
progesterone receptor component 
2 66 70,071,223 37.3
PSMD4 NP_002801.1
26S proteasome non-ATPase 
regulatory subunit 4 35 62,518,723 35.0
RPS18 NP_072045.1 40S ribosomal protein S18 48 57,117,491 6.1
CANX NP_001737.1 calnexin precursor 45 55,936,078 32.0







Gene Accession Protein name Peptides Intensity Ratio
VIM NP_003371.2 vimentin 149 51,228,342 9.2
SRPRB NP_067026.3
signal recognition particle receptor 
subunit beta 32 50,600,885 34.3
RUVBL1 NP_003698.1 ruvB-like 1 41 49,426,661 22.3
UBQLN2 NP_038472.2 ubiquilin-2 110 48,481,757 16.9
LRP6 NP_002327.2
low-density lipoprotein receptor-
related protein 6 precursor 2 47,660,212 *
HSPA9 NP_004125.3
stress-70 protein, mitochondrial 
precursor 68 46,895,126 9.4
RUVBL2 NP_006657.1 ruvB-like 2 69 43,992,314 23.8
HADHA NP_000173.2
trifunctional enzyme subunit alpha, 
mitochondrial precursor 6 40,555,041 *
HSPA13 NP_008879.3
heat shock 70 kDa protein 13 
precursor 32 38,638,833 36.7
UBQLN3 NP_059509.1 ubiquilin-3 6 37,744,268 *
XRCC6 NP_001460.1
X-ray repair cross-complementing 
protein 6 31 37,241,513 11.0
PHB NP_002625.1 prohibitin 60 36,626,028 8.7
TMPO NP_001027454.1 thymopoietin isoform beta 71 35,882,630 4.6
HSPD1 NP_002147.2
60 kDa heat shock protein, 
mitochondrial 75 30,892,294 9.5
LMAN1 NP_005561.1 protein ERGIC-53 precursor 22 30,598,064 28.2
APMAP NP_065392.1
adipocyte plasma membrane-
associated protein 24 27,997,910 28.4
DESI1 NP_056519.1 desumoylating isopeptidase 1 3 27,576,818 48.9
HSD17B12 NP_057226.1
estradiol 17-beta-dehydrogenase 
12 27 25,961,357 41.3
HNRNPU NP_114032.2
heterogeneous nuclear 
ribonucleoprotein U isoform a 137 25,961,062 11.7
CCT7 NP_006420.1
T-complex protein 1 subunit eta 
isoform a 69 25,090,552 28.8
PSMA5 NP_002781.2
proteasome subunit alpha type-5 
isoform 1 23 24,936,883 6.5
CYP51A1 NP_001139624.1
lanosterol 14-alpha demethylase 
isoform 2 22 24,315,419 33.9
WDR77 NP_077007.1 methylosome protein 50 53 24,112,350 1.6
B3GNT1 NP_006867.1
N-acetyllactosaminide beta-1,3-N-
acetylglucosaminyltransferase 25 24,061,034 42.9
GPX8 NP_001008398.2 probable glutathione peroxidase 8 26 23,446,373 40.9
TMPO NP_003267.1 thymopoietin isoform alpha 43 21,503,973 25.5
JTB NP_006685.1 protein JTB precursor 8 21,283,575 40.9
ATL3 NP_056274.3 atlastin-3 27 20,957,768 41.3
ATP5D NP_001678.1
ATP synthase subunit delta, 
mitochondrial precursor 8 20,888,193 *
KCTD5 NP_061865.1
BTB/POZ domain-containing 
protein KCTD5 11 20,558,071 8.1
ACSL3 NP_004448.2 long-chain-fatty-acid--CoA ligase 3 26 20,112,711 *
HNRNPH1 NP_005511.1
heterogeneous nuclear 
ribonucleoprotein H 15 19,896,168 5.5








Gene Accession Protein name Peptides Intensity Ratio
NIPSNAP1 NP_001189431.1
protein NipSnap homolog 1 
isoform 2 22 18,935,926 14.7
ATP1A1 NP_001153706.1
sodium/potassium-transporting 
ATPase subunit alpha-1 isoform d 72 18,416,828 37.1
COL14A1 NP_066933.1
collagen alpha-1(XIV) chain 




ase family member 1 26 18,279,118 49.2
CYB5A NP_001905.1 cytochrome b5 isoform 2 2 18,278,104 44.3
XRCC5 NP_066964.1
X-ray repair cross-complementing 
protein 5 47 17,797,045 19.9
GOLGA3 NP_001166028.1
Golgin subfamily A member 3 
isoform 2 24 17,580,325 *
RPL10A NP_009035.3 60S ribosomal protein L10a 5 17,054,620 3.2
COX4I1 NP_001852.1
cytochrome c oxidase subunit 4 
isoform 1, mitochondrial precursor 14 16,740,282 25.2
MOGS NP_006293.2
mannosyl-oligosaccharide 
glucosidase isoform 1 31 16,715,502 36.0
CENPE NP_001804.2 centromere-associated protein E 4 16,415,994 *
CHPT1 NP_064629.2 cholinephosphotransferase 1 2 15,901,853 36.3
CD320 NP_001159367.1
CD320 antigen isoform 2 
precursor 36 15,550,847 19.6
CCT4 NP_006421.2
T-complex protein 1 subunit delta 
isoform a 47 15,475,755 20.8
COMT NP_009294.1
catechol O-methyltransferase 
isoform S-COMT 6 14,557,316 29.0
SIGMAR1 NP_671513.1
sigma non-opioid intracellular 
receptor 1 isoform 2 5 14,417,517 15.8
BNIP1 NP_001196.2
vesicle transport protein SEC20 
isoform BNIP1 20 14,364,283 34.7
RPS5 NP_001000.2 40S ribosomal protein S5 24 14,329,949 7.3
GBAS NP_001474.1
protein NipSnap homolog 2 
isoform 1 19 14,006,533 9.7
MYH9 NP_002464.1 myosin-9 79 13,946,803 1.5
LOC1010604
53 XP_003960578.1
fatty acid-binding protein, 
epidermal-like 6 13,842,703 *
ESYT2 NP_065779.1 extended synaptotagmin-2 28 13,838,452 39.0
UBIAD1 NP_037451.1
ubiA prenyltransferase domain-
containing protein 1 17 13,631,830 39.7
INSR NP_001073285.1
insulin receptor isoform Short 
preproprotein 34 13,433,903 45.5
GET4 NP_057033.2
Golgi to ER traffic protein 4 
homolog 3 13,159,561 38.4
SNRPD2 NP_004588.1
small nuclear ribonucleoprotein 
Sm D2 isoform 1 4 12,455,213 2.3
TMX1 NP_110382.3
thioredoxin-related 
transmembrane protein 1 
precursor 16 12,419,587 27.8
UBL4A NP_055050.1 ubiquitin-like protein 4A 12 12,071,042 *








### Gene Accession Protein name Peptides Intensity Ratio
TSPAN3 NP_001161884.1 tetraspanin-3 isoform 3 2 11,941,421 14.7
PHGDH NP_006614.2
D-3-phosphoglycerate 
dehydrogenase 38 11,933,629 24.6
ZNF622 NP_219482.1 zinc finger protein 622 2 11,619,221 3.2
RPS19 NP_001013.1 40S ribosomal protein S19 11 11,511,914 5.6
STK38 NP_009202.1 serine/threonine-protein kinase 38 17 11,393,473 6.0
VKORC1L1 NP_775788.2
vitamin K epoxide reductase 
complex subunit 1-like protein 1 4 11,164,414 42.2
PSMA6 NP_002782.1 proteasome subunit alpha type-6 28 11,120,482 4.4
CFL1 NP_005498.1 cofilin-1 14 10,802,909 2.3
PSMA3 NP_687033.1
proteasome subunit alpha type-3 
isoform 2 23 10,622,791 3.7
PSMC4 NP_694546.1
26S protease regulatory subunit 
6B isoform 2 12 10,591,618 24.9
NAP1L1 NP_004528.1
nucleosome assembly protein 1-
like 1 6 10,163,414 *
PCYOX1 NP_057381.3 prenylcysteine oxidase 1 precursor 12 9,949,536 27.1
NUP210 NP_079199.2
nuclear pore membrane 
glycoprotein 210 precursor 34 9,943,088 35.8
TMEM9 NP_057540.1
transmembrane protein 9 
precursor 20 9,937,456 41.2
ERH NP_004441.1 enhancer of rudimentary homolog 15 9,888,875 2.1
SURF4 NP_149351.1 surfeit locus protein 4 16 9,711,653 57.3
PSMC2 NP_002794.1
26S protease regulatory subunit 7 
isoform 1 17 9,693,260 34.3
ERGIC3 NP_057050.1
endoplasmic reticulum-Golgi 
intermediate compartment protein 
3 isoform b 12 9,649,457 31.6
KIAA1467 NP_065904.1 uncharacterized protein KIAA1467 20 9,593,174 52.9
DMBT1 NP_060049.2
deleted in malignant brain tumors 
1 protein isoform c precursor 4 9,473,327 *




amidase isoform 4 10 9,444,537 *
BCLAF1 NP_001070908.1
bcl-2-associated transcription 
factor 1 isoform 2 58 9,373,942 7.7
CCT5 NP_036205.1
T-complex protein 1 subunit 
epsilon 26 9,301,113 3.8
S100A8 NP_002955.2 protein S100-A8 14 9,294,132 *
PSMA4 NP_002780.1
proteasome subunit alpha type-4 
isoform 1 19 9,185,475 3.3
DHCR24 NP_055577.1
delta(24)-sterol reductase 
precursor 14 9,089,530 44.2
CTNS NP_004928.2 cystinosin isoform 2 precursor 5 9,086,485 *
LMNB1 NP_005564.1 lamin-B1 isoform 1 19 8,962,864 5.9
POLR2H NP_006223.2
DNA-directed RNA polymerases I, 








Gene Accession Protein name Peptides Intensity Ratio
TMX3 NP_061895.3
protein disulfide-isomerase TMX3 
precursor 8 8,838,083 42.7
SNRPB NP_003082.1
small nuclear ribonucleoprotein-
associated proteins B and B' 
isoform B 17 8,745,331 1.9
YWHAZ NP_003397.1 14-3-3 protein zeta/delta 37 8,724,986 1.8
SYNGR1 NP_663783.1 synaptogyrin-1 isoform 1b 2 8,638,878 40.2





subunit 1 precursor 28 8,483,175 11.3
SRP54 NP_003127.1
signal recognition particle 54 kDa 
protein isoform 1 11 8,306,498 22.2
SERBP1 NP_056455.3
plasminogen activator inhibitor 1 
RNA-binding protein isoform 4 40 8,224,543 1.6
CCT3 NP_005989.3
T-complex protein 1 subunit 
gamma isoform a 29 8,168,658 2.8
PCCA NP_001171475.1
propionyl-CoA carboxylase alpha 
chain, mitochondrial isoform c 
precursor 2 8,117,199 *
EEF2 NP_001952.1 elongation factor 2 38 8,063,770 5.0
RPS4X NP_000998.1
40S ribosomal protein S4, X 
isoform X isoform 25 8,029,211 5.4
RAB10 NP_057215.3 ras-related protein Rab-10 9 7,942,720 33.3
RPS3 NP_001243731.1
40S ribosomal protein S3 isoform 
1 27 7,858,748 8.8
SEC61B NP_006799.1
protein transport protein Sec61 
subunit beta 6 7,841,422 *
SPCS2 NP_055567.2
signal peptidase complex subunit 
2 3 7,778,377 9.0
PGRMC1 NP_006658.1
membrane-associated 
progesterone receptor component 
1 18 7,748,049 31.9
SLC25A11 NP_001158890.1
mitochondrial 2-
oxoglutarate/malate carrier protein 
isoform 3 4 7,735,390 48.6
CCT2 NP_001185771.1
T-complex protein 1 subunit beta 
isoform 2 26 7,733,345 10.1
SRPR NP_001171313.1
signal recognition particle receptor 
subunit alpha isoform 2 8 7,590,978 *
CLPTM1 NP_001285.1
cleft lip and palate 
transmembrane protein 1 12 7,502,274 33.2
C14orf166 NP_057123.1 UPF0568 protein C14orf166 19 7,501,554 10.2
PSMB7 NP_002790.1
proteasome subunit beta type-7 
proprotein 12 7,500,380 5.2
RPS9 NP_001004.2 40S ribosomal protein S9 19 7,441,320 5.9
PSMC3 NP_002795.2
26S protease regulatory subunit 
6A 10 7,428,274 *
SPTLC1 NP_006406.1
serine palmitoyltransferase 1 
isoform a 14 7,337,668 23.0
PPHLN1 NP_001137260.1 periphilin-1 isoform 7 6 7,226,268 5.6
UQCRC1 NP_003356.2
cytochrome b-c1 complex subunit 








### Gene Accession Protein name Peptides Intensity Ratio
RTCB NP_055121.1
tRNA-splicing ligase RtcB 
homolog 23 6,990,097 10.7
HAL NP_001245263.1
histidine ammonia-lyase isoform 
3 5 6,953,413 *
SYS1 NP_291020.1 protein SYS1 homolog isoform a 2 6,834,028 *
LOR NP_000418.2 loricrin 8 6,810,220 *
IGF1R NP_000866.1
insulin-like growth factor 1 
receptor precursor 6 6,779,164 24.8
PSMD2 NP_002799.3
26S proteasome non-ATPase 





subunit 2 isoform 1 precursor 16 6,700,806 36.6
MTMR11 NP_870988.2
myotubularin-related protein 11 
isoform b 2 6,698,175 *
TOR1AIP2 NP_659471.1
torsin-1A-interacting protein 2 
isoform b 8 6,375,276 36.5
RTN3 NP_006045.1 reticulon-3 isoform a 9 6,373,949 30.1
FAM20B NP_055679.1 glycosaminoglycan xylosylkinase 14 6,360,198 84.6
EMD NP_000108.1 emerin 26 6,312,588 6.9
RAB7A NP_004628.4 ras-related protein Rab-7a 14 6,267,977 1.5
CASP14 NP_036246.1 caspase-14 precursor 6 6,143,468 *
PTPLB NP_940684.1
very-long-chain (3R)-3-hydroxyacyl-
[acyl-carrier protein] dehydratase 2 2 6,102,677 15.8
SACM1L NP_054735.3
phosphatidylinositide 
phosphatase SAC1 3 6,039,957 24.9
INA NP_116116.1 alpha-internexin 8 6,013,918 3.9
TGM3 NP_003236.3
protein-glutamine gamma-
glutamyltransferase E 24 5,861,565 *
EIF3E NP_001559.1
eukaryotic translation initiation 
factor 3 subunit E 18 5,606,517 9.5
LPCAT1 NP_079106.3
lysophosphatidylcholine 
acyltransferase 1 7 5,580,369 *
ADPGK NP_112574.3
ADP-dependent glucokinase 
precursor 6 5,512,495 27.8
NONO NP_031389.3
non-POU domain-containing 
octamer-binding protein isoform 1 27 5,434,759 7.8
TPD52 NP_005070.1 tumor protein D52 isoform 3 5 5,361,826 29.8
TECR NP_612510.1
very-long-chain enoyl-CoA 
reductase 15 5,342,189 15.8
FBXW11 NP_387449.2
F-box/WD repeat-containing 
protein 11 isoform A 10 5,338,306 12.6
HNRNPF NP_004957.1
heterogeneous nuclear 
ribonucleoprotein F 10 5,322,380 10.7
CYB5B NP_085056.2 cytochrome b5 type B 2 5,303,989 63.8
BPIFB1 NP_149974.2
BPI fold-containing family B 
member 1 precursor 8 5,302,573 *
LAMP1 NP_005552.3
lysosome-associated membrane 
glycoprotein 1 precursor 8 5,293,087 *








Gene Accession Protein name Peptides Intensity Ratio
COX5B NP_001853.2
cytochrome c oxidase subunit 5B, 
mitochondrial precursor 4 5,240,323 *
LGALS7B NP_001035972.1 galectin-7 28 5,217,975 *
RBBP4 NP_001128727.1
histone-binding protein RBBP4 
isoform b 13 5,196,123 7.3
ARL6IP1 NP_055976.1
ADP-ribosylation factor-like protein 
6-interacting protein 1 4 5,180,588 36.3
PHB2 NP_001138303.1 prohibitin-2 isoform 1 8 5,164,569 10.1
VAT1 NP_006364.2
synaptic vesicle membrane 
protein VAT-1 homolog 17 5,156,357 16.5
CPT2 NP_000089.1
carnitine O-palmitoyltransferase 2, 
mitochondrial precursor 11 5,105,239 *
YWHAQ NP_006817.1 14-3-3 protein theta 42 5,100,992 15.2
VAPB NP_004729.1
vesicle-associated membrane 
protein-associated protein B/C 
isoform 1 19 5,093,408 31.6
SLC25A3 NP_998776.1
phosphate carrier protein, 
mitochondrial isoform b precursor 22 4,992,073 22.7
SDHB NP_002991.2
succinate dehydrogenase 
[ubiquinone] iron-sulfur subunit, 
mitochondrial precursor 9 4,962,431 33.7
DCTN2 NP_001248342.1 dynactin subunit 2 isoform 3 8 4,899,823 11.4
SDHA NP_004159.2
succinate dehydrogenase 
[ubiquinone] flavoprotein subunit, 
mitochondrial 10 4,877,438 18.8
FAF2 NP_055428.1 FAS-associated factor 2 10 4,754,437 *
BCAP31 NP_001132913.1
B-cell receptor-associated protein 
31 isoform b 26 4,728,528 8.1
RBBP7 NP_002884.1
histone-binding protein RBBP7 
isoform 2 10 4,695,771 8.0
RHEB NP_005605.1 GTP-binding protein Rheb 2 4,655,396 *
PSMC1 NP_002793.2 26S protease regulatory subunit 4 10 4,638,047 5.0
DPM1 NP_003850.1
dolichol-phosphate 
mannosyltransferase 9 4,633,730 17.8
PAM16 NP_057153.8
mitochondrial import inner 
membrane translocase subunit 
TIM16 2 4,613,469 13.8
SPRR2B NP_001017418.1 small proline-rich protein 2B 33 4,608,791 *
EIF2B3 NP_001248347.1
translation initiation factor eIF-2B 
subunit gamma isoform 3 12 4,512,557 23.9
VRK3 NP_057524.3
inactive serine/threonine-protein 
kinase VRK3 isoform 1 9 4,510,949 24.9
NDUFS3 NP_004542.1
NADH dehydrogenase 
[ubiquinone] iron-sulfur protein 3, 
mitochondrial precursor 4 4,506,037 18.6
ARG1 NP_000036.2 arginase-1 isoform 2 4 4,470,771 *
MTAP NP_002442.2
S-methyl-5'-thioadenosine 
phosphorylase 8 4,459,219 4.6
EFNB1 NP_004420.1 ephrin-B1 precursor 6 4,396,454 63.5
TBC1D15 NP_001139685.2
TBC1 domain family member 15 
isoform 3 2 4,366,299 *
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KPNB1 NP_002256.2 importin subunit beta-1 isoform 1 18 4,241,667 9.8
APOD NP_001638.1 apolipoprotein D precursor 6 4,198,501 *
YKT6 NP_006546.1 synaptobrevin homolog YKT6 2 4,184,975 *
HSD17B10 NP_004484.1
3-hydroxyacyl-CoA dehydrogenase 
type-2 isoform 1 10 4,175,952 22.8
UBE2J2 NP_477515.2
ubiquitin-conjugating enzyme E2 
J2 isoform 2 4 4,160,528 *
TPD52L2 NP_001230821.1 tumor protein D54 isoform h 4 4,151,320 *
ADAM9 NP_003807.1
disintegrin and metalloproteinase 
domain-containing protein 9 
precursor 4 4,090,459 *
AIFM1 NP_665811.1
apoptosis-inducing factor 1, 
mitochondrial isoform 2 precursor 8 4,084,090 *
TGM1 NP_000350.1
protein-glutamine gamma-
glutamyltransferase K 10 4,051,795 *
RPL17 NP_001186274.1
60S ribosomal protein L17 
isoform b 8 3,992,606 2.4
LPCAT3 NP_005759.4
lysophospholipid acyltransferase 
5 5 3,992,043 *
BLMH NP_000377.1 bleomycin hydrolase 5 3,973,842 *
PGM3 NP_001186847.1
phosphoacetylglucosamine 
mutase isoform 3 6 3,954,877 46.2
KPNA2 NP_002257.1 importin subunit alpha-2 6 3,823,181 13.2
ABCB7 NP_001258626.1
ATP-binding cassette sub-family B 
member 7, mitochondrial isoform 
3 2 3,822,709 *
EIF3F NP_003745.1
eukaryotic translation initiation 
factor 3 subunit F 18 3,790,241 8.1
SLC25A10 NP_036272.2
mitochondrial dicarboxylate carrier 
isoform 2 6 3,785,996 17.6
UBXN4 NP_055422.1 UBX domain-containing protein 4 10 3,785,341 *
UMPS NP_000364.1
uridine 5'-monophosphate 
synthase 9 3,785,090 10.5
PSMA1 NP_002777.1
proteasome subunit alpha type-1 
isoform 2 10 3,777,622 5.0
CDK1 NP_203698.1
cyclin-dependent kinase 1 isoform 
2 6 3,723,973 65.4
CALML5 NP_059118.2 calmodulin-like protein 5 2 3,709,612 *
PYCRL NP_075566.2
pyrroline-5-carboxylate reductase 
3 8 3,690,341 20.8
EIF4A3 NP_055555.1 eukaryotic initiation factor 4A-III 20 3,680,947 2.3
SLC3A2 NP_001013269.1
4F2 cell-surface antigen heavy 
chain isoform f 17 3,651,460 47.8
IGJ NP_653247.1 immunoglobulin J chain precursor 9 3,644,293 *
LMNB2 NP_116126.3 lamin-B2 7 3,630,553 5.1
PSMB5 NP_001124197.1
proteasome subunit beta type-5 
isoform 2 8 3,600,192 1.6
RPL30 NP_000980.1 60S ribosomal protein L30 2 3,559,107 6.2
PTPN1 NP_002818.1
tyrosine-protein phosphatase non-
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PSMD12 NP_777360.1
26S proteasome non-ATPase 
regulatory subunit 12 isoform 2 12 3,498,070 24.7
PSMD8 NP_002803.2
26S proteasome non-ATPase 
regulatory subunit 8 8 3,487,743 25.5
LTF NP_001186078.1 lactotransferrin isoform 2 13 3,464,281 *
PRDX6 NP_004896.1 peroxiredoxin-6 13 3,461,880 5.2
GTF2I NP_001509.3
general transcription factor II-I 
isoform 4 20 3,434,610 12.8
LPCAT2 NP_060309.2
lysophosphatidylcholine 
acyltransferase 2 6 3,429,520 42.1
ALDH1B1 NP_000683.3
aldehyde dehydrogenase X, 
mitochondrial precursor 6 3,413,744 *
SERPINA12 NP_776249.1 serpin A12 precursor 2 3,405,400 *
CXADR NP_001329.1
coxsackievirus and adenovirus 
receptor isoform 1 precursor 4 3,362,722 *
YBX1 NP_004550.2
nuclease-sensitive element-
binding protein 1 14 3,360,612 1.7
AGK NP_060708.1
acylglycerol kinase, mitochondrial 
precursor 2 3,357,970 22.4
COPB2 NP_004757.1 coatomer subunit beta' 10 3,356,402 35.1
NOMO2 NP_775885.1
nodal modulator 2 isoform 2 
precursor 10 3,355,437 31.0
IGLL5 NP_001171597.1
immunoglobulin lambda-like 
polypeptide 5 isoform 1 6 3,324,964 *
NUBP2 NP_036357.1
cytosolic Fe-S cluster assembly 
factor NUBP2 5 3,290,008 *
ME1 NP_002386.1 NADP-dependent malic enzyme 2 3,270,656 *
MT1G NP_005941.1 metallothionein-1G 4 3,225,870 *
SNRPB2 NP_937863.1
U2 small nuclear 
ribonucleoprotein B'' 12 3,169,809 2.6
GEMIN4 NP_056536.2 gem-associated protein 4 2 3,160,408 *
SFN NP_006133.1 14-3-3 protein sigma 16 3,154,492 *
CHCHD3 NP_060282.1
coiled-coil-helix-coiled-coil-helix 
domain-containing protein 3, 
mitochondrial precursor 13 3,150,449 9.9
KIF11 NP_004514.2 kinesin-like protein KIF11 21 3,131,237 8.2
TUFM NP_003312.3
elongation factor Tu, mitochondrial 
precursor 4 3,060,744 4.0
CADM1 NP_001091987.1
cell adhesion molecule 1 isoform 
2 precursor 6 3,046,328 44.3
PIGR NP_002635.2
polymeric immunoglobulin 
receptor precursor 14 3,040,489 *
GAA NP_000143.2
lysosomal alpha-glucosidase 
preproprotein 2 3,003,548 *
GLUD2 NP_036216.2
glutamate dehydrogenase 2, 
mitochondrial precursor 2 2,997,476 *
PFKFB3 NP_001138915.1
6-phosphofructo-2-kinase/fructose-
2, 6-bisphosphatase 3 isoform 2 8 2,997,199 9.8
XRCC1 NP_006288.2 DNA repair protein XRCC1 4 2,993,191 12.7
DDX1 NP_004930.1
ATP-dependent RNA helicase 
DDX1 16 2,969,709 3.6
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GNB4 NP_067642.1
guanine nucleotide-binding 
protein subunit beta-4 2 2,955,743 32.5
CASP6 NP_116787.1 caspase-6 isoform beta 2 2,929,913 1.8
CMBL NP_620164.1
carboxymethylenebutenolidase 
homolog 4 2,925,413 3.9
SFXN1 NP_073591.2 sideroflexin-1 4 2,915,349 48.8
VIMP NP_060915.2 selenoprotein S 2 2,864,976 *
SEC61A2 NP_001136099.1
protein transport protein Sec61 
subunit alpha isoform 2 isoform c 7 2,850,968 12.4
MARS NP_004981.2
methionine--tRNA ligase, 
cytoplasmic 8 2,832,721 33.7
THRAP3 NP_005110.2
thyroid hormone receptor-
associated protein 3 21 2,828,342 4.3
PRPF19 NP_055317.1 pre-mRNA-processing factor 19 6 2,825,671 2.2
DNAJA2 NP_005871.1
dnaJ homolog subfamily A 
member 2 6 2,801,144 17.5
TMX2 NP_001137484.1
thioredoxin-related 
transmembrane protein 2 isoform 
2 4 2,763,227 *
BAG6 NP_001186626.1
large proline-rich protein BAG6 
isoform c 7 2,748,888 35.4
RPL7 NP_000962.2 60S ribosomal protein L7 10 2,745,159 6.8
CLCC1 NP_001265132.1
chloride channel CLIC-like protein 
1 isoform 4 precursor 10 2,743,653 *
NCLN NP_064555.2 nicalin precursor 10 2,739,175 11.1
NDUFAF3 NP_951033.1
NADH dehydrogenase 
[ubiquinone] 1 alpha subcomplex 
assembly factor 3 isoform b 2 2,708,423 9.7
FDFT1 NP_004453.3 squalene synthase 6 2,700,627 *
OXNAD1 NP_612390.1
oxidoreductase NAD-binding 
domain-containing protein 1 
precursor 4 2,695,366 *
RPL31 NP_001093163.1
60S ribosomal protein L31 
isoform 3 2 2,690,805 *




ubiquitin-like domain member 1 
protein isoform 4 6 2,618,938 76.6
TRIM21 NP_003132.2 E3 ubiquitin-protein ligase TRIM21 10 2,605,038 7.1
UFSP2 NP_060829.2 ufm1-specific protease 2 2 2,596,652 *
TFRC NP_003225.2 transferrin receptor protein 1 10 2,596,089 28.7
FUS NP_001164408.1
RNA-binding protein FUS isoform 
3 7 2,578,978 4.3
SSB NP_003133.1 lupus La protein 8 2,575,790 4.5
HSPA4L NP_055093.2 heat shock 70 kDa protein 4L 3 2,570,329 *
ATRAID NP_057169.2
all-trans retinoic acid-induced 
differentiation factor isoform a 2 2,550,591 *
DNAJB6 NP_005485.1
dnaJ homolog subfamily B 
member 6 isoform b 8 2,536,719 *
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RPA1 NP_002936.1
replication protein A 70 kDa DNA-
binding subunit 5 2,527,025 18.8
DDX3X NP_001180346.1
ATP-dependent RNA helicase 
DDX3X isoform 3 8 2,516,157 11.6
ATP5H NP_006347.1
ATP synthase subunit d, 
mitochondrial isoform a 6 2,473,466 26.4
EDF1 NP_694880.1
endothelial differentiation-related 
factor 1 isoform beta 2 2,468,841 3.8
SCO2 NP_001162580.1
protein SCO2 homolog, 
mitochondrial precursor 8 2,448,974 15.1
CDH2 NP_001783.2 cadherin-2 preproprotein 2 2,441,173 *
SNRPA NP_004587.1
U1 small nuclear 
ribonucleoprotein A 10 2,439,989 6.2
RAB32 NP_006825.1 ras-related protein Rab-32 6 2,411,307 3.7
SEC62 NP_003253.1 translocation protein SEC62 2 2,392,672 *
COPG2 NP_036265.3 coatomer subunit gamma-2 8 2,384,936 *
LOC1010605
41 XP_003960226.1
RNA-binding protein 8A-like 
isoform 1 3 2,382,919 2.2
HEATR2 NP_060272.3 HEAT repeat-containing protein 2 10 2,374,657 7.5
IDI2 NP_150286.1
isopentenyl-diphosphate Delta-
isomerase 2 2 2,365,235 *
SMPDL3B NP_055289.2
acid sphingomyelinase-like 
phosphodiesterase 3b isoform 1 
precursor 2 2,360,323 33.9
MAGT1 NP_115497.4 magnesium transporter protein 1 6 2,358,292 *
PSMD1 NP_001177966.1
26S proteasome non-ATPase 
regulatory subunit 1 isoform 2 10 2,357,334 30.5
EIF3L NP_057175.1
eukaryotic translation initiation 
factor 3 subunit L isoform 1 6 2,351,826 9.2
DDB1 NP_001914.3 DNA damage-binding protein 1 12 2,349,674 6.4
TMEM33 NP_060596.2 transmembrane protein 33 2 2,347,001 94.6
SERPINB8 NP_001027018.1 serpin B8 isoform b 2 2,318,941 *
LOC1010605
78 XP_003960503.1
COBW domain-containing protein 
5-like 2 2,318,397 *
RPL35 NP_009140.1 60S ribosomal protein L35 2 2,314,143 6.2
CYC1 NP_001907.2
cytochrome c1, heme protein, 
mitochondrial 2 2,311,201 58.6
PRDX2 NP_005800.3 peroxiredoxin-2 8 2,311,195 1.8
TMEM209 NP_116231.2 transmembrane protein 209 3 2,304,225 *
PRDX1 NP_859048.1 peroxiredoxin-1 14 2,290,139 3.2
ALG1 NP_061982.3
chitobiosyldiphosphodolichol beta-
mannosyltransferase 4 2,282,316 10.2
DLD NP_000099.2
dihydrolipoyl dehydrogenase, 
mitochondrial precursor 4 2,253,354 *
NDUFB11 NP_001129470.1
NADH dehydrogenase 
[ubiquinone] 1 beta subcomplex 
subunit 11, mitochondrial isoform 
2 4 2,244,452 14.2
CPVL NP_112601.3
probable serine carboxypeptidase 
CPVL precursor 2 2,241,983 *
COL1A2 NP_000080.2
collagen alpha-2(I) chain 
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FKBP8 NP_036313.3
peptidyl-prolyl cis-trans isomerase 
FKBP8 12 2,229,131 10.8
TOR1AIP1 NP_056417.2
torsin-1A-interacting protein 1 
isoform 2 14 2,228,679 *
ATP2A2 NP_001672.1
sarcoplasmic/endoplasmic 
reticulum calcium ATPase 2 
isoform a 28 2,218,552 36.0
GPR107 NP_066011.2 protein GPR107 isoform 3 5 2,211,005 17.1




precursor 2 2,202,659 18.5
EIF4E NP_001959.1
eukaryotic translation initiation 
factor 4E isoform 1 2 2,154,096 *
A2ML1 NP_653271.2
alpha-2-macroglobulin-like protein 
1 precursor 2 2,148,219 *
FARSA NP_004452.1
phenylalanine--tRNA ligase alpha 
subunit 5 2,137,145 18.0
TRIM28 NP_005753.1
transcription intermediary factor 1-
beta 2 2,126,812 *
SLC25A15 NP_055067.1
mitochondrial ornithine transporter 
1 4 2,117,641 23.9
C1orf68 NP_001019850.1 skin-specific protein 32 8 2,096,818 *
PLIN3 NP_001157661.1 perilipin-3 isoform 2 6 2,094,439 *
PDCD10 NP_665858.1 programmed cell death protein 10 2 2,084,178 *
MMGT1 NP_775741.1
membrane magnesium 
transporter 1 precursor 2 2,074,075 *
NUP93 NP_055484.3
nuclear pore complex protein 
Nup93 isoform 1 6 2,052,141 89.4
RPS7 NP_001002.1 40S ribosomal protein S7 6 2,042,348 2.4
TP53 NP_001263625.1
cellular tumor antigen p53 isoform 
i 4 2,033,638 6.5
PSMD3 NP_002800.2
26S proteasome non-ATPase 
regulatory subunit 3 8 2,023,599 25.3
CTNNB1 NP_001895.1 catenin beta-1 9 2,021,507 14.0
RAB5C NP_958842.1
ras-related protein Rab-5C 
isoform a 2 2,020,646 *
COQ7 NP_001177912.1
ubiquinone biosynthesis protein 
COQ7 homolog isoform 2 2 2,018,133 *
TMEM164 NP_115603.2
transmembrane protein 164 
isoform b 4 2,015,190 *
PFKP NP_002618.1
6-phosphofructokinase type C 
isoform 1 3 1,993,617 *
LSM14A NP_056393.2
protein LSM14 homolog A isoform 
b 5 1,987,975 *
RABL3 NP_776186.2 rab-like protein 3 7 1,966,061 19.4
VAMP3 NP_004772.1
vesicle-associated membrane 
protein 3 2 1,965,718 25.0
TM9SF3 NP_064508.3
transmembrane 9 superfamily 
member 3 precursor 6 1,920,456 *
POLR2E NP_002686.2
DNA-directed RNA polymerases I, 
II, and III subunit RPABC1 2 1,913,497 20.6
ZFYVE27 NP_001167592.1 protrudin isoform f 2 1,905,870 *
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PRKAR2A NP_004148.1
cAMP-dependent protein kinase 
type II-alpha regulatory subunit 3 1,873,493 1.7
HNRNPUL2 NP_001073027.1
heterogeneous nuclear 
ribonucleoprotein U-like protein 2 6 1,867,407 6.3
PARP1 NP_001609.2 poly [ADP-ribose] polymerase 1 7 1,862,809 28.5
TMED7 NP_861974.1
transmembrane emp24 domain-
containing protein 7 precursor 4 1,852,988 *
TIPIN NP_060328.2 TIMELESS-interacting protein 2 1,844,619 2.6
CYP20A1 NP_803882.1 cytochrome P450 20A1 11 1,839,933 44.1
RAB34 NP_001138414.1
ras-related protein Rab-34 isoform 
4 5 1,838,845 *
RAB12 NP_001020471.2 ras-related protein Rab-12 6 1,832,949 *
TBRG4 NP_112162.1 protein TBRG4 isoform 2 2 1,832,864 *
RPS3A NP_000997.1
40S ribosomal protein S3a 
isoform 1 8 1,819,025 18.3
MCM7 NP_877577.1
DNA replication licensing factor 
MCM7 isoform 2 4 1,814,536 *
NDUFC2-
KCTD14 NP_001190191.1
NDUFC2-KCTD14 protein isoform 
3 2 1,799,464 *
ATP1B3 NP_001670.1
sodium/potassium-transporting 
ATPase subunit beta-3 5 1,785,430 *
TMEM230 NP_054864.3
transmembrane protein 230 
isoform 2 2 1,782,227 *
AHNAK NP_001611.1
neuroblast differentiation-
associated protein AHNAK isoform 
1 22 1,762,291 *
LYPLAL1 NP_620149.1 lysophospholipase-like protein 1 5 1,762,001 *
LEMD2 NP_851853.1
LEM domain-containing protein 2 
isoform 1 4 1,756,739 *
ACTL6A NP_817126.1 actin-like protein 6A isoform 2 2 1,753,009 4.6
PTDSS2 NP_110410.1 phosphatidylserine synthase 2 4 1,751,657 *
SDF4 NP_057260.2
45 kDa calcium-binding protein 
isoform 2 precursor 2 1,732,595 *
GNA13 NP_006563.2
guanine nucleotide-binding 
protein subunit alpha-13 2 1,732,095 *
NBAS NP_056993.2
neuroblastoma-amplified 
sequence 2 1,731,572 *
EPHX1 NP_001129490.1 epoxide hydrolase 1 precursor 8 1,729,617 *
GBA NP_001165282.1 glucosylceramidase isoform 2 2 1,720,060 6.4
REEP6 NP_612402.1
receptor expression-enhancing 
protein 6 4 1,688,926 *
OAT NP_000265.1
ornithine aminotransferase, 
mitochondrial isoform 1 precursor 4 1,666,924 *
PPIL1 NP_057143.1
peptidyl-prolyl cis-trans isomerase-
like 1 2 1,664,061 2.0
TXNDC15 NP_078991.3
thioredoxin domain-containing 
protein 15 precursor 2 1,659,630 *
COX15 NP_004367.2
cytochrome c oxidase assembly 
protein COX15 homolog isoform 2 2 1,648,392 *
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PHF5A NP_116147.1
PHD finger-like domain-containing 
protein 5A 6 1,640,308 1.6
ZMYM3 NP_001164633.1
zinc finger MYM-type protein 3 
isoform 2 2 1,607,789 *
LSS NP_001138909.1 lanosterol synthase isoform 3 2 1,601,908 *
RPA2 NP_002937.1
replication protein A 32 kDa 
subunit 4 1,587,505 *
GHDC NP_001136095.1
GH3 domain-containing protein 
isoform 3 precursor 4 1,583,764 *
NDUFV1 NP_001159574.1
NADH dehydrogenase 
[ubiquinone] flavoprotein 1, 
mitochondrial isoform 2 precursor 4 1,578,549 *
PRPF31 NP_056444.3
U4/U6 small nuclear 
ribonucleoprotein Prp31 5 1,573,405 7.2
LBR NP_919424.1 lamin-B receptor 10 1,570,800 2.2
MPDU1 NP_004861.2
mannose-P-dolichol utilization 
defect 1 protein 3 1,560,907 5.6
SLC25A1 NP_005975.1
tricarboxylate transport protein, 
mitochondrial isoform a precursor 4 1,551,847 17.9
RPL11 NP_000966.2
60S ribosomal protein L11 
isoform 1 3 1,546,305 2.8
LIG3 NP_002302.2
DNA ligase 3 isoform beta 
precursor 6 1,544,634 32.0
PTK7 NP_690620.1
inactive tyrosine-protein kinase 7 
isoform c precursor 2 1,542,499 *
FYTTD1 NP_001011537.2 UAP56-interacting factor isoform 2 5 1,539,580 4.6
MRPL10 NP_660298.2
39S ribosomal protein L10, 
mitochondrial isoform a precursor 2 1,538,966 *
THEM6 NP_057731.1 protein THEM6 precursor 2 1,525,427 *
HYOU1 NP_006380.1
hypoxia up-regulated protein 1 
precursor 2 1,525,107 23.0
LACRT NP_150593.1
extracellular glycoprotein lacritin 
precursor 2 1,522,653 *
NUP85 NP_079120.1
nuclear pore complex protein 
Nup85 2 1,509,585 *
JAGN1 NP_115881.3 protein jagunal homolog 1 2 1,490,872 21.3
ITGB1 NP_596867.1
integrin beta-1 isoform 1A 
precursor 2 1,478,618 *
CALU NP_001124146.1 calumenin isoform b precursor 3 1,464,837 *
POR NP_000932.3
NADPH--cytochrome P450 
reductase 8 1,463,492 45.3
SEC22B NP_004883.3
vesicle-trafficking protein SEC22b 
precursor 12 1,455,997 7.5
RAP2C NP_001258115.1
ras-related protein Rap-2c isoform 
1 precursor 3 1,453,325 *
CBS NP_000062.1 cystathionine beta-synthase 6 1,451,850 *
RAB18 NP_001243341.1
ras-related protein Rab-18 isoform 
5 3 1,444,550 26.1
CUL3 NP_003581.1 cullin-3 isoform 1 2 1,407,604 *
CD2BP2 NP_001230575.1
CD2 antigen cytoplasmic tail-
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UGT8 NP_003351.2
2-hydroxyacylsphingosine 1-beta-
galactosyltransferase precursor 2 1,398,777 *
MTA2 NP_004730.2
metastasis-associated protein 
MTA2 2 1,394,406 *
STARD3NL NP_114405.1
MLN64 N-terminal domain 
homolog 2 1,392,639 *
LRPPRC NP_573566.2
leucine-rich PPR motif-containing 
protein, mitochondrial precursor 3 1,382,791 30.3
EIF4A1 NP_001191439.1
eukaryotic initiation factor 4A-I 
isoform 2 4 1,371,642 15.3
ATXN10 NP_001161093.1 ataxin-10 isoform 2 4 1,371,192 *
GAR1 NP_061856.1
H/ACA ribonucleoprotein complex 
subunit 1 2 1,366,101 4.5
CCDC167 NP_612502.1
coiled-coil domain-containing 
protein 167 2 1,356,647 *
SCD NP_005054.3 acyl-CoA desaturase 2 1,351,057 *
VPS4A NP_037377.1
vacuolar protein sorting-
associated protein 4A 2 1,329,382 37.7
TUBG1 NP_001061.2 tubulin gamma-1 chain 4 1,326,233 40.5
MAT2A NP_005902.1
S-adenosylmethionine synthase 
isoform type-2 4 1,324,268 *
TMEM30A NP_001137430.1
cell cycle control protein 50A 
isoform 2 2 1,318,756 *
PANK4 NP_060686.1 pantothenate kinase 4 2 1,316,739 *
CLPX NP_006651.2
ATP-dependent Clp protease ATP-
binding subunit clpX-like, 
mitochondrial precursor 2 1,308,891 *
EPRS NP_004437.2
bifunctional glutamate/proline--
tRNA ligase 2 1,306,204 8.6
SLC33A1 NP_004724.1 acetyl-coenzyme A transporter 1 2 1,286,248 *
CKAP4 NP_006816.2 cytoskeleton-associated protein 4 5 1,282,681 7.6
SPTLC2 NP_004854.1 serine palmitoyltransferase 2 2 1,280,886 *
ZMYM4 NP_005086.2 zinc finger MYM-type protein 4 11 1,279,354 10.6
HAT1 NP_003633.1
histone acetyltransferase type B 
catalytic subunit 2 1,256,903 *
DCTPP1 NP_077001.1 dCTP pyrophosphatase 1 2 1,251,824 *
PRKDC NP_008835.5
DNA-dependent protein kinase 
catalytic subunit isoform 1 7 1,250,546 *
NTPCR NP_115700.1
cancer-related nucleoside-
triphosphatase 2 1,250,471 *
NDUFS7 NP_077718.3
NADH dehydrogenase 
[ubiquinone] iron-sulfur protein 7, 
mitochondrial 4 1,246,136 20.8
CDC42EP1 NP_689449.1 cdc42 effector protein 1 2 1,244,618 *
DRAP1 NP_006433.2 dr1-associated corepressor 4 1,238,665 *
RPL19 NP_000972.1 60S ribosomal protein L19 4 1,222,981 4.9
MAN1A1 NP_005898.2
mannosyl-oligosaccharide 1,2-
alpha-mannosidase IA 8 1,222,367 *
SLC35A1 NP_001161870.1
CMP-sialic acid transporter 
isoform b 2 1,217,098 *
SAMM50 NP_056195.3
sorting and assembly machinery 
component 50 homolog 2 1,215,272 *
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VAPA NP_919415.2
vesicle-associated membrane 
protein-associated protein A 
isoform 2 2 1,204,874 10.9
CAMP NP_004336.3
cathelicidin antimicrobial peptide 




mitochondrial precursor 6 1,192,015 *
SYNGR2 NP_004701.1 synaptogyrin-2 7 1,190,482 17.7
GART NP_001129477.1
trifunctional purine biosynthetic 
protein adenosine-3 isoform 1 6 1,181,277 14.5
PPID NP_005029.1
peptidyl-prolyl cis-trans isomerase 
D 4 1,166,983 *
RAB8A NP_005361.2 ras-related protein Rab-8A 4 1,165,323 *
SMCR7L NP_061881.2
mitochondrial dynamic protein 
MID51 4 1,162,188 *
RHOA NP_001655.1
transforming protein RhoA 
precursor 4 1,156,165 *
SLC25A18 NP_113669.1 mitochondrial glutamate carrier 2 2 1,151,077 *
TADA2B NP_689506.2 transcriptional adapter 2-beta 2 1,150,299 *
MSH2 NP_001245210.1
DNA mismatch repair protein 
Msh2 isoform 2 4 1,148,678 *
RAB2A NP_001229573.1
ras-related protein Rab-2A isoform 
b 7 1,137,126 66.2
CHTOP NP_001231593.1
chromatin target of PRMT1 protein 
isoform 3 2 1,131,060 4.4
ATP2C1 NP_001186114.1
calcium-transporting ATPase type 
2C member 1 isoform 1c 2 1,125,665 *
ZMYM3 NP_963893.1
zinc finger MYM-type protein 3 




acetylglucosaminyltransferase 2 1,119,565 22.2
PEPD NP_001159529.1 xaa-Pro dipeptidase isoform 3 4 1,109,390 2.4
MMS19 NP_071757.4
MMS19 nucleotide excision repair 
protein homolog 2 1,096,266 *
SAAL1 NP_612430.2 protein SAAL1 4 1,090,963 25.9
SH3GL1 NP_001186873.1 endophilin-A2 isoform 3 2 1,089,768 *
RTN2 NP_996784.1 reticulon-2 isoform C 2 1,089,575 *
NXT1 NP_037380.1 NTF2-related export protein 1 2 1,089,361 *
ACLY NP_942127.1 ATP-citrate synthase isoform 2 4 1,086,407 1.9
PI4K2A NP_060895.1
phosphatidylinositol 4-kinase type 
2-alpha 2 1,086,154 *
ELOVL4 NP_073563.1
elongation of very long chain fatty 
acids protein 4 2 1,083,413 *
TELO2 NP_057195.2
telomere length regulation protein 
TEL2 homolog 5 1,080,764 *
SPIN3 NP_001010862.2 spindlin-3 2 1,079,819 1.8
RAB6A NP_001230647.1
ras-related protein Rab-6A isoform 
d 4 1,079,766 *
GM2A NP_000396.2
ganglioside GM2 activator isoform 
1 precursor 2 1,076,485 *
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NLGN4Y NP_001193779.1 neuroligin-4, Y-linked isoform 3 2 1,061,612 *
NSUN2 NP_001180384.1
tRNA (cytosine(34)-C(5))-
methyltransferase isoform 2 4 1,051,526 *
CD59 NP_001120695.1 CD59 glycoprotein preproprotein 2 1,048,284 7.4
ARMC6 NP_219483.1
armadillo repeat-containing 
protein 6 isoform 2 2 1,047,630 *
POLR2B NP_000929.1
DNA-directed RNA polymerase II 
subunit RPB2 2 1,039,508 11.4
DLST NP_001924.2
dihydrolipoyllysine-residue 
succinyltransferase component of 
2-oxoglutarate dehydrogenase 
complex, mitochondrial isoform 1 
precursor 4 1,027,928 4.7
VKORC1 NP_996560.1
vitamin K epoxide reductase 
complex subunit 1 isoform 2 
precursor 6 1,023,425 *
RPS2 NP_002943.2 40S ribosomal protein S2 2 1,022,369 *
COX18 NP_776188.1
mitochondrial inner membrane 
protein COX18 4 1,020,943 *
MAPRE1 NP_036457.1
microtubule-associated protein 
RP/EB family member 1 2 1,014,788 *
SNAP23 NP_570710.1
synaptosomal-associated protein 
23 isoform SNAP23B 2 1,005,053 *
ECE1 NP_001106819.1
endothelin-converting enzyme 1 
isoform 4 2 1,000,531 17.5
PLXNA1 NP_115618.3 plexin-A1 precursor 2 1,000,384 *
GIGYF2 NP_001096618.1
PERQ amino acid-rich with GYF 
domain-containing protein 2 
isoform c 2 1,000,110 3.9
GOSR1 NP_001007025.1
Golgi SNAP receptor complex 
member 1 isoform 3 2 999,968 *
LPCAT4 NP_705841.2
lysophospholipid acyltransferase 
LPCAT4 2 998,164 *
BZW1 NP_055485.2
basic leucine zipper and W2 
domain-containing protein 1 
isoform 4 2 994,100 *
VTI1B NP_006361.1
vesicle transport through 
interaction with t-SNAREs 
homolog 1B 2 983,057 *
TTC27 NP_001180438.1
tetratricopeptide repeat protein 27 
isoform 2 6 980,613 26.6
RAB1A NP_004152.1
ras-related protein Rab-1A isoform 
1 4 974,988 *
CDIPT NP_006310.1
CDP-diacylglycerol--inositol 3-
phosphatidyltransferase 2 971,299 *
MCM4 NP_877423.1
DNA replication licensing factor 
MCM4 2 969,246 *
ESYT1 NP_056107.1
extended synaptotagmin-1 isoform 
2 6 965,899 *
RPS8 NP_001003.1 40S ribosomal protein S8 6 965,546 4.5
NDUFAF4 NP_054884.1
NADH dehydrogenase 
[ubiquinone] 1 alpha subcomplex 
assembly factor 4 2 964,176 *








Gene Accession Protein name Peptides Intensity Ratio
MRPL46 NP_071446.2
39S ribosomal protein L46, 
mitochondrial 2 961,358 3.6
ATP11B NP_055431.1
probable phospholipid-
transporting ATPase IF 2 960,629 *
ATP5F1 NP_001679.2
ATP synthase subunit b, 
mitochondrial precursor 2 951,956 1.5
GRWD1 NP_113673.3
glutamate-rich WD repeat-
containing protein 1 2 949,705 3.6
PCDH7 NP_002580.2
protocadherin-7 isoform a 
precursor 4 944,895 *
CAPRIN1 NP_976240.1 caprin-1 isoform 2 2 943,613 *
ITGA6 NP_000201.2
integrin alpha-6 isoform b 
precursor 4 935,356 *
APLP2 NP_001135750.1
amyloid-like protein 2 isoform 4 
precursor 2 931,606 54.2
TIMMDC1 NP_057673.2
translocase of inner mitochondrial 
membrane domain-containing 
protein 1 precursor 4 929,921 5.8
ROBO1 NP_001139317.1 roundabout homolog 1 isoform d 2 924,016 *
GGT7 NP_821158.2 gamma-glutamyltransferase 7 2 909,035 *
OS9 NP_001248352.1 protein OS-9 isoform 8 precursor 2 902,460 *
TMEM245 NP_114401.2 transmembrane protein 245 2 901,646 *
LMNA NP_005563.1 lamin isoform C 2 894,311 *
OPA1 NP_570844.1
dynamin-like 120 kDa protein, 
mitochondrial isoform 2 2 889,767 *
MRPL43 NP_115488.2
39S ribosomal protein L43, 
mitochondrial isoform a 2 883,994 *
AMY2B NP_066188.1 alpha-amylase 2B precursor 2 882,937 *
NCSTN NP_056146.1 nicastrin precursor 2 878,916 19.4
C1orf112 NP_060656.2 uncharacterized protein C1orf112 2 874,913 *
IMMT NP_001093640.1
mitochondrial inner membrane 
protein isoform 3 4 873,169 8.1
NAA16 NP_078837.3
N-alpha-acetyltransferase 16, 
NatA auxiliary subunit isoform 1 2 872,826 *
VTI1A NP_660207.2
vesicle transport through 
interaction with t-SNAREs 
homolog 1A 4 870,848 32.8
IGF2R NP_000867.2
cation-independent mannose-6-
phosphate receptor precursor 2 867,620 *
ARMC10 NP_001154485.1
armadillo repeat-containing 
protein 10 isoform f 2 843,341 *
NDUFA8 NP_055037.1
NADH dehydrogenase 
[ubiquinone] 1 alpha subcomplex 
subunit 8 2 826,043 *
MST4 NP_001035918.1
serine/threonine-protein kinase 
MST4 isoform 2 6 826,040 *
CLGN NP_004353.1 calmegin precursor 2 825,371 *
SCO1 NP_004580.1
protein SCO1 homolog, 
mitochondrial 2 795,512 2.0
SPIN1 NP_006708.2 spindlin-1 2 792,518 3.6
CERS1 NP_937850.1 ceramide synthase 1 isoform 2 2 785,026 *
SF3B1 NP_036565.2
splicing factor 3B subunit 1 








Gene Accession Protein name Peptides Intensity Ratio
SDR39U1 NP_064580.2
epimerase family protein 
SDR39U1 4 778,893 *
PARP2 NP_001036083.1
poly [ADP-ribose] polymerase 2 
isoform 2 2 773,721 *
SEL1L NP_005056.3
protein sel-1 homolog 1 isoform 1 
precursor 2 752,030 *
HELLS NP_060533.2 lymphoid-specific helicase 2 747,226 *
GSTM2 NP_001135840.1
glutathione S-transferase Mu 2 
isoform 2 2 733,154 6.7
OSBPL8 NP_001003712.1
oxysterol-binding protein-related 
protein 8 isoform b 3 730,303 *
SATB2 NP_056080.1 DNA-binding protein SATB2 2 720,166 7.1
DCTN3 NP_077324.1 dynactin subunit 3 isoform 2 2 718,119 15.6
PTPRF NP_569707.2
receptor-type tyrosine-protein 
phosphatase F isoform 2 
precursor 2 700,692 46.4  
Only proteins with more than 1 peptide were included unless the protein was clearly part of a marked complex. Protein and 
peptide false discovery rates were set at 1% for the Proteome Discoverer database search. Proteins were sorted by intensity. 
Gene is the gene name. Blue text indicates proteins identified in the SG proteome. Orange text indicates SG proteome 
proteins that are hnRNPs. Peptides are the peptide spectrum matched hits. Intensity is the total integrated precursor ion peak 
density. SILAC ratio is the average HEAVY (UBQLN2)/LIGHT (Control) peptide ratio. * indicates a corresponding light 
peptide was not automatically identified by the search software. Red bars indicate proteins identified in this study.  Orange 




Appendix B: Ubiquilin specific tools developed 
INTRODUCTION 
The human ubiquilin paralogs UBQLN1, 2, and 4 are highly similar with UBQLN4 most closely related 
to the single yeast homolog Dsk2. The original studies on the ubiquilins proteins grouped them 
together functionally due to the lack of paralog-specific reagents. In the course of completing this 
work, I characterized a number of paralog specific antibodies and shRNA’s, generated a number of 
mammalian expression plasmids, cell lines, and worm lines and optimized purification of the UBQLN2 
protein from E. coli. These tools are presented here to supplement the methods in the previous chapters 
and as a reference for future lab members. 
 
RESULTS 
Characterization of UBQLN specific antibodies and shRNAs 
Previous efforts to characterize the unique functional roles of the ubiquilin paralogs UBQLN1, 2 and 
4 in humans were hampered by the high degree of similarity between the ubiquilin proteins. For 
example, ubiquilin paralogs UBQLN2 and UBQLN1 are 75% identical and 87% similar, while 
UBQLN2 and UBQLN4 are 58% identical and 77% similar (Lalign).  UBQLN2 however, contains a 
unique 12x PXX repeat region and all the ubiquilins have unique amino-termini.  Commercially 
available peptide and monoclonal antibodies that recognize this central variable region of UBQLN1, 
2, and 4 were chosen to uniquely recognize UBQLN1, 2, and 4 (Table B-1, Figure B-1). Notably, early 
lots of the Sigma Prestige rabbit anti-UBQLN2 antibody raised against a 149 amino acid peptide 
containing this PXX repeat region (Cat. No. HPA006431 Lot#A08472) were highly specific for the 67 
kDa UBQLN2 band. Based on this specificity, the majority of Western blot and immunofluorescence 
assays were performed with this antibody.  However, later lots of HPA006431 (especially lot #A89939) 
showed considerably more background bands by Western blot.  The Novus 6H9 mouse anti-UBQLN2 
monoclonal antibody made against the full-length recombinant protein is highly specific for UBQLN2 
and may be a suitable alternative for the less reliable Sigma peptide rabbit antibody. This antibody does 
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however require the presence of the amino-terminal Ubl domain of UBQLN2 to detect UBQLN2 by 
Western blot, which could be a limitation for studying the native UBQLN2 fragments (Figure B-3B).  
Overall, these tools provided the basis for studying the role of UBQLN2 in SG formation in cells 
described. 
Cell lines that inducibly express or constitutively suppress UBQLN expression 
To investigate specific cellular functions of the UBQLN2 protein, I constructed four sets of stable cell 
lines using two different strategies: selection of random integration events, and flippase-short flippase 
recognition target site (FLP-FRT) recombination.  
First, to quantitatively analyze proteins that coimmunoprecipitate with the UBQLN2 protein, I selected 
HEK293T cells that spontaneously integrated FLAG-UBQLN2 under control of a tetracycline 
inducible CMV promoter in a vector carrying the puromycin resistance gene.  Despite artifacts 
potentially introduced by treating cells with the tetracycline analog doxycycline, I reasoned that the Tet 
repressor would minimize selection for suppressors of toxicity associated with overexpressing 
UBQLN2 protein (Huang et al., 2016).  Following lipofectamine 2000 transfection with linearized 
vector, cells were continuously selected with 3 μg/mL puromycin until individual colonies appeared 
(after approximately 2 weeks).  Individual clones were characterized by Western blot and clones that 
expressed UBQLN2, 1, and 4 at levels close to endogenous expression were selected for the SILAC 
IP (Figure B-3 A).  HEK293T cells were selected for this analysis due to their ease of transfection and 
the broad range of proteins that they express, including some neuronal markers (Stepanenko and 
Dmitrenko, 2015). 
HEK293T cells, however are not ideal for imaging due to their irregular shape and weak adherence to 
glass coverslips. To study the localization of UBQLN2 to SGs microscopically, I thus turned to HeLa 
cells, a commonly used cell line to study SG formation. The same strategy of selecting for the random 
integration of both tetracycline inducible expression constructs and constitutive shRNA knockdown 
constructs was performed.  The highest concentration of puromycin under which integrant clones 
carrying constitutively expressed shRNA’s appeared was 2 μg/mL puromycin. These clones were not 
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used for the UBQLN2 depletion time course experiments because transient transfection proved to be 
a more efficient method to effectively deplete UBQLN2. By selecting for random integration of 
regulatable FLAG-UBQLN2 in HeLa cells I also tried to generate stable cell lines for imaging. 
Unfortunately, no HeLa clones that inducibly express the UBQLN proteins were selected under these 
conditions. 
To study the effects of UBQLN overexpression on SG formation in HeLa cells, I integrated UBQLN2 
into the FRT site in a HeLa Flp-In cell line with the Flp recombinase.  Stable integrants were selected 
by treatment with Hygromycin B (400 μg/mL) over a period of 2 weeks and were pooled to avoid a 
founder effect.  A relatively low level of UBQLN expression was visible by treating cells in this 
tetracycline inducible system (Figure B-3 B) which was optimal for looking at UBQLN2 fragment 
localization.  I observed that UBQLN2 fragment expression level varied greatly due to the loss of 
fragment stability in the absence of the Ubl domain (Figure B-3 B).  I also introduced these UBQLN 
fragments into a HEK293T Flp-In cell line in which all three UBQLN proteins have been removed 
via CRISPR-Cas9 (Itakura et al., 2016) (Table B-3), but did not make use of this cell line in the current 
studies due to time constraints. This Flp-In system allows the rapid generation of isogenic clones for 
expression studies relatively quickly (within 2-3 weeks).  Some consideration should be given to the 
site at which the Tet-repressor is integrated for tetracycline inducible expression from a tetracycline 
operator.  I did see that HeLa cells with the Tet-repressor integrated, more rapidly formed SGs than 
our lab HeLa strain, indicating a difference in sensitivity. 
Worm lines for studying ubiquilin function in C. elegans 
Transgenic Worm Line Generation 
To characterize the function of the human UBQLN2 protein in neurons in vivo I generated transgenic 
Caenorhabditis elegans worm lines that constitutively express the human UBQLN2 wild type or mutant 
(P497H, P506T) protein under control of the synaptobrevin neuronal promoter (psnb-1). With help 
from Jiou and the talented postdoc Tao Zhang I began by generating an extrachromosomal array, then 
screened for array integrants generated by UV/TMP mutagenesis. To generate worm lines carrying an 
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extrachromosomal array, Jiou coinjected a 20 ng/μL psnb-1::hUBQLN2 in pPD30_38 (Fire Lab Vector, 
Addgene) with 2.5 ng/μL pmyo-2::RFP into the gonad of hermaphrodite worms. Progeny carrying the 
red fluorescent protein (RFP) marker were moved to new plates and inspected daily for lines that had 
stable extrachromosomal arrays (Mello et al., 1991). These worm lines were expanded and frozen 
(Table B-5). 
Worms carrying an extrachromosomal array were used to generate worm lines with stably integrated 
copies of the human UBQLN2 gene, L4 hermaphrodite extrachromosomal array worms were treated 
with 30 μg/mL trimethylpsoralen and 300 μJ 365 nm UV light. Progeny were moved to new plates 
and screened for stable integration of the extrachromosomal array. Expression of the hUBQLN2 
transgene was assessed by Western blot of whole worm lysate. Select integrated lines were then 
backcrossed with the Bristol N2 strain at least four times prior to freezing using standard methods 
(TableB-5). 
Endogenous worm ubiquilin, ubql-1 null worm lines 
To characterize the function of the endogenous worm ubiquilin, ubql-1, I used two uncharacterized 
worm ubiquilin null strains from the Caenorhabditis Genetics Center ubql-1 (tm1574) and ubql-1 (ok997) 
previously obtained by the lab.  These strains were backcrossed six times to the Bristol N2 strain. 
Neither strain appeared to show a movement defect (Table B-6). 
Worm crosses 
To characterize the phenotype of worms deficient in endogenous ubql-1 or overexpressing wild type 
or mutant UBQLN2, I performed preliminary worm movement assays and crossed worms to strain 
carrying fluorescently labelled autophagy markers, other ALS/FTD-linked proteins prone to aggregate 
and a daf-2 insulin receptor mutant strain.  RFP, expressed in the pharyngeal muscle was used to trace 
segregation of transgenic ubiquilin alleles (Table B-7).   
Optimization of native UBQLN2 purification from E. coli 
To perform in vitro studies on the UBQLN2 protein, I optimized its purification from E. coli. I started 
with a protocol shared by a lab member from Dr. Mervin Monteiro’s lab (University of Maryland) to 
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purify 6xHis-UBQLN2 and adapted it to a 6xHis-GFP-TEV-UBQLN2 construct. 6xHis-GFP-
UBQLN2 expression was induced overnight at 16C with 1 mM IPTG in pRosettaII BL21DE3 E. coli 
cells.  Cell were pelleted at 4000 x g, 4C, 20 min and resuspended in 50 mM Tris-Cl, pH 8.0, 300 mM 
NaCl, 10% glycerol, 10 mM imidazole with a Roche EDTA-free Complete protease inhibitor cocktail 
at a ratio of 2 mL of Lysis/Resuspension buffer per gram of wet cell pellet.  Cells were lysed via French 
Press and cell debrís/unlysed cells were removed by pelleting at 20000 x g, 4C, 20 min twice. 
6xHisGFP-UBQLN2 was then batch purified via NiNTA affinity chromatography as follows: the 
supernatant was incubated overnight with NiNTA beads.  Beads were washed with 350 mM salt buffer, 
175 mM salt buffer, 0 mM salt buffer, then 150 mM NaCl buffer containing 50 mM Tris-Cl, pH 8.0, 
10% glycerol and 30 mM imidazole buffer.  The majority of the protein was eluted with 250 mM 
imidazole.  The affinity purified protein was then simultaneously dialyzed against 50 mM Tris-Cl, pH 
8.0, 10% glycerol and 10 mM imidazole buffer and cleaved with TEV protease to remove the 6xHis-
GFP tag overnight at 4C in Snakeskin 3.5 MWCO dialysis tubing spiked with sodium chloride. 
Cleaved protein was then passed back over the cleaned and recharged Ni-NTA beads and the flow-
through was collected.  This flow-through was spin concentrated in an Amicon-Ultra 10 MWCO spin 
filter to an appropriate volume to inject into a Superdex 200 size exclusion column at a flow rate of 0.5 
mL/min.  Fractions were checked via Coomassie gel for molecular weight and Western blot.  The 
second size exclusion peak contained purified UBQLN2 protein (Figure B-4). Protein fractions were 
then pooled and again spin concentrated in a 50 MWCO Amicon spin filter to approximately 10 
mg/mL before the protein was flash frozen in liquid nitrogen. 
At concentrations above 10 mg/mL the protein appeared to precipitate out of solution.  When warmed 
to room temperature the solution became cloudy and phase separated as previously described (Dao et 
al., 2018), so all steps were performed on ice. Highly concentrated fractions were thawed on ice and 
spun 10,000 x g, 4C, 10 min and absorbance was measured prior to use in the FUS-UBQLN2 
interaction assays described (=11460 M-1cm-1 (Protparam), and MW= 65896.32 Da) (Chapter 3). 
144 
 
The 6xHis-GFP-UBQLN2 protein itself was stable in a 10% buffered glycerol solution at 4C for more 
than 2 years.  UBQLN2 P497H and P506T mutants were purified as described for the wild type 
protein.  The purified protein has a Serine, Isoleucine residue upstream of the initiator methionine in 
the consensus human sequence (RefSeq NP_038472.2).  This protein was sufficiently pure to set up 
crystal trays to test for UBQLN2 crystallization in collaboration with Jurgen Bosch’s lab.  
Unfortunately, I did not see the formation of crystals under any of the conditions that we tested.  I was 
later, however able to use this optimized purification protocol to purify sufficient protein for the in 
vitro FUS-RNA smFRET studies performed in collaboration with the Myong lab that form the basis 
of our current mechanistic understanding of UBQLN2’s function in SG formation. 
 
DISCUSSION 
Here I have highlighted several tools that I developed to investigate UBQLN2 function.   
Identifying UBQLN2 specific antibodies and shRNA’s was critical to differentiating UBQLN2 from 
UBQLN1 and 4 by Western Blot and immunocytochemistry.  The pan-ubiquilin antibody was also 
useful for staining all forms of UBQLN2 simultaneously.  Although to clearly separate UBQLN2 and 
4 a gradient or 8% isocratic Tris-Gly SDS-PAGE gel worked best. Previous efforts to characterize the 
functions of UBQLN1 and 2 were hampered by the lack of ubiquilin specific tools, so I hope this brief 
characterization is helpful to future studies and evaluating past studies despite the fact that new 
antibodies continue to be commercially developed.   
Some cell lines such as the Flp-In HeLa cell line and the HEK293T stable cells lines that inducibly 
express UBQLN2 were critical to the experiments described.  The stable HEK293T stable cell line that 
inducibly expresses the UBQLN proteins was important for the SILAC experiments to ensure 




Other cell lines, such as the HEK293T UBQLN2 knockout cell lines and HeLa UBQLN constitutive 
knockdown cell were not employed in the experiments described here, but may be useful to the lab in 
the future. Originally, I constructed the UBQLN 1, 2, 4 CRISPR knockout cell lines that inducibly 
express UBQLN2 and its fragments to perform SG fluorescence recovery after photobleaching 
experiments in collaboration with the Myong lab to show that UBQLN2 increases the dynamics of 
FUS exchange in and out of SGs.  However due to technical problems with FUS-GFP bleaching and 
time constraints, I was unable to complete these experiments.  The constitutive knockdown HeLa cells 
were also constructed to optimize reproducibility in SG timecourse experiments, but the knockdown 
failed to be as efficient as that obtained from a 72-96 hr transient transfection.  
The worm lines that I made may be useful to future lab members in characterizing UBQLN2 neuronal 
function in SGs in vivo. Hopefully the optimized UBQLN2 purification protocol will prove useful for 
future in vitro experiments to study UBQLN2 function. I still, of course, dream of a full-length structure 
of UBQLN2 in complex with its functional interactors. 
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Figure B-1 UBQLN1, 2, 4 specific antibodies reveal specific shRNA depletion 
(A) Domain maps of UBQLN2, 1, and 4 showing the position of the unique peptide antigens targeted 
by the antibodies used in (B).  The antigen positions correspond to amino acid residues 502-519 
in UBQLN1, 443-591 in UBQLN2, and 100-116 in UBQLN4. 
(B) Western blot (WB) of SDS-PAGE separated HEK293T cell lysate, 72 hrs post-transfection with 
the specified shRNA’s.  Two shRNA’s specific to UBQLN1, UBQLN2, and UBQLN4 are shown. 
Mouse anti-UBQLN4 (Santa Cruz H-2) and rabbit anti-UBQLN1 (Sigma U7258) distinguished 
UBQLN1 and UBQLN4 from UBQLN2 recognized by rabbit anti-UBQLN2 (Sigma Prestige 
HPA0006431). Mouse anti-β-actin was used as a loading control. UBQLN2 migrates more slowly 
than UBQLN1, consistent with its larger molecular weight (65.7 kDa vs. 62.5 kDa). 
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(C) WB of overexpressed FLAG-UBQLN1, 2, and 4. FLAG-GUS (β-glucuronidase) a plant protein 
with a similar molecular weight was used as a control. The mouse monoclonal anti-UBQLN2 (Uba) 








Figure B-2. UBQLN shRNA target sites 
Diagrams of UBQLN1, 2, and 4 mRNA with numbered exons and specific shRNA target sites shown 
in magenta.  UBQLN2 is encoded by a single exon on the X-chromosome.  The unique PXX repeat 
in UBQLN2 is marked with a green box. mRNA is shown in the 5’-3’ direction.  The UBQLN2 specific 
shRNA in the 3’ UTR was used to deplete endogenous UBQLN2 levels while exogenously expressing 






Figure B-3. UBQLN integrated cell line expression 
(A) Western blot (WB) of tetracycline-inducible FLAG-UBQLN expression before and after 1 μg/mL 
doxycycline treatment in stable HEK293T cells used for proteomic analysis of UBQLN interacting 
partners.  The anti-UBQLN2 blot shows less than two-fold overexpression of the UBQLN2 
protein after 24 hrs of induction. GAPDH was used as a loading control. 
(B) WB of FLAG-UBQLN2 expression induced by Flp-In HeLa cell treatment with 1 μg/mL 
tetracycline for 24 hrs following 72 hrs exposure to UBQLN2 specific shRNA to deplete 
endogenous UBQLN2 protein.  The UBQLN2 protein expression level is less than endogenous 







Figure B-4. Native UBQLN2 purification from E. coli 
(A) Diagram of the pET-6xHis-GFP-UBQLN2 construct showing the location of the TEV site and 
Ser, Ile residues left upstream of the Met start site after the TEV cleavage site. 
(B) Size exclusion chromatogram, showing elution of pure UBQLN2 protein in P2 (yellow dot). 
(C) Western blot analysis of size exclusion peak fractions.  Size exclusion removed the majority of 









Table B-2. UBQLN shRNA target sequences 
shRNA target sequences 
 
siRNA targeting sequences were from Origene.  The hairpin loop introduced was TCAAGAG followed by the reverse 
complement of the target sequence.  All shRNA’s were cloned into the BamHI/BglII-HindIII sites in the pRFP-C-RS vector 





Target Epitope Host Isotype Source Cat. No.
UBQLN1 502-519 Rabbit Polyclonal Sigma U7258
UBQLN2 443-591 Rabbit Polyclonal Sigma Prestige HPA006431
UBQLN4 100-116 Mouse Monoclonal (H-2) Santa Cruz sc-515250
Alternative UBQLN specific antibodies
UBQLN1 1-19 Rabbit Polyclonal Sigma U7383
UBQLN2 Ubl Mouse Monoclonal (6H9) Novus NBP2-25164
UBQLN4 Central Rabbit Polyclonal Aviva Biosystems ARP57355
UBQLN4 Central Mouse Monoclonal (M398) Santa Cruz sc-136146
pan-UBQLN antibody
UBQLN2 555-624 Mouse Monoclonal (5F5) Sigma WH0029978M3
Gene shRNA plasmid Target sequence
non-targetting shCTRL-RFP-C-RS gcactaccagagctaactcagatagtact
UBQLN2 shUBQLN2-RFP-C-RS #54 tgtatatgaccttaatctttgtgcagcct
UBQLN2 shUBQLN2-RFP-C-RS #55 aaccacgagtcctacatcagaatctggac
UBQLN1 shUBQLN1-RFP-C-RS #31 ctgaactacagagtcagatgcagcgacaa
UBQLN1 shUBQLN1-RFP-C-RS #32 tacatcctctggtgaaggtagtcaacctt
UBQLN4 shUBQLN2-RFP-C-RS #21 gctgctcagatgatggtgaatgtgccgct
UBQLN4 shUBQLN2-RFP-C-RS #22 ggcttcatcaatcgtgaggctaacctgca
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HEK293T UBQLN2 pcDNA3.1* Random PuroR 3 μg/mL Puromycin
HEK293T UBQLN2 P497H pcDNA3.1* Random PuroR 3 μg/mL Puromycin
HEK293T UBQLN2 P506T pcDNA3.1* Random PuroR 3 μg/mL Puromycin
HEK293T UBQLN1 pcDNA3.1* Random PuroR 3 μg/mL Puromycin
HEK293T UBQLN4 pcDNA3.1* Random PuroR 3 μg/mL Puromycin
HEK293T GFP pcDNA3.1* Random PuroR 3 μg/mL Puromycin
Endogenous level expression
Flp-In HeLa UBQLN2 pcDNA5_DEST FRT site HygR 400 μg/mL Hygromycin B
Flp-In HeLa UBQLN2 P497H pcDNA5_DEST FRT site HygR 400 μg/mL Hygromycin B
Flp-In HeLa UBQLN2 P506T pcDNA5_DEST FRT site HygR 400 μg/mL Hygromycin B
Flp-In HeLa UBQLN2 Ubl-Sti1 pcDNA5_DEST FRT site HygR 400 μg/mL Hygromycin B
Flp-In HeLa UBQLN2 Sti1-Uba pcDNA5_DEST FRT site HygR 400 μg/mL Hygromycin B
Flp-In HeLa UBQLN2 Sti1 pcDNA5_DEST FRT site HygR 400 μg/mL Hygromycin B
Flp-In HeLa eGFP pcDNA5_DEST FRT site HygR 400 μg/mL Hygromycin B
Unused HEK293T  Triple UBQLN Knockout Cell Lines
TKO UBQLN HEK293T UBQLN2 pcDNA5_DEST FRT site HygR 400 μg/mL Hygromycin B
TKO UBQLN HEK293T UBQLN2 P497H pcDNA5_DEST FRT site HygR 400 μg/mL Hygromycin B
TKO UBQLN HEK293T UBQLN2 P506T pcDNA5_DEST FRT site HygR 400 μg/mL Hygromycin B
TKO UBQLN HEK293T UBQLN2 Ubl-Sti1 pcDNA5_DEST FRT site HygR 400 μg/mL Hygromycin B
TKO UBQLN HEK293T UBQLN2 Sti1-Uba pcDNA5_DEST FRT site HygR 400 μg/mL Hygromycin B
TKO UBQLN HEK293T UBQLN2 Sti1 pcDNA5_DEST FRT site HygR 400 μg/mL Hygromycin B
TKO UBQLN HEK293T eGFP pcDNA5_DEST FRT site HygR 400 μg/mL Hygromycin B
Unused HeLa Constituitive Knockdown Cell Lines
HeLa UBQLN2 shRNA 1 pRFP-C-RS** Random PuroR 2 μg/mL Puromycin
HeLa UBQLN2 shRNA 2 pRFP-C-RS** Random PuroR 2 μg/mL Puromycin
HeLa UBQLN1 shRNA 1 pRFP-C-RS** Random PuroR 2 μg/mL Puromycin
HeLa UBQLN1 shRNA 2 pRFP-C-RS** Random PuroR 2 μg/mL Puromycin
HeLa UBQLN4 shRNA 1 pRFP-C-RS** Random PuroR 2 μg/mL Puromycin
HeLa UBQLN4 shRNA 2 pRFP-C-RS** Random PuroR 2 μg/mL Puromycin
HeLa Ctrl shRNA pRFP-C-RS** Random PuroR 2 μg/mL Puromycin
*CMV/TO_Nt-3xFLAG_DEST_TetR-IRES-PuroR
**pRFP MluI /BglII digested and religated to remove RFP  
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Table B-4. UBQLN cDNA constructs for mammalian and E. coli expression
 
SILAC IP HEK293T Stable Cell Line Construction
cDNA Insertion site Vector backbone
UBQLN2 attR1-attR2 pcDNA3.1*_TetR_IRES_PuroR_DEST
UBQLN2 P497H attR1-attR2 pcDNA3.1*_TetR_IRES_PuroR_DEST





FLAG IP Interaction Validation
cDNA Insertion site Vector backbone
UBQLN2 attR1-attR2 pcDNA3.1*
UBQLN2 P497H attR1-attR2 pcDNA3.1*
UBQLN2 P506T attR1-attR2 pcDNA3.1*
UBQLN2 UBL attR1-attR2 pcDNA3.1*
UBQLN2 UBA attR1-attR2 pcDNA3.1*
UBQLN2 STI1 attR1-attR2 pcDNA3.1*
UBQLN2 STCH BD attR1-attR3 pcDNA3.1*
UBQLN2 UBL-STI1 attR1-attR2 pcDNA3.1*
UBQLN2 STI1-UBA attR1-attR2 pcDNA3.1*
UBQLN1 attR1-attR2 pcDNA3.1*
UBQLN1 UBL attR1-attR2 pcDNA3.1*
UBQLN1 UBA attR1-attR2 pcDNA3.1*
UBQLN1 STI1 attR1-attR2 pcDNA3.1*
UBQLN1 UBL-STI1 attR1-attR2 pcDNA3.1*
UBQLN1 STI1-UBA attR1-attR2 pcDNA3.1*
UBQLN4 attR1-attR2 pcDNA3.1*
UBQLN4 UBL attR1-attR2 pcDNA3.1*
UBQLN4 UBA attR1-attR2 pcDNA3.1*
UBQLN4 STI1 attR1-attR2 pcDNA3.1*
UBQLN4 UBL-STI1 attR1-attR2 pcDNA3.1*
UBQLN4 STI1-UBA attR1-attR2 pcDNA3.1*
GUS attR1-attR2 pcDNA3.1*  
Flp-In HeLa and HEK293T cell line construction
cDNA Insertion site Vector backbone
UBQLN2 attR1-attR2 pcDNA5-FRT_DEST
UBQLN2 P497H attR1-attR2 pcDNA5-FRT_DEST
UBQLN2 P506T attR1-attR2 pcDNA5-FRT_DEST
UBQLN2 UBL attR1-attR2 pcDNA5-FRT_DEST
UBQLN2 UBA attR1-attR2 pcDNA5-FRT_DEST
UBQLN2 STI1 attR1-attR2 pcDNA5-FRT_DEST
UBQLN2 STCH BD attR1-attR2 pcDNA5-FRT_DEST
UBQLN2 UBL-STI1 attR1-attR2 pcDNA5-FRT_DEST
UBQLN2 STI1-UBA attR1-attR2 pcDNA5-FRT_DEST
UBQLN1 attR1-attR2 pcDNA5-FRT_DEST
UBQLN1 STI1 attR1-attR2 pcDNA5-FRT_DEST
UBQLN4 attR1-attR2 pcDNA5-FRT_DEST





UBQLN myc expression vectors
cDNA Insertion site Vector backbone
UBQLN2 XhoI/XhoI pRK5-myc (Wang Lab)
UBQLN2 P497H XhoI/XhoI pRK5-myc (Wang Lab)
UBQLN2 P506T XhoI/XhoI pRK5-myc (Wang Lab)
UBQLN1 SalI/SalI pRK5-myc (Wang Lab)
UBQLN4 SalI/SalI pRK5-myc (Wang Lab)
UBQLN2 XhoI/XhoI pRK5-myc**
UBQLN2 P497H XhoI/XhoI pRK5-myc**




cDNA Insertion site Vector backbone
UBQLN2 shRNA 2.54 BamHI/HindIII pRFP-C-RS
UBQLN2 shRNA 2.55 BamHI/HindIII pRFP-C-RS
UBQLN1 shRNA 1.31 BamHI/HindIII pRFP-C-RS
UBQLN1 shRNA 1.32 BamHI/HindIII pRFP-C-RS
UBQLN4 shRNA 4.21 BamHI/HindIII pRFP-C-RS
UBQLN4 shRNA 4.22 BamHI/HindIII pRFP-C-RS
Ctrl shRNA BamHI/HindIII pRFP-C-RS
UBQLN2 shRNA 2.54 BamHI/HindIII pRFP-C-RS***
UBQLN2 shRNA 2.55 BamHI/HindIII pRFP-C-RS***
UBQLN1 shRNA 1.31 BamHI/HindIII pRFP-C-RS***
UBQLN1 shRNA 1.32 BamHI/HindIII pRFP-C-RS***
UBQLN4 shRNA 4.21 BamHI/HindIII pRFP-C-RS***
UBQLN4 shRNA 4.22 BamHI/HindIII pRFP-C-RS***
Ctrl shRNA BamHI/HindIII pRFP-C-RS***
E. coli expression vectors
cDNA Insertion site Vector backbone
UBQLN2 SspI pET-6xHis-GFP-LIC
UBQLN2 P497H SspI pET-6xHis-GFP-LIC
UBQLN2 P506T SspI pET-6xHis-GFP-LIC
UBQLN2 NdeI/XhoI pET28a-6xHis
UBQLN2 P497H NdeI/XhoI pET28a-6xHis
UBQLN2 P506T NdeI/XhoI pET28a-6xHis
*pcDNA3.1_CMV/TO-n3xFLAG
**MluI/AgeI  digested and religated to remove foreign long 3'UTR.
***MluI/BglII   digested and religated to remove RFP.
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Table B-5. Transgenic hUBQLN2 C. elegans lines 
Transgenic extrachromosomal arrays
strain allele [genotype]
IW180 iwEx69 [psnb-1::hUBQLN2; pmyo-2::RFP]
IW203 iwEx68 [psnb-1::hUBQLN2 P497H; pmyo-2::RFP]
IW278 iwEx67 [psnb-1::hUBQLN2 P506T; pmyo-2::RFP]
Integrated arrays
IW200 iwIs52 [psnb-1::hUBQLN2 WT int; pmyo-2::RFP]
IW301 iwIs40 [psnb-1::hUBQLN2 P497H int; pmyo-2::RFP]
IW302 iwIs41 [psnb-1::hUBQLN2 P497H int; pmyo-2::RFP]
IW303 iwIs42 [psnb-1::hUBQLN2 P497H int; pmyo-2::RFP]
IW304 iwIs43 [psnb-1::hUBQLN2 P497H int; pmyo-2::RFP]
IW305 iwIs44 [psnb-1::hUBQLN2 P497H int; pmyo-2::RFP]
IW306 iwIs45 [psnb-1::hUBQLN2 P497H int; pmyo-2::RFP]
IW307 iwIs46 [psnb-1::hUBQLN2 P497H int; pmyo-2::RFP]
IW309 iwIs47 [psnb-1::hUBQLN2 P497H int; pmyo-2::RFP]
IW316 iwIs48 [psnb-1::hUBQLN2 P497H int; pmyo-2::RFP]
IW319 iwIs50 [psnb-1::hUBQLN2 P497H int; pmyo-2::RFP]
IW320 iwIs51 [psnb-1::hUBQLN2 P497H int; pmyo-2::RFP]
Outcrossed strains
IW295 iwIs52 [psnb-1::hUBQLN2; pmyo-2::RFP]
IW318 iwIs43 [psnb-1::hUBQLN2 P497H int; pmyo-2::RFP]
IW321 iwIs46 [psnb-1::hUBQLN2 P497H int; pmyo-2::RFP]
IW323 iwIs45 [psnb-1::hUBQLN2 P497H int; pmyo-2::RFP]  
 




Outcrossed null allele strains
IW296 ubql-1(tm1574)
IW298 ubql-1(ok997)
Null allele; Transgenic hUBQLN2
IW310 ubql-1(tm1574) ; iwIs52  [psnb-1 ::hUBQLN2 ; pmyo-2 ::RFP]
IW341 ubql-1(tm1574); iwIs43 [psnb-1::hUBQLN2 P497H int; pMyo-2::RFP]









Table B-7 Transgenic hUBQLN2 and null ubql-1 C. elegans strains 
Lgg1::GFP
IW328 ubql-1(tm1574); adls2122 [lgg-1::GFP; rol-6(su1006)]
IW343 ubql-1(tm1574); iwIs43  [psnb-1::hUBQLN2 P497H int; pmyo-2::RFP]; adls2122
IW311 iwIs52 [psnb-1::hUBQLN2; pMyo-2::RFP]; adls2122 [GFP::Lgg-1; rol-6(su1006)]
IW342 iwIs43 [psnb-1::hUBQLN2 P497H int; pmyo-2::RFP]; adls2122 [lgg-1::GFP + rol-6(su1006)]
IW355 iwIs45 [psnb-1::hUBQLN2 P497H int; pmyo-2::RFP]; adls2122[lgg-1::GFP + rol-6(su1006)]
SOD1G85::YFP
IW337 ubql-1(ok997); iwIs8 [psnb-1::hSOD1 G85R::YFP]
IW338 ubql-1(tm1574); iwIs8 [psnb-1::hSOD1 G85R::YFP] 
IW339 iwIs52 [psnb-1::hUBQLN2; pmyo-2::RFP]; iwIs8 [psnb-1::hSOD1 G85R::YFP] 
TDP43::YFP
IW365 ubql-1(tm1574); IwIs22 [psnb-1::hTDP43::YFP] 
polyQ67::YFP
IW333 ubql-1(ok997); rmIs284 [pF25B3.3::Q(67)::YFP]
IW334 ubql-1(tm1574); rmIs284 [pF25B3.3::Q(67)::YFP]
IW335 iwIs52 [psnb-1::hUBQLN2; pmyo-2::RFP]; rmIs284 [pF25B3.3::Q(67)::YFP ]
daf-2(e1370)
IW414 adls2122[lgg-1::GFP + rol-6(su1006)]; daf-2(e1370)
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 PhD Club – Department of Biochemistry & Molecular Biology, Baltimore, MD 
 
2014, 2015 “Ubiquitin-like protein, Ubiquilin 2 Function and Role in ALS Pathology” 
presentation. Alexander EJ, Nirujogi RS, Pandey A, Wang J 
 Hopkins Ubiquitin Club, Baltimore, MD 
 
POSTER PRESENTATIONS 
2015 “Investigating a Novel Nuclear Role for ubiquilin Proteins” 
 Alexander EJ, Nirujogi RS, Pandey A, Wang J 
 Annual Retreat- Department of Biochemistry & Molecular Biology  
 Shephard Pratt Conference Center, Towson, MD 
2014 “Ubiquitin-like protein, Ubiquilin 2 Function and Role in ALS Pathology” 
 Alexander EJ, Nirujogi RS, Pandey A, Wang J 
 Annual Retreat- Department of Biochemistry & Molecular Biology 
 Shephard Pratt Conference Center, Towson, MD 
2003 “Amyloid β (1-42) Fusion Peptide Overexpression and Purification from Inclusion 
Bodies in E. coli” 
 Alexander EJ and Chen L 
 Annual STARS Symposium. Indiana University, Bloomington, IN 
2002 “Amyloid β (40, 42) Interaction with the GroEL Chaperonin Complex” 
 Alexander EJ and Chen L 
 Annual STARS Symposium. Indiana University, Bloomington, IN 
2001 “Bifurcation of Planar Conservative Systems & Its Application to a Biological 
System” 
 Alexander EJ and Wang S 
 Annual STARS Symposium. Indiana University, Bloomington, IN 
 
TEACHING & MENTORING EXPERIENCE 
Lab Mentoring: 
2016 Nathan Magalit (Undergraduate student): Stress granule ImageJ quantitation, 
confocal microscopy, cell culture techniques to track the role of ubiquilin 2 in stress 
granule formation 
2015-2016 Yajas Shah (MHS student): Isca1 cloning for in vivo magnetic manipulation 
178 
 
2014-2015 Justin Chu (MHS student): Ubiquilin 2 mutant cloning 
2013-2014 Luis Rendon (Undergraduate student): Confocal microscopy, cell culture, cell 
fixation and staining to monitor the role of ubiquilin 2 in autophagy 
Group/Individual tutoring: Molecular Biology (Fall 2014), Pola Olzak (2015), Shuo Li (2016) 
Teaching: 
Fall 2016  Core Research Literature 
Lead a graduate level discussion class on protein quality control. 
 
Springs Cellular Stress in Physiology & Disease 
2013-2016 Teaching assistant for graduate level course. 
 Lead a discussion on protein homeostasis in 2016. 
 
Summers  Introduction to Biological Sciences  
2014-2016  Graduate level course for non-majors entering the School of Public Health 
Taught 15 min segments on the “Nervous System” and “Autonomic Nervous 
System” incorporating active learning activities. 
Designed and participated in a 3 hr “Molecular Biology Session” with a team. 
Gave a 1 hr lecture on Motor Neuron Disease in 2016. 
 
Summer 2016  JHU Teaching Institute Teaching Academy 
Participated in 3-day workshop on course planning, active learning, and assessment. 
 
Summer 2016 PhD Education Reform Focus Group 
Participated in focus groups to revise the School of Public Health’s PhD program. 
 
Fall 2005 Hmong Refugee Volunteer Teacher, Madison, WI. 
Taught newly arrived refugees improvised lessons in English 1-4 hours/week. 
 
Summer 2005 Teaching English as a Foreign Language Certification 
Wisconsin English Language Institute. 
Participated in a 5-week intensive teacher training program focusing on the using the 
communicative method to teach English as a foreign language. 
Designed lesson plans for and taught 12 hours of English class. 
Worked with Turkish and Korean conversation partners 1-4 hours/week. 
 
